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ABSTRACT
This study explored the symptom experience of patients receiving epidermal
growth factor receptor inhibitors (EGFRIs) for breast, colon, head and neck, and colon
cancer. EGFRIs are targeted therapies used at various points along the treatment
continuum for these solid tumors, and may be first, second or third-line agents which can
be used as single agents or in combination with other therapies. The most common side
effect of these agents include dermatologic effects, such as rashes, hair, and nail changes,
but they can also contribute to other side effects such as fatigue, anxiety and diarrhea.
Most previous work has addressed the dermatologic side effects and has not addressed the
holistic patient experience. A descriptive, correlational design, guided by the theory of
unpleasant symptoms, explored the overall symptom experience, including dermatologic
and other symptoms, in patients receiving these treatments. The relationship of key
variables (age, diagnosis, gender, EGFRI therapy, and symptom clusters) to the outcomes
of quality of life, psychological status, and functional status was also explored. Cooccurring symptoms (symptom clusters) were identified by factor analysis procedures.
Three symptom clusters were identified: a psychological-cognitive cluster; a treatmentrelated dermatologic cluster that has not been previously identified as a symptom cluster;
and, a mucocutaneous and fatigue cluster. These symptom clusters had differing impacts
on outcomes, so knowledge of the effects of these symptom clusters can guide nursing
practice in the care of patients receiving these targeted therapies.
xiv

Keywords: Symptom experience, factor analysis, theory of unpleasant symptoms,
epidermal growth factor receptor inhibitor, quality of life, functional performance,
psychological status, symptom cluster.
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CHAPTER ONE
INTRODUCTION
Significance of the Problem
People living with cancer must cope not only with the threat of serious illness, but
also with bothersome and disruptive symptoms brought on by rigorous cancer therapies.
Chemotherapy and radiation therapy are associated with well-known symptoms, such as
hair loss, nausea and vomiting, and myelosuppression, as well as symptoms resulting
from organ toxicities, and an array of long-term side effects. The symptom experiences of
patients receiving these traditional modalities of treatment have been extensively studied
and are well understood by health care providers. In recent years, however, targeted and
biologic therapies have outpaced traditional chemotherapy for new drug approvals in
oncology, and much remains to be discovered about the symptom experience associated
with these agents.
The newer targeted therapies exert their therapeutic effects differently than
cytotoxic chemotherapies. Rather than killing both healthy and cancer cells, targeted
therapies aim to more precisely alter cellular function. Some focus on cell signaling
pathways, others induce apoptosis (programmed cell death), some influence the immune
system, while others deliver radiation or other substances to cancer cells (Targeted
Cancer Therapies, 2014). Treatment with targeted therapies, such as the epidermal
growth factor receptor inhibitors (EGFRIs), may result in a challenging symptom
1
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experience that features novel dermatologic symptoms that patients may not expect to be
associated with cancer treatment.
The present study explored the symptom experience of patients receiving
epidermal growth factor receptor inhibitors (EGFRIs), also called anti-EGFR therapies or
signal transduction inhibitors. Rather than exerting their mechanism of action through the
cytotoxic effects characteristic of conventional chemotherapy, targeting rapidly dividing
cells at various points in the cell cycle, EGFRIs work by influencing human epidermal
growth factor receptor (EGFR) signaling pathways. The human epidermal growth factor
family comprises four tyrosine kinase receptors, including ErbB1 or HER1 (EGFR),
ErbB2 (HER 2/neu), ErbB3 or HER3, and ErbB4 or HER4 (Mahipal, Kothari, & Gupta,
2014), but for this research study, the focus is on EGFRIs.
EGFRIs are currently indicated for selected patients diagnosed with advanced
non-small cell lung cancer, breast cancer, colon cancer, pancreatic cancer, head and neck
cancers, and other solid tumors of epithelial origin where epidermal growth factor
receptors (EGFR) are overexpressed.
New Targets for Cancer Therapy
The unstable genome of the cancer cell has been described as its Achilles’ heel
(Levitzki & Klein, 2010), highlighting the genome as a susceptible target. Abnormal and
overactive cell signaling pathways result from chromosomal mutations, mutations of
oncogenes and tumor suppressor genes, and other epigenetic changes. Most readers will
be familiar with an early and newsworthy application of a targeted therapy, using the
drug imatinib (Gleevec®), for a chronic form of leukemia associated with the Bcr-Abl
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tyrosine kinase oncogene. Patients treated with this agent demonstrate a remarkably
improved remission rate of greater than 90% (Balagula, Rosen, & Lacouture, 2011),
offering a glimpse of the potential of targeted therapies in cancer. As molecular profiling
of tumors continues to be refined, subtype characteristics of tumors will influence the
type of targeted therapy prescribed, as in the case of EGFRIs.
Science is just beginning to identify these molecular changes that lead to the
development of cancer, and as they are discovered, future therapies will target these
genetic aberrations. One such mutation affects the EGFR protein on the surface of cancer
cells, contributing to the development of various solid tumors. The EGFR gene encodes a
type of protein kinase which serves as a receptor for the epidermal growth factors family.
In normal cells, epidermal growth factor binds to EGFRs and spurs activation of
signaling pathways, which in turn, help to govern cell growth, proliferation, and
migration. Activation of overexpressed or mutated EGFRs requires a process of binding,
dimerization and phosphorylation. When a mutation creates an excess number of
receptors, the result is pathway dysregulation and subsequent abnormal cell growth, cell
proliferation, avoidance of apoptosis (programmed cell death), cell migration and
neovascularization of tumors.
EGFRs include an extracellular ligand-binding domain, a transmembrane region,
and an intracellular tyrosine kinase domain. Both the extracellular and intracellular
domains of these proteins are treatment targets. EGFRIs include both monoclonal
antibodies (MOABs), cetuximab and panitumumab, which are given by infusion, and
tyrosine kinase inhibitors (TKIs), afatinib, erlotinib, gefitinib, and lapatinib, which are
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oral agents. MOABs target tyrosine kinase receptors outside of the cell, while TKIs are
small molecules that target the intracellular domain.
Lung cancer has a projected incidence in the United States of 224,210 (Siegel,
Ma, Zou, & Jemal, 2014), and is the most common cause of cancer death globally,
contributing to more than a million deaths (Network, 2014). Activated oncogenes such
as EGFR or other mutations (e.g. ALK) occur to varying degrees in various patient
populations, but the impact of EGFRI therapy on the patient symptom experience will be
significant, primarily because of the prevalence of lung cancer. In lung cancer,
approximately 10-15% of Caucasian, and 40% of Asian non-small cell lung cancer
patients carry the EGFR mutation (Cooper, Lam, O’Toole, & Minna, 2013), making
treatment with EGFRIs a first treatment option over chemotherapy. Genetic signposts,
such as this mutation and others, now influence treatment selection, allowing providers to
tailor therapy, when possible, for each patient.
Activating EGFR mutations occur most commonly in patients in lung cancer
patients with no prior history of smoking, in adenocarcinoma, in females, and in Asians,
and occur in a small area of the EGFR gene. Because EGFRIs have a different
mechanism of action than traditional chemotherapy, their symptom profile is different
and less familiar to practitioners and patients alike. The impact of these agents on the
symptom experience is just beginning to be understood, and this study will add to the
evidence on this topic.

5
Overview of EGFRI-Related Symptoms
The on-target effects of EGFRIs result in a high incidence of dermatologic
toxicities, such as skin, hair and nail changes, because EGFRI is essential for the normal
physiology of the skin. EGFR is expressed in the basal cell layer of the epidermis, in the
outer layers of the hair follicles, as well as in the sebaceous epithelium (Lacouture, 2006;
Lynch et al., 2007; Andreis et al., 2010; Lacouture, Maitland, et al., 2010; Chan & Tan,
2011; Chanprapaph, Vachiramon, & Rattanakaemakorn, 2014). Normal epidermal
growth and development depends upon EGFR signaling, and its absence or disruption,
such as occurs in a mutation, has been illustrated in an animal model. Mice lacking
normal EGFR expression and signaling displayed skin defects like those experienced by
patients on EGFRIs (Mascia et al., 2013).
Dermatologic changes resulting from EGFRI therapy include primarily rash and
xerosis (dry skin), but also erythema, telangiectasia, hyperpigmentation, and nail and hair
changes. These are the most commonly reported side effects associated with the EGFRIs,
with an incidence of all grade skin toxicity ranging from 47 to over 90%, depending on
the specific agent (Ocvirk, Heeger, McCloud, & Hofheinz, 2013). With a protracted
treatment course, most patients will develop one or more of these dermatologic
symptoms. For example, a study of 16 patients treated with the EGFRIs cetuximab,
panitumumab, or erlotinib for more than six months reported that 100% developed some
form of cutaneous symptom (Osio et al., 2009); however, more severe Grade 3 or 4 skin
toxicities occur in only about one of five patients (Peuvrel et al., 2012 ; Brodell, Hepper,
Lind, Gru, & Anadkat, 2013). With the advent of prophylactic skin care protocols, the
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severity of dry skin, itching and rash can be ameliorated in some patients, but a solid
evidence base for many treatments is currently lacking. Specific symptoms will be
addressed more fully in chapter two.
Other Factors Affecting the Symptom Experience
The symptom experience of patients receiving EGFRI therapy may also be
exacerbated by other concurrent treatment modalities, such as chemotherapy and
radiotherapy (e.g. concurrent cetuximab and radiation in head and neck cancer) (Pryor,
Burmeister, Burmesiter, Poulsen, & Porceddu, 2011), as well as by other symptoms
common in the oncology population, such as fatigue or lack of energy. In addition, many
patients receiving these therapies may also have advanced disease and may be
experiencing a greater symptom burden, both physical and psychological, as a result of
their disease status (Wong et al., 2010). As a result, the overall symptom experience of
patients treated with EGFRIs may be much more complex and multifaceted than the
widely-reported profile depicting primarily dermatologic toxicities.
Impact on Outcomes
Collectively, both a cancer diagnosis and the side effects of treatment
significantly impact quality of life (Fox & Lyon, 2006, 2007; So et al., 2009; Joshi et al.,
2010; Deshields, Potter, Olsen, Liu, & Dye, 2011; Dodd et al., 2011; Husain, Myers,
Selby, Thomson, & Chow, 2011; Roiland & Heidrich, 2011), functional status (Dodd,
Miaskowski, & Paul, 2001; Given, Given, Azzouz, Kozachik, & Stommel, 2001; Chen &
Tseng, 2006; Miaskowski et al., 2006; Cheng & Lee, 2011; Dodd et al., 2011), and
psychological status (Adler & Page, 2008; Breen et al., 2009). Due to their unique side
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effect profile, EGFRIs carry a significant symptom burden (Wu, Balagula, Lacouture, &
Anadkat, 2011), and may exert a negative psychological and physical effect on healthrelated quality of life (Joshi et al., 2010; Rosen et al., 2013), and can even lead to
treatment interruption (Boucher, Olson, & Piperdi, 2011). All of the TKIs are selfadministered oral medications, so adherence to treatment amidst a difficult symptom
experience is also a concern (Mancini, McBride, & Kruczynski, 2013; Matthews &
Caprera, 2014). A better understanding the overall symptom experience associated with
EGFRIs will provide actionable knowledge that can proactively address patient
symptoms so that treatment adherence concerns are minimized.
Most research addressing symptoms associated with EGFRIs has explored the
obvious rash and other dermatologic symptoms, while a broader focus on the overall
symptom experience has been limited (Osio et al., 2009; Andreis et al., 2010; Joshi et al.,
2010; Rosen et al., 2013). Joshi et al. (2010) found EGFRI-related skin toxicities
affected emotional well-being, while Wagner and Lacouture (2007) reported physical
symptoms like pain, itching and stinging had an impact on quality of life. One study did
not find a correlation between skin rash and psychological distress, but did find highly
significant relationships between perceived quality of life and psychological distress and
social avoidance (Romito et al., 2010). Despite the fact that there is some evidence that
quality of life and psychological status are affected by patients receiving EGFRIs, most
clinical and research literature suggests that patients are most bothered by the esthetic
complications of the rash (Wu et al., 2011). This misconception suggests that there is a
need for a greater understanding of the symptom experience so that providers fully
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appreciate how patients are impacted by EGFRI treatment. As there are only a few
published studies exploring these relationships, with none in the nursing literature, the
interplay between EGFRI-related symptoms and the overall symptom experience has not
been fully explored, so this study is a first step in this direction.
Purpose of the Study
EGFRI treatment-related symptoms constitute a significant burden for patients
undergoing treatment for cancer. To date, there is a paucity of research on the overall
symptom experience associated with these therapies, and there is no nursing research that
addresses this topic. Most research exploring side effects of EGFRIs has been conducted
in the context of clinical trials, and focuses on dermatologic symptoms, but not on the
overall symptom experience of the patient receiving these therapies. Along with
uncomfortable and visible dermatologic symptoms, patients can also experience other
symptoms such as dry mouth, fatigue, and psychological distress.
Significance to Nursing
This study was a descriptive, correlational survey designed to explore the
symptom experience, including discovery of any co-occurring symptoms (symptom
clusters), associated with EGFRI therapy. In addition to describing the full range of
symptoms associated with EGFRI therapies, this study explored the impact of these
symptoms on key outcomes. Co-occurring symptoms, or symptom clusters, were
identified by factor analysis procedures and supported by hierarchical cluster analysis.
The relationship of key variables (age, diagnosis, gender, EGFRI therapy, and symptom
clusters) to outcomes was explored.
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The study of the symptom experience, including any identified symptom clusters,
in patients receiving EGFRIs contributes to the nursing literature by: a) fully describing
the symptom experience of patients receiving EGFRIs; b) providing data to support the
co-occurrence of symptoms in patients receiving EGFRIs; c) providing preliminary
information about the relationship of symptoms or identified symptom clusters and key
outcomes; and, d) providing preliminary data to help generate hypotheses for
interventional research to improve symptom control, as well as symptom management
interventions for symptom clusters. Specific applications to nursing practice, education
and research are outlined below.
Relevance to nursing practice. The American Cancer Society estimates that
1,665,540 new cancer cases will be diagnosed, and 585,720 Americans are expected to
die of cancer, in 2014 (Siegel et al., 2014). Lung and colorectal cancers are projected to
be among the most common cancers in men (exceeded only by prostate cancer), and
breast, lung and colorectal cancers will be the top three cancer diagnoses in women in
2014. If even 10% of these newly diagnosed patients with lung, breast, or colon cancer
were eventually treated with an EGFRI, this would amount to a considerable number of
patients who could potentially benefit from the new knowledge generated by this study.
Overall, the number of cancer survivors has more than quadrupled since 1971,
when 3 million people were identified as survivors. In 2007, 11.7 million people in the
United States were described as cancer survivors (Rowland et al., 2011). By 2012, the
number of U.S. cancer survivors had risen to 13.4 million people in 2012, or just under
5% of the population, according to a recent report from the Centers for Disease Control
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(Ekwueme et al., 2014). About 68% of cancer survivors were still alive five or more
years after their diagnosis (Siegel et al., 2012), and nearly 60% of those individuals were
older than 65. Many cancer diagnoses can now be considered to be more like chronic
diseases which require a series of treatments over time. An improved understanding of
the symptom experience of patients receiving EGFRIs may benefit a significant number
of patients who may be treated with these drugs, whether they are among the newly
diagnosed with advanced disease, or are receiving EGFRIs later in the treatment
continuum.
An essential role of the health care team is to help each patient to manage their
symptom experience, allaying its impact on important outcomes. Since patients perceive
their illness and its treatment through their collective symptom experience, optimal
patient care should address the occurrence of all symptoms in order to tailor symptom
management strategies (Brown, Cooley, Chernecky, & Sarna, 2011), many of which will
require multiple interventions. Describing dermatologic symptoms along with other
symptoms that co-occur, and exploring their relationship to important outcomes will
create a better understanding of what patients experience and lead to enhanced patient
care. In addition, the majority of oncology patient care has shifted to the outpatient arena
away from the infusion suite (Neuss et al., 2013), where patients may have less in-person
contact with oncology nurses. Some EGFRI agents, such as cetuximab and panitumumab,
are given as infusions, but other agents, such as the TKIs in this study, are taken orally.
When patients receive oral agents, patient teaching strategies in the practice setting must
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be highly focused, delivered in new formats, or via new technologies due to limited
interaction with oncology nurses.
The EGFRI symptom experience is illustrated by this case example. A 65 yearold retired woman taking erlotinib for advanced lung cancer develops an itchy facial rash
after six weeks of therapy. The rash causes her anxiety and discomfort, and although she
has been advised that its presence may be indicative of a therapeutic response, it still
causes psychological distress. The rash, as well as her severe dry skin and dry eyes,
cause her to be irritable. Upon waking, her eyelashes are covered with crusts, causing
inconvenience and irritation. Everyday tasks like housekeeping are more difficult due to
changes in her nail beds and sore fingers, and she isn’t sure how her grandchildren will
react when they come to visit, as she looks different and is unable to prepare their
favorite foods for them. A holistic plan of care could not only preemptively manage her
dry skin, but could help her identify other interventions such as caring for her eyes,
soaking her nails, and using relaxation techniques or meditation to help her cope with any
distress symptoms may cause.
Despite experiencing multiple symptoms, it is possible that patients such as the
woman described above may prioritize and receive advice only for the most pressing or
overt (e.g. dermatologic) symptoms during their brief encounter with health care
providers. But other associated symptoms, such as dry eyes, or feeling sad or nervous,
could remain untreated. Evidence suggests that patients may underreport their symptoms
for a variety of reasons, such as thinking a symptom is too minor to mention, blaming a
symptom on aging or comorbidity, prior minimization by the provider, failure to receive
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helpful information upon previous reporting, and lack of time in the patient-provider
interaction (Royer, Phelan, & Heidrich, 2009). Further, patients may assign symptom
priorities “based on the meanings they ascribe to them” (Maguire, Stoddart, Flowers,
McPhelim, & Kearney, 2014). For example, about half of all patients who experienced
fatigue in one study did not report it to their physician, perhaps due to resignation over its
inevitability, its relative unimportance, or because they perceived a lack of treatment
options to address it (Stone et al., 2000; Passik et al., 2002), so it is possible that some
EGFRI-related symptoms could be viewed by patients as unavoidable discomforts.
Further, clinicians tend to “underestimate the incidence, severity, or distress of symptoms
experienced by cancer patients” (Xiao, Polomano, & Bruner, 2014). Thorough
assessment is the first step in addressing all of the EGFRI-related symptoms, and for
some symptoms, use of a questionnaire may result in an increase in the symptom
prevalence reported by patients, as patients may feel less encumbered by time restraints,
and may feel more able to surface symptoms not part of routine clinical assessments
(Teunissen et al., 2007).
Treating all symptoms, rather than individual symptoms, could prove beneficial to
both providers and patients (Chan, Richardson, & Richardson, 2011) by anticipating
possible problems, preventing symptoms from worsening, reducing the number of
medications used, decreasing medication side-effects, averting unplanned visits to a
health care provider, reducing costs, and enhancing patient well-being and satisfaction
(Walsh & Rybicki, 2006; Berger, Yennu, & Million, 2013). Patients experiencing poor
symptom management incur unnecessary health care costs for hospitalizations and
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emergency consultations to manage toxicities and out-of-control symptoms (Fortner,
Okon, & Portenoy, 2002). Reduced direct and indirect costs of health care are a potential
benefit of optimal and novel symptom management, a model which has been explored in
patients receiving chemotherapy (Given, Bradley, You, Sikorskii, & Given, 2010). In
addition, treatments used for one symptom could affect other symptoms (Kapella, Larson,
Patel, Covey, & Berry, 2006) and offer a “crossover” benefit, as in the examples of
cognitive-behavioral therapies used for both pain management and amelioration of
fatigue (Fleishman, 2004). At present, these benefits are largely theoretical, and need to
be explored in future research, as very few intervention studies have investigated
treatment protocols for multiple symptoms.
Relevance to oncology nursing education. Although oncology nurses have
always assessed symptoms using a whole person approach, nursing education about
symptom management traditionally has focused on single, high-incidence symptoms,
such as fatigue, pain, and nausea and vomiting. As a result, both nurses and nursing
students are oriented to the management of those symptoms as they occur individually, a
situation which contributes to a reductionist approach to patient care. Studies of the
symptom experience related to specific treatments create a more realistic picture of what
patients face, and nursing education content can be based on this new knowledge.
Symptom clusters can be viewed as correlates of quality of life and other
outcomes in chronic conditions, and addressing interventions that target them can impact
outcomes (Motl & McAuley, 2009). Nursing education could emphasize an awareness of
symptoms that cluster together in various cancer diagnoses or in relation to specific
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treatments. In turn, oncology nurses will have a heightened awareness of symptoms
likely to co-occur, and can proactively teach patients relevant self-care skills, such as
symptom management strategies that might offer the “crossover” effect as described
above. Nursing education on symptom assessment and management strategies must
continually evolve to address the symptom experience associated with new therapies as
they are introduced.
Relevance to oncology nursing research. The Oncology Nursing Society (ONS)
conducts a research priorities survey and produces a research agenda every few years,
and for 2013, symptom management: self-management symptom control was rated as the
fourth highest priority. Fatigue, pain, nausea, psychological distress, and neuropathy
were ranked by all respondents as the top five symptoms causing patient distress, and two
of these (fatigue and psychological distress) have been addressed in the current study
(Lobiondo-Wood et al., 2014).
The 2013 ONS research survey also ranked research priorities separately by the
educational degrees of respondents. For nurses with advanced degrees, self-management
interventions to improve symptom control, symptom management interventions and
management interventions of symptom clusters were ranked as the top three priorities.
These topics were also ranked in the top 20 for nurses with basic nursing degrees, but at
lower priorities. The present research provides a foundation for addressing all three of
these priorities as well as for two of the prioritized symptoms, fatigue and psychological
distress, in patients receiving EGFRIs (Lobiondo-Wood et al., 2014).
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Oncology nurses continue to prioritize symptom management as a topic worthy of
research, with a greater focus on self-management, multiple concurrent symptoms, and
technology, with each of these elements included in the current work. Nursing research in
the area of concurrent symptoms or symptom clusters has proliferated over the last
decade; however, symptom clusters in patients receiving EGFRIs have not been
systematically studied to date, and the preponderance of research on EGFRIs has focused
on the dermatologic symptoms. The present study included a more comprehensive
assessment of symptoms than in previously published work because 38 possible
symptoms were included, and data were collected on symptoms beyond skin, hair and
nail changes, with the intent of discovering the existence of symptom clusters in this
patient population.
Nursing research studies featuring interventions for symptom clusters are limited
(Xiao, 2010) and have only recently increased, and none related to EGFRI therapy have
been published at this writing. A recent review described 24 studies that included
interventions for patients experiencing symptom clusters, with eighteen focused on early
cancer and six on advanced disease (Berger et al., 2013), but none included patients
receiving EGFRIs. This study is a first step toward the identification of symptom clusters
in these patients so that interventions can be developed.
Purpose of the Study
The current study was designed to describe the symptom experience, including
any symptom clusters, in patients receiving EGFRIs, and to explore the relationships
between symptoms, any identified symptom clusters, and key outcome variables of
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quality of life, performance status, and psychological functioning. The intent is to
develop a more comprehensive understanding of the symptom experience of patients
receiving these therapies, and to provide a foundation for the development of hypotheses
for interventions aimed at helping these patients to better self-manage their symptoms.
Specific Study Aims
The specific study aims were to:
1. Describe the symptom experience (symptom frequency and distress) of
patients receiving EGFRI therapy.
2. Describe the quality of life, functional performance and psychological status
of patients receiving EGFRI therapy.
3. Identify any co-occurring symptoms or symptom clusters in patients receiving
epidermal growth factor receptor inhibitors.
4. Explore the relationships between any identified symptom clusters and key
variables, including gender, age, primary cancer, EGFRI, and the outcome
variables of quality of life, functional performance and psychological status.

CHAPTER TWO
LITERATURE REVIEW
Even as cancer care evolves to a paradigm of personalized medicine based on
molecular profiles and targeted therapies, newer treatments continue to create symptom
management challenges. Oncology nurses help patients to navigate their treatment
course, assisting them to manage the unpleasant symptoms they confront, regardless of
modality of therapy. Underpinning this continually evolving clinical practice is nursing
research, such as the present study, designed to address the gaps in knowledge about how
patients experience symptoms.
In this chapter, the theoretical framework used to guide this study will be
presented. The concepts of symptoms, the symptom experience, and symptom clusters
will be briefly reviewed as they relate to this theoretical framework. The available
literature on the symptom experience of patients receiving EGFRIs will be summarized,
and the relationship between EGFRI-related symptoms and key variables, such as age,
gender, primary diagnosis, and type of agent, as well as performance outcomes of
interest, including functional status, quality of life and psychological functioning, will be
presented. Finally, the current knowledge about EGFRI symptoms and gaps in
knowledge will be summarized.
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Conceptual Framework: The Theory of Unpleasant Symptoms
The revised theory of unpleasant symptoms (Revised Theory of Unpleasant
Symptoms, Figure 1) is the model selected to guide this research study (Lenz & Pugh,
2003). The TOUS has been described by its authors as a middle-range theory (Lenz &
Pugh, 2008) “designed to integrate knowledge about a variety of symptoms” (p. 159). As
Lenz and Pugh (2008) noted, symptom management is a central component of nursing
clinical practice. The TOUS is valuable as a general tool to address the “multivariate
assessment of the symptom experience itself and of possible influencing factors, and
provides a rationale and framework for applying a biopsychosocial
approach….suggesting that multiple management strategies may need to be applied
simultaneously” (p. 85).
The TOUS has served as the theoretical scaffold for a number of discussion
papers and nursing research studies in oncology (Redeker, Lev, & Ruggiero, 2000;
Carpenter et al., 2004; Lee, 2005; Fox & Lyon, 2006; Fox, Lyon, & Farace, 2007; Fox &
Lyon, 2007; Myers, 2009; So et al., 2013; Hsu & Tu, 2014); and in studies of patients
with Alzheimer’s disease, cardiac disease and heart failure, cirrhosis, domestic violence,
fatigue, renal failure, stroke, chronic obstructive pulmonary disease, inflammatory bowel
disease, multiple sclerosis, Parkinson’s disease, and in pregnant, postpartum and
breastfeeding women (Hutchinson & Wilson, 1998; McCann & Boore, 2000; Corwin,
Klein, & Rickelman, 2002; Gift, Stommel, Jablonski, & Given, 2003; Gift, Jablonski,
Stommel, & Given, 2004; Crane, 2005; Reishtein, 2005; Kapella et al., 2006; Liu, 2006;
Rychnovsky, 2007; Jurgens et al., 2009; Motl & McAuley, 2009; Song, Moser, & Lennie,
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2009; Farrell & Savage, 2010; Woods, Kozachik, & Hall, 2010; Robinson et al., 2013;
Eckhardt, Devon, Piano, Ryan, & Zerwic, 2014).
Model Components
The TOUS comprises three major concepts: the symptom or symptoms,
influencing factors (physiological, psychological, and situational), and performance
outcomes (Lenz, Suppe, Gift, Pugh, & Milligan, 1995; Lenz, Pugh, Milligan, Gift, &
Suppe, 1997; Lenz & Pugh, 2003, 2008). In the present study, in an effort to
operationalize all three major concepts, the symptoms or symptom clusters align with the
symptom element of the model; the influencing factors are the primary cancer diagnosis,
EGFRI therapy, gender, and age; and the performance element (cognitive, physical and
social functioning) includes the outcome measures of quality of life, performance status
and psychological functioning. For the purpose of this study, all of these elements make
up the patient’s symptom experience, as represented in Figure 2.
All three components of the model—symptoms, influencing factors and
performance outcomes—can affect the symptom experience. When the original TOUS
model was published (Lenz et al., 1995), a single symptom was represented in the model
schematic since the original work was derived from the study of single symptoms. A
major revision to the model (Lenz, Pugh, Milligan, Gift, & Suppe, 1997) added the
concurrent measurement of more than one symptom, including interaction and
multiplicity between and among multiple symptoms (Myers, 2009). The revised model is
a more realistic foundation for research on symptoms, particularly in patients with
advanced cancer when patients are likely to experience multiple concurrent symptoms
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(Vainio & Auvinen, 1996; Walsh & Rybicki, 2006; Kirkova, Aktas, Walsh, Rybicki, &
Davis, 2010).
The TOUS model is not without limitations. For example, the distinct attributes
of the three categories of influencing factors are somewhat hazy. The theorists have
wrestled with how to categorize social support and similar constructs as either situational
factors or psychological factors. For example, social support and level of education
would be considered as situational factors, while level of trust and self-efficacy might be
described as psychologic factors, so the classification seems somewhat arbitrary. Further,
the distinction between psychologic and physiologic factors is blurry. According to the
theorists, “Psychologic factors represent one of the more complex and controversial
components of the model…..As psychobiological research underscores the physiological
basis for mood, the psychologic and physiologic factors impacting the symptom
experience become difficult to separate” (Lenz and Pugh, 2001, pp. 77-78).
Lenz and Pugh concede that “the complex relationships among the three
categories of influencing factors and between these factors and the symptom experience
need much fuller elaboration, and the categories themselves need continuing
clarification” (p. 87). Additionally, the theorists recognize the need for additional
development of the performance or outcomes aspect of the theory, including the addition
of more inclusive outcomes beyond performance that “that may be important
consequences of the symptom experience” (p.88). The “meaning” of the symptom
experience is also not included in the model (Armstrong, 2003), and might be considered
a significant omission, although it could be argued that the distress component of
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symptom measurement and the cognitive element of performance could address symptom
meaning. However, Lenz and Pugh (2008) state that the concept of meaning is distinct
from distress.
Further, by characterizing psychologic constructs as influencing factors, perceived
symptoms such as anxiety and worry are not addressed by the model. The model has been
critiqued for an overemphasis on physical symptoms since there is not a clear distinction
between psychological symptoms and the psychologic influencing factors, so these
concepts overlap (Xiao, 2010). Although TOUS is not a perfect model (Brant, Beck, &
Miaskowski, 2009), it fits with the current study by embracing the multiplicity and
synergy inherent in the symptom experience, and allowing for the incorporation of other
performance-related constructs as part of the overall symptom experience.
Symptoms Component of the Model
The Oxford American Dictionary defines symptom as “a physical or mental
feature that is regarded as indicating a condition of disease, particularly such a feature
that is apparent to the patient: a sign of the existence of something, especially of an
undesirable situation” (Mc Kean, 2005). Symptom is derived from the, late Middle
English synthoma, symptom of a disease, from Medieval Latin based on the Greek
sumptoma, a happening. Symptoms, defined as “the perceived indicators of change in
normal function as experienced by patients” (Rhodes & Watson, 1987), and as
“subjective experiences reflecting changes in a person’s biopsychosocial function,
sensation, or cognition” (Larson et al., 1994), are the subjective heart of the human illness
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experience. Symptoms can also include deviations in sensation and appearance (Tse,
2003).
The TOUS model accounts not only for the presence of symptoms, but reflects the
multidimensionality of symptoms by including the dimensions of distress, timing,
intensity, and quality as part of the model. The distress dimension captures the
bothersome nature of the symptom, or its affective impact. The dimension of quality
describes the unique characteristics of a symptom, such as burning or stinging. The
dimension of intensity refers to the degree, strength, or severity of a symptom. Finally,
the dimension of timing refers to the duration and/or frequency of a symptom, and/or its
temporal relationship to any precipitating factor or situation. Lenz and Pugh (2008) note
that while measuring all of these dimensions would be ideal when conducting symptom
research, selection of “one, two, or three characteristics is still valid and informative for
health care providers in managing symptoms” (p.167), and is the approach used in the
current study.
Symptom clusters. Despite the fact that oncology patients often experience
multiple symptoms, until recently, much symptom research has focused on single
symptoms. Researchers at the University of California at San Francisco (Dodd, Janson,
et al., 2001; Dodd, Miaskowski, et al., 2001) were the first to discuss the concept of
symptom clusters in oncology. The definition of symptom clusters used in the current
study is derived from this early work on symptom clusters and then later refined.
Symptom clusters are defined as a set of two (Chow, Fan, Hadi & Filipczak, 2007; Kim,
McGuire, Tulman & Barsevick, 2005) or perhaps three (Dodd, Janson, et al., 2001;
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Miaskowski, Aouizerat, Dodd, & Cooper, 2007) or more symptoms that occur together
and appear to be related to each other, such as nausea, vomiting and anorexia, but which
are not required to share causation (Dodd, Miaskowski & Lee, 2004. p. 77).
Kim et al. defined a symptom cluster as:
…2 or more symptoms that are related to each other and that occur together.
Symptom clusters are composed of stable groups of symptoms, are relatively
independent of other clusters, and may reveal specific underlying dimensions of
symptoms. Relationships among symptoms within a cluster should be stronger
than relationships among symptoms across different clusters. Symptoms in a
cluster may or may not share etiology. (p. 278)
Symptom clusters have also been described as a “group of concurrent symptoms
that may have a synergistic effect as a predictor of patient outcome” (Ferreira et al.,
2008) and morbidity (Fan, Filipczak, & Chow, 2007). Synergy among symptoms is
consistent with the definition used for symptom clusters in this study and is supported by
the theory of unpleasant symptoms. Although there is agreement that concurrency of
symptoms is necessary, there is no consensus on temporal aspects of each symptom, or
how long symptoms must be present to be considered as part of a symptom cluster
(Dodd, Miaskowski, & Paul, 2001). In addition, there is no consensus on the interactivity
and the strength of relationship required between and among symptoms, despite
suggestions that symptom clusters are characterized as the “degree to which symptoms
are inextricably interactive, where any single symptom is largely codependent on changes
in other symptoms” (Tilden, Tolle, Drach & Hickman, 2002, p. 74).
Symptom experience. Patients do not experience symptoms as isolated events,
but rather through the totality of their symptoms. The term symptom experience
embraces the multidimensional aspects of having symptoms, including the “individual’s
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perception of a symptom, evaluation of the meaning of a symptom and response to a
symptom” (Dodd, Janson, et al., 2001). The concept of the symptom experience was first
characterized as an individual’s perception and response to both the occurrence of
symptoms and the resulting distress (Watson, Rhodes, & Germino, 1987), and later
described as the manifestation of symptom occurrence and symptom distress (Rhodes,
McDaniel, Homan, Johnson, & Madsen, 2000). The symptom (Dodd, Janson, et al.,
2001) or symptoms experience (Armstrong, 2003) is particularly complex and
multidimensional in oncology patients, who rarely experience single symptoms,
depending on their treatment and physiologic status.
Armstrong (2003), in a concept analysis of the symptoms experience, noted that
while the phrase is commonly used in the oncology literature, the concept has not been
well-defined. For the purposes of her analysis, Armstrong referred to the “experience of
multiple symptoms as the ‘symptoms experience’” (p. 601), defined as “the perception of
the frequency, intensity, distress, and meaning occurring as symptoms are produced and
expressed” (p. 602), and subsequently developed the Symptoms Experience Model to
address how patients perceive symptoms.
The symptom experience component of TOUS is implied, rather than directly
stated. However, through utilization of valid instrumentation, the symptom experience
can be adequately measured. All of the major TOUS concepts, including influencing
factors (operationalized in this study as age, disease, specific EGFRI, and gender),
outcomes (operationalized as quality of life, performance, and psychological status) and
symptoms (e.g. symptom assessment instruments), can be empirically measured with
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good reliability and validity, and serve as a basis for describing the symptom experience
in patients receiving EGFRIs.
Operationalization of the symptoms component. In the present study, the
symptoms were measured on the dimensions of timing and distress. As noted by the
model developers, measurement of one or more dimensions of each symptom is
acceptable, so timing and distress were included as they are measured by the symptom
instrument. Timing of symptoms was addressed through assessment of symptoms over
the past week, which is the time frame employed by the symptom assessment
instruments. Distress was measured by directly asking how much each symptom
distressed or bothered the respondent. Intensity was not included in this study, nor was
quality. Asking participants to evaluate four dimensions of their reported symptoms
would have proven daunting and may have led to incomplete surveys, so response burden
was considered when choosing the MSAS-SF over the original version.
Influencing Factors Component of Model
In the TOUS model, influencing factors are classified as physiological,
psychological and situational factors. Physiologic factors can include disease status and
severity, such as cancer diagnosis and stage of illness, as well as comorbidities.
Psychological factors address mood, response to illness, understanding of disease, and
other mental and emotional aspects. Situational factors may include socioeconomic
factors, family and social support, and lifestyle behaviors (Gift, 2009). Application of the
TOUS model places the patient in the context of family, community and environment,
and considers how these factors can contribute to the symptom experience, and in turn
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can affect performance (Lenz & Pugh, 2008). In the TOUS model, these influencing
factors can also interact, synergize and impact each other.
Critiques of the model have asserted that there is a lack of clarity with regard to
influencing factors (or antecedents), symptoms and outcomes (Brant et al., 2009) in that
they are sometimes overlapping (Hutchinson & Wilson, 1998), with the authors
responding that the “components of the TOUS …are better conceptualized as fluid and
possibly interchangeable depending on context” (Lenz & Pugh, 2003, p. 84). This
remark is relevant to the present study, as psychological symptoms, such as worrying,
feeling sad, feeling irritable, and feeling nervous are viewed as symptoms and overall
psychological status is an element of performance and is measured as an outcome.
Operationalization of the influencing factors. As noted above, the influencing
factors included in the present study are primarily physiologic and include age, gender,
primary cancer diagnosis, and specific EGFRI, and were included as part of the
demographic questionnaire.
Performance Component of the Model
Performance, including cognitive, physical and social functioning, represents how
the patient lives with their health issues, and encompasses activities of daily living, social
interaction, ability to problem solve, ability to concentrate, role performance and quality
of life (Gift, 2009). Lenz and Pugh (2008) acknowledge that the performance component
of the model should be further refined, and specifically note that one of the limitations of
the model is the omission of quality of life as an element of the performance outcome,
which has also been noted in other critiques of the model (Myers, 2009).
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Operationalization of the performance factors. In this study, outcome
measures serve as a proxy for performance, and include measures of quality of life,
performance status, and psychological functioning.
Review of the Literature on the Symptom Experience
of Patients Receiving EGFRIs
Because the original conception of this study included the concept of symptom
clusters, multiple literature searches were conducted to determine the state of the science
on symptoms, symptom experience, symptom clusters, and EGFRIs, using the following
databases: Academic Search Premier; CINAHL Plus; Health Source: Nursing/Academic
Edition; PsychInfo; MEDLINE via OvidSP; and ProQuest Dissertations. No studies
reporting on “symptom clusters” associated with EGFRIs were found.
Separate searches using the same databases for each EGFRI drug (afatinib,
cetuximab, erlotinib, gefitinib, lapatinib, panitumumab) using the “AND” operator with
the term “symptom clusters” and “symptom experience” yielded few relevant studies.
Publications related to the outcomes of interest using MeSH terms skin
diseases/psychology AND epidermal growth factor receptor inhibitor as well as
psychology AND epidermal growth factor receptor inhibitor resulted in several relevant
citations, although none included a discussion of symptom clusters (Wagner, 2007;
Wagner & Lacouture, 2007; Coleman, Kovtun, Nguyen, Pittelkow, & Jatoi, 2010; Joshi
et al., 2010; White, Roydhouse, & Scott, 2011; Boers-Doets et al., 2013).
No research exploring the symptom clusters associated with EGFRIs and their
impact on the outcome of quality of life, while explicitly addressing functional
performance and psychological status was found. Quality of life (Jatoi, Green, Rowland,
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Sargent, & Alberts, 2009; Andreis et al., 2010; Joshi et al., 2010; Ensslin, Rosen, Wu, &
Lacouture, 2013) associated with EGFRIs has been explored, and four studies using a
qualitative approach exploring the symptom experience of patients receiving EGFRIs
have been published (Wagner & Lacouture, 2007; Coleman, Kovtun, Nguyen, Pittelkow,
& Jatoi, 2011), including three focused on instrument development (Wagner &
Lacouture, 2007; Boers-Doets et al., 2013; Wagner et al., 2013).
Qualitative Research Related to EGFRI Therapy
Four qualitative papers, primarily using structured interviews and content analysis
(although this was not always explicitly stated), have explored the symptom experience
of EGFRI therapy. In a brief report, Wagner and Lacouture (2007) reported on
interviews of 20 patients about their experiences with an EGFRI-related rash, generating
new information about the overall EGFRI-related symptom experience beyond
dermatologic symptoms, but also confirming the distressing nature of the dermatologic
effects of these therapies.
This was the first outward physical appearance of the disease...it's a pretty
significant burden to carry around...people look at you and say, 'What is wrong
with that woman?' Where before they did not know... before, you could choose
who you told about your cancer...and that puts a burden on you, it creates a
dynamic that did not exist before...when before you could keep your privacy.
(Wagner & Lacouture, 2007, Discussion Section, para. 5)
The above comment illustrated that the facial rash caused by cetuximab became a sign of
cancer made visible, with the impact of violating the privacy of the patient (Boers-Doets
et al., 2013). This outward sign might require an explanation of the rash to others with
consequences to psychological status.
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The distress caused by physical symptoms associated with EGFRIs was
emphasized, as noted by a participant.
I could not get away from the dryness. The dry, cracking...It felt like I had been
sitting in the Arctic in the elements, the rawest elements—the salt, the wind, the
abrasion, and the cold. And there was no sense of humidity for like months. It had
basically torn away the entire skin and it felt this way...so I would say it was the
dryness, the sensitivity and the burning, and the inflammation of the actual
pustule. (Wagner & Lacouture, 2007, Results Section, para. 3)
The authors also described other physical symptoms associated with EGFRIs, as
illustrated in the following quote:
It was difficult to sleep because it hurt. And the burn. I had to lay sitting up so
the skin would not move because it hurt so much. It was hard to wash. You
could not put on any makeup, combing my hair hurt like hell because I have had a
lot of hair loss. (Wagner & Lacouture, 2007, Results Section, para.4)
In an extension of this work, the authors reported on additional interviews with
patients that reinforced the premise that physical symptoms are most relevant to quality
of life. Items highly endorsed by patients reflected skin hurting, burning or stinging, skin
irritation, concern about hair loss or change in texture, and pain in fingers and toes
(Wagner et al., 2013).
Another qualitative study of 15 patients who had developed an EGFRI-induced
rash focused on the dermatologic toxicities and associated co-morbidities of EGFRIs
(Coleman et al., 2011). Four themes emerged from structured interview content: actual
physical discomfort, concerns about physical appearance, social isolation, and what the
authors termed high medical morbidity (Coleman et al., 2011, p.1248), which consisted
of bleeding or pain that required hospitalization for a morphine drip. The findings
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associated with the high medical morbidity theme are novel findings not previously
reported.
A paper exploring the utility of the FACT-EGFR-18 in a native-speaking
population in The Netherlands included a structured interview survey to learn more about
participant responses. Boers-Doets et al. (2013) anecdotally reported that physical
symptoms recorded by the FACT-EGFRI-18 influenced quality of life adversely, with the
most distressing symptoms having the greatest impact on quality of life, although no
statistical analysis of items was performed.
Overall, the impact of EGFRIs on quality of life was considerable, as exemplified
by the following comments (Boers-Doets et al., 2013).
Do you see how I look? I even (sic) no longer have a face; I look stupid; that
makes me sad…I get grumpy; easily irritated. I don’t allow the grandchildren to
kiss me. I find it unpalatable…I have very much difficulty with sitting and lay
down because of pimples between my buttocks… (p. 1922-1924)
In summary, these papers offer important insights into the symptom experience of
patients receiving EGFRIs, but have several limitations. Each of the studies included a
small sample size, ranging from 10 to 20 participants. Two of the papers reported on the
same sample (Wagner, 2007; Wagner et al., 2013), so the findings discussed above are
based on the responses of 45 participants in total. Two of these papers were actually
focused on instrument development and one on linguistic evaluation, but researchers did
ask about the most bothersome aspects of dermatologic toxicity associated with EGFRIs
and their impact on quality of life. Three of the studies were conducted at a single site,
which in all cases was a tertiary care center in the Midwest, so findings may not be
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applicable in other settings; the last was conducted at three hospitals in the Netherlands,
so the findings may not be generalizable to patients in the United States.
Quantitative Research Related to EGFRI Therapy
Studies exploring the impact of EGFRIs on the performance outcomes of quality
of life, functional performance and psychological status are summarized here. In addition,
a review of symptoms associated with EGFRIs, largely derived from clinical trials work,
will also be presented in order to help characterize the physical symptoms associated with
EGFRIs.
EGFRIs and quality of life. Several papers have explored quality of life as an
outcome measure using dermatology-specific quality of life instruments (Osio et al.,
2009; Andreis et al., 2010; Jatoi et al., 2010; Joshi et al., 2010) with some evidence of a
negative impact of these treatments on quality of life. Osio expressed concern that
because of this impact on quality of life, treatment interruption or dose reduction could be
required. Andreis et al. (2010) reported on the impact on quality of life in advanced colon
cancer patients receiving EGFRIs (presumed to be cetuximab and panitumumab).
Women between the ages of 55-65, as well as patients who experienced a partial
remission (as opposed to those with no response to treatment), and those with most
severe symptoms, demonstrated the greatest declines in quality of life as measured by the
Skindex-29. Joshi et al. (2010) also reported on the impact of EGFRI toxicity (rash,
xerosis, paronychia, and pruritus) on QOL, using the Skindex-16, and found no
difference with respect to cancer type, gender, or treatment type with regard to
symptoms, emotions, function or overall score. In the Joshi study, about half the patients
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were treated with erlotinib (49.3%), so this variation in treatment and primary cancer site
(i.e. lung cancer) may have contributed to an inconsistent impact on quality of life.
In another group of patients receiving a variety of EGFRIs (described as erlotinib
or other small molecule inhibitors and cetuximab or other monoclonal antibody), skin
symptoms, including itching, burning and stinging, and psychological symptoms, such as
worry and embarrassment, were reported. These symptoms accompanied the occurrence
of rash, and negatively impacted self-reported quality of life as measured by the Skindex16 (Jatoi et al., 2010, p. 1021), but results by age and gender were not reported, so how
these findings relate to the above studies is not clear.
A recent study comparing quality of life as measured by the Skindex-16 in
patients receiving targeted therapy vs. non-targeted therapies revealed that quality of life
in patients on targeted therapies was worse, and that rash and pruritus had the greatest
adverse impact on quality of life (Rosen et al., 2013). In addition, these patients had
more adverse events than patients on non-targeted therapies. Both the total Skindex-16
score and the emotion subdomain were significantly different between the two groups.
Despite the general agreement by the above studies that these therapies impact
quality of life adversely, it is possible that effective treatment with EGFRIs may also
ameliorate symptoms and result in improved quality of life, as has been documented
repeatedly in clinical trials. A study reporting quality of life outcomes in a sample of
Chinese patients with EGFR mutation-positive advanced NSCLC receiving erlotinib or
chemotherapy found that the erlotinib arm compared favorably with the chemotherapy
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group on several measures (Chen et al., 2013), but a different quality of life instrument,
not specific to dermatologic therapy, was used in this study.
Another trial that added afatinib to best supportive care reflected improvement of
several symptoms (cough, dyspnea, pain, fatigue) as well as in physical functioning and
health-related quality of life (Hirsh, 2011; Hirsh et al., 2013). Gefitinib therapy was also
associated with improvement in health-related quality of life when compared with
combination chemotherapy, although symptom improvement varied by EGFR mutation
status, showing greater improvement in EGFR-mutated tumors, as would be expected
(Thongprasert et al., 2011). Similarly, another study documented improvements in global
quality of life, functioning, cough, pain and dyspnea in patients with EGFR mutations
(Di Maio et al., 2012).
To summarize, although there is evidence of an adverse impact on quality of life
with EGFRI therapy, improvement in quality of life has also been documented, possibly
reflecting changes in health status and relief of disease-related symptoms resulting from
successful treatment. In addition, the various targeted therapies may exert differing
impacts on quality of life (Joshi et al., 2010), and variations in the measurement strategy,
such as the specific quality of life instrument used in each study, may also play a role in
these inconsistent results. However, it can be concluded that quality of life is among the
most important patient-reported outcomes. A large study exploring content validity of a
quality of life in lung cancer patients revealed that quality of life, independence and
performance, rather than physical symptoms, were ranked as most concerning by
patients (Gralla, Hollen, Msaouel, Davis, & Petersen, 2014).
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EGFRIs and functional status. Functional status, or performance status, has
been described as the ability to engage in the performance of normal daily activities
required to address basic needs, to engage in role performance, and to maintain health
and well-being (Leidy, 1994; Wilson & Cleary, 1995). The capacities to ambulate, to
function in chosen roles, and to work are all activities that fall within the realm of
functional status.
In symptom cluster research, the available evidence suggests that the more
numerous and severe symptoms are, the greater the impact on functional status (Dodd,
Miaskowski, et al., 2001; Given et al., 2001; Gift et al., 2004; Barsevick, Dudley, &
Beck, 2006; Chen & Tseng, 2006; Fox & Lyon, 2006; Chen & Lin, 2007; Chow, Fan,
Hadi, & Filipczak, 2007; Fox et al., 2007; Fox & Lyon, 2007; Ferreira et al., 2008; Hadi.
et al., 2008; Dodd, Cho, Cooper, & Miaskowski, 2010; Ryu et al., 2010; Tsai, Wu, Chiu,
& Chen, 2010; Dodd et al., 2011; Roiland & Heidrich, 2011; Kim, Barsevick, Beck, &
Dudley, 2012). Although functional status has not been studied extensively with
EGFRIs, several authors reported that activities of daily living and social activity were
affected by EGFRI treatment (Joshi et al., 2010; Boers-Doets et al., 2013).
EGFRIs and psychological status. While most people treated for cancer have
normal psychological functioning (Kornblith, 1998), a significant number of patients can
experience distress and other disruptions of psychological status, with estimates of 29 to
43 percent of patients experiencing such distress (Zabora, Brintzenhofe Szoc, Curbow,
Hooker, & Piantadosi, 2001). A cancer diagnosis, cancer treatment, and living with the
associated life changes can both generate distress and exacerbate existing psychological
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issues (Adler & Page, 2008). In general, patients undergoing cancer therapy are at risk for
distress and disruption of psychological well-being (Fox & Lyon, 2006, 2007), and
patients with severe symptoms are at risk for concurrent psychoneurologic symptoms
(Kim, Barsevick, Beck, et al., 2012).
The logically consistent conclusion relating rash to psychological distress may not
be so clear cut. Paradoxically, development of rash was perceived by some patients as a
sign of hope and effectiveness of therapy, reflecting the suggested correlation of the rash
occurrence to treatment effectiveness. In fact, in patients receiving erlotinib, there is
evidence to suggest that skin rash is associated with improved response and survival time
(Pérez-Soler et al., 2004; Wacker et al., 2007); similar findings have been reported with
cetuximab, panitumumab, and gefitinib (Lacouture, et al., 2011).
In patients receiving EGFRI therapy, psychologic distress was reported in 41% of
Italian patients receiving cetuximab for advanced colon cancer (Romito et al., 2010), but
when compared to an instrument validation sample, there were no significant differences
found (p = 0.583). While the impact of EGFRI-related symptoms on psychological wellbeing is presumed, patients did not rate items related to social function as highly
important to quality of life as often as clinical experts did in instrument development
work for the EGFRI-18 (Wagner, 2007); rather, patients ranked social well-being items
as less distressing than items affecting physical and functional well-being. However, in
open-ended interviews, items reflecting an impact on social well-being were identified by
patients as being somewhat important. The ambiguity around patient ratings of items that
impact quality of life related to EGFRI therapy, as well as the lack of congruence
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between the ratings of patients and professionals, warrants further exploration (BoersDoets et al., 2013).
Research Related to Influencing Factors and EGFRI Therapy
The following discussion summarizes available research related to the influencing
factors of age and gender, both with respect to symptoms in general, as well as to
symptoms associated with EGFRI therapy.
Age. It has been suggested that in patients with advanced cancer, symptom
severity for common symptoms decreases with age (Kirkova, Rybicki, Walsh, & Aktas,
2012), and older patients had lower occurrence rates for many symptoms, as well as
lower severity, frequency, and distress ratings for some symptoms when compared to
younger patients (Cataldo et al., 2013). However, a recent study comparing cancer
patients in various older age groups (60-69, 70-79, and 80-89) with regard to
psychological and somatic symptoms suggests that the impact of age on the symptom
experience may not be linear, with the 70-79 year old group reporting the lowest scores
for depressive, anxiety and somatic symptoms, while those 80 and older reported the
highest (Cohen, 2014), suggesting that comorbidities may be related to symptom severity
in older patients. The relationship between age and the symptom experience demands
further study as findings have also varied with specific symptoms, with fatigue and
drowsiness more common in younger patients (Cheung, Le, Gagliese, & Zimmerman,
2011).
The overall impact of age on EGFRI-related symptoms in oncology patients also
requires further study, but the literature seems to suggest possible, but inconsistent
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relationships. For example, rash related to erlotinib is more likely to be associated with
age older than 70 (as well as nonsmokers and people with fair skin), while cetuximab
rash is associated with age younger than 70 (Lacouture et al., 2011). In another study,
Jatoi et al. found that men, and those under 70, receiving cetuximab, were more likely to
develop a Grade 3 or 4 rash. Age was further explored by treating it as a continuous
variable, with the subsequent discovery of an inverse relationship between severity of
rash and age. The risk factors of male sex and younger age were described as additive,
with age less than 70 and male sex resulting in an 8% risk of rash (Jatoi et al., 2009, p.
122). However, two studies specifically designed to explore the impact of age on
cetuximab- and erlotinib-related rash did not find it to be a predictor of appearance,
duration and grade of the rash (Giuliani & Marzola, 2013a, 2013b), although the age cutoff was 65 (as opposed to 70 in other studies), and the sample sizes were small.
Jatoi et al. (2009) suggested that the purported less dramatic dermatologic toxicity
in the older patient may be a function of fewer epidermal growth factor receptors and
therefore fewer targets for EGFRIs, but it is unclear whether this is true across different
therapies. In fact, no relationship between rash development and various risk factors,
including age and type of therapy, was found in a subsequent retrospective analysis of
over 4,000 patients with a variety of cancer diagnoses (Solomon & Jatoi, 2011).
Inconclusive evidence linking age to rash severity for cetuximab and erlotinib has also
been reported, so much remains to be discovered about this potential relationship
(Giuliani & Marzola, 2013a, 2013b).
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As noted earlier in the discussion of quality of life, age may be a factor with
respect to perceived quality of life. An interaction between age and quality of life has
been reported with the EGFRIs, with patients younger than 50 reporting a greater impact
on QOL than older participants with similar symptom profiles (Jatoi, et al., 2009; Joshi,
et al., 2010).
Gender. The role of gender in the cancer symptom experience is not clear. In
early work in this area, research in lung cancer patients suggested that there was no effect
of gender on symptom scores (Kurtz, Kurtz, Stommel, Given, & Given, 2000); this
finding was similar to the conclusions of other studies (Cooley, Short, & Moriarty, 2003;
Gift et al., 2004; Hoffman, Given, von Eye, Gift, & Given, 2007). However, gender was
found to contribute to distress scores in patients with metastatic cancer, where women
had worse scores for anxiety and appetite (Zimmermann, Burman, & Follwell, 2010), and
to a higher incidence of depression in female patients with colon cancer (Kurtz, Kurtz,
Stommel, Given, & Given, 2002).
Recent work on symptom clusters in advanced cancer has not yielded consistent
findings with respect to gender, most likely because of disparate patient populations and
cancer diagnoses. An increased prevalence of a gastrointestinal symptom cluster in
women has been reported in one study (Jiménez et al., 2011); in another study, women
reported worse nausea scores than men (Cheung et al., 2011). Gender may play a role in
the severity of rash associated with the EGFRIs, as suggested by a preliminary secondary
analysis of 933 stage III colon cancer patients treated with surgery and cetuximab, where
more men than women developed a Grade 3 rash, odds ratio 2.0, 95% CI [1.14–3.88]
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(Jatoi et al., 2009), so the authors speculated about a hormonal influence on rash
development.
Symptoms Experienced by Patients on EGFRI Therapy
In order to provide a basis for understanding the overall symptom experience of
patients who receive EGFRI therapy, which is the major aim of this study, a review of
symptoms caused by these agents is included here. As noted in chapter one, the most
common dermatologic symptoms related to EGFRI therapy include changes in skin such
as rash, xerosis (dry skin), erythema, telangiectasia, hyperpigmentation, and nail and hair
changes.
Rash. The EGFRI-related skin toxicity most frequently reported in the literature
is a papulopustular rash occurring from two to eight weeks after the start of treatment,
with a peak intensity occurring at about four weeks, although there is variability in
patients, among agents, and with respect to dosage and treatment schedule. Often
incorrectly described as acneiform, but more correctly characterized as a folliculitis, the
rash generally appears on the scalp, face (forehead, cheeks, nose and chin), chest, upper
back, shoulders, and behind the ears, all areas replete with sebaceous glands (Segaert et
al., 2009).
The genesis of EGFRI-related rash is not completely understood, but has been
described as inflammation of the pilo-sebaceous follicle (Peuvrel et al., 2012 ) and as a
superficial, predominantly neutrophilic, suppurative folliculitis with disruption of the
epithelial lining (Brodell et al., 2013). The pathophysiology of these changes is related to
disruption of the normal hair cycle and the disruption of normal EGFR activity in the
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basal keratinocytes, with a resultant proliferation of pro-inflammatory cytokines and an
attendant inflammatory response. Although not yet definitive, preliminary evidence
suggests that skin phototype correlates to some extent with rash severity in patients
receiving erlotinib, wherein lower phototypes (i.e. lighter skin that burns more easily
when exposed to sunlight) tend to be more likely to exhibit severe rash (Luu, Lai, Patel,
Guitart, & Lacouture, 2007; Lacouture et al., 2011). However, more research is required
as others have found no correlation with skin phenotype (Joshi et al., 2010). Genetic
changes to the EGFRs may contribute to the occurrence of rash in patients receiving
EGFRIs (Parmar et al., 2013), but other factors may also play a role, with nonsmokers, as
well as patients over the age of 70 more commonly exhibiting rash in patients treated
with erlotinib (Rosen et al., 2013; Balagula & Lacouture, 2014). Conversely, age
younger than 70 has been associated with rash in male patients receiving cetuximab.
Rash is a symptom prevalent across all EGFRIs, with reviews citing an incidence
of 83% in patients receiving TKIs (Curry et al., 2013), and 85-93% in patients on
cetuximab or panitumumab (Molinari, De Quatrebarbes, Andre, & Aractingi, 2005; Curry
et al., 2013). In general, a higher grade rash occurs with greater frequency in patients
treated with monoclonal antibodies (10-17%) in comparison to the small molecule
tyrosine-kinase inhibitors (5-9%) (Lacouture et al., 2011), but studies have included
patients on a variety of therapies, so the impact of each agent is not entirely understood.
Regardless of grade, these adverse effects constitute far more than a nuisance, causing
dose reductions, treatment interruptions, poor adherence, and even infections, all of
which can impact treatment outcomes (Boone et al., 2007).
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In one series, 96 of 138 individuals (69%) who received cetuximab, panitumumab
(MOABs) or erlotinib (a TKI) developed a rash (Solomon & Jatoi, 2011), consistent with
findings in another study where 65% experienced papulopustular rash (Chan & Tan,
2011). This trend was confirmed by a subsequent meta-analysis of 13 studies reporting
EGFRI-related rash that revealed an overall risk difference of 74% for all rashes, and
12% for Grade 3 and 4 rashes in patients receiving cetuximab and panitumumab when
compared with those on non-EGFRI therapy (Mittman, 2011).
A literature review assessing severe (Grade 3-4) folliculitis, when focused on an
analysis of lung cancer patients, demonstrated a greater incidence with cetuximab (9%)
and erlotinib (8%) in comparison to gefitinib (2%) (p < .0001) (Bachet et al., 2012),
suggesting a comparable rate of rash between a TKI and a MOAB, as well as a
differential impact between two TKIs. These findings confirm earlier work documenting
that in the small molecule kinase inhibitors, rash was reported in 44% of patients
receiving gefitinib, with an expected higher incidence of 49-75% in patients receiving
erlotinib (Lacouture, Mitchell, et al., 2010). Mild rash and acneiform lesions were
reported in 73% of patients on afatinib, with a grade 3 rash seen in about 13% (Lacouture
et al., 2013). In addition, palmar-plantar erythrodysesthesia was reported in 7% of
patients on afatinib, and bullous, blistering lesions have also been reported.
Xerosis. Dry skin, or xerosis, develops after several weeks in some patients
taking EGFRIs, and virtually all patients receiving these therapies for six months will
develop this cutaneous manifestation, which can evolve into a chronic form of eczema.
A further complication associated with xerosis is infection and inflammation, as the
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barrier protection of the skin is compromised. Painful fissures of the fingertips and on
the feet have been described (Osio et al., 2009; Segaert et al., 2009).
Nail changes. Nail changes occurred in approximately 10-15% of patients treated
with EGFRIs after four to eight or more weeks of treatment (Osio et al., 2009; Becker,
van Wijk, Smit, & Postmus, 2010; Lacouture, Maitland, et al., 2010). In a meta-analysis
(n = 2107) of EGFRIs and nail toxicity, the overall incidence reported was 17.2%, 95%
CI [13.8%, 21.3%], with a risk of high grade nail toxicity suggested to be relatively small
at 1.4%, 95 CI [0.9%, 2.1%] (Garden, Wu, & Lacouture, 2011). No statistically
significant difference in nail changes were noted among the EGFRIs included in the
meta-analysis, suggesting a general effect of EGFRI inhibitors on keratinocytes in the
vicinity of the nail (Garden et al., 2011).
Nail fold inflammation (paronychia) often involves the great toe, although other
toes, as well as fingernails, are often affected. Granuloma-like lesions may result in nail
bed inflammation and onycholysis (described as a loosening or separation of the nail
plate from its supporting structures), although this occurs rarely (Stevenson & El-Modir,
2011). Onychodystrophy, or nail malformation, as well as slower nail growth and nail
brittleness, have also been described.
Hair changes. EGFRI treatment that spans from seven to ten weeks or longer has
been linked with an array of hair growth changes. Trichomegaly, which describes curly,
long, and rigid eyelashes, and trichiasis, or misdirected eyelashes, as well eyebrow
overgrowth, can develop following long-term treatment with EGFRIs. Interestingly, scalp
alopecia also may occur, and both frontal and total alopecia, as well as scarring alopecia
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have been reported (Pongpudpunth, Demierre, & Goldberg, 2009). Other hair
abnormalities, such as facial hypertrichosis in women, reduced facial hair growth in men,
loss of hair on arms and legs, and changes in texture, color, and overall manageability of
hair have been documented (Segaert & Van Cutsem, 2005; Osio et al., 2009;
Pongpudpunth et al., 2009; Segaert et al., 2009; Balagula, Lacouture, & Cotliar, 2010).
Ocular toxicities. About one third of patients receiving EGFRIs experience
ocular reactions (Basti, 2007), most commonly blepharitis and dysfunctional tear
syndrome (i.e. dry eye) (Borkar, Lacouture, & Basti, 2013), but also including
iridocyclitis, and corneal epithelial defect, as well as conjunctivitis, meibomitis and
periocular skin changes (Fraunfelder & Fraunfelder, 2012).
Pruritus. A meta-analysis of studies including many different targeted therapies
found an incidence of 17.4% all-grade pruritus (Ensslin et al., 2013). An early theory
accounting for the pathophysiology of pruritus or itching is the accumulation of mast
cells in the skin tissue, as demonstrated in a small sample of patients treated with
erlotinib (Gerber et al., 2010).
Associated mucocutaneous symptoms. Depending on the specific agent,
EGFRIs may also cause mucocutaneous symptoms such as erythema, flushing, radiation
dermatitis, balanitis, hyposalivation, mucositis and taste changes (Osio et al., 2009;
Lacouture, Maitland, et al., 2010; Katakami et al., 2013).
Other symptoms. Other symptoms reported to occur with EGFRIs include
anorexia, fatigue, nausea (Ross et al., 2010), insomnia, anxiety (Wagner & Lacouture,
2007), electrolyte imbalances and diarrhea (e.g. erlotinib and afatinib) (Hirsh, 2011;
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Katakami et al., 2013), infusion reactions (e.g. cetuximab) (Ouwerkerk & Boers-Doets,
2010), interstitial lung disease and associated pulmonary symptoms, (Nguyen & Neal,
2012; Katakami et al., 2013), and pain (Wong et al., 2010).
Gaps in the Literature
The purpose of the current study was to describe the symptom experience of
patients receiving EGFRIs and to explore their impact on performance, including quality
of life, functional status and psychological status. The symptom experience of the patient
undergoing EGFRI therapy has not been fully described, and concurrent symptoms or cooccurring symptoms associated with these targeted therapies have not yet been
systematically explicated in the nursing literature. Most of the EGFRI symptom-oriented
literature published to date focuses on specific aspects of EGFRI therapy, such as the
dermatologic effects of these agents (Garden et al., 2011; Wu et al., 2011; Ensslin et al.,
2013; Urban & Anadkat, 2013); hypersensitivity or infusion reactions (Lenz, 2007); or
reflects the grading of toxicities as in clinical trials. No nursing studies exploring
symptoms or symptom clusters associated with EGFRIs have been published at this
writing, and none explore the impact of EGFRIs on outcomes.
The symptom experience resulting from treatment with these agents, as well as
from a diagnosis of cancer, includes an array of symptoms that go beyond skin, hair and
nails changes, and may affect quality of life, functional performance and psychological
status, so gaps in knowledge on this topic remain. The current health care environment
requires that care be delivered as cost-effectively as possible. Proactive identification and
treatment of high incidence symptoms should be implemented whenever possible in order
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to enhance the effectiveness and efficiency of care processes, but even more importantly,
to helpp maintain and improve every patient’s quality of life, psychological status and
functional performance.

Figure 1. Revised Theory of Unpleasant Symptoms Model
Reprinted with permission. Lenz, E. R., Pugh L.C., Milligan, R. A., Gift A. &
Suppe, F. (1997). The middle
middle-range
range theory of unpleasant symptoms: an update.
Advances in Nursing Science, 19
19(3): 14-27.
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Figure 2. Application of the Theory of Unpleasant Symptoms

CHAPTER THREE
METHODS
The purpose of this cross-sectional descriptive study was to describe the symptom
experience of patients receiving any currently available FDA-approved epidermal growth
factor receptor inhibitors (EGFRIs) (such as erlotinib, gefitinib [continuing patients],
afatinib, lapatinib, cetuximab and panitumumab) as part of their cancer therapy, which
could include those diagnosed with breast, colorectal, head and neck, lung, and pancreatic
cancers.
Specific Aims
The specific study aims were to:
1. Describe the symptom experience (symptom frequency and distress) of
patients receiving EGFRI therapy.
2. Describe the quality of life, functional performance and psychological status
of patients receiving EGFRI therapy.
3. Identify any co-occurring symptoms or symptom clusters in patients receiving
epidermal growth factor receptor inhibitors.
4. Explore the relationships between any identified symptom clusters and key
variables, including gender, age, primary cancer, EGFRI, and the outcome
variables of quality of life, functional performance and psychological status.
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Design and Setting
A cross-sectional, descriptive, correlational design using primarily a web-based
format (with an option for paper format) has been used for this study. Because EGFRI
therapy is appropriate for only a small percentage of patients with breast, colorectal, head
and neck, lung, and pancreatic cancers, recruitment for this study included several
strategies designed to reach a large potential volunteer pool. See Figure 3 for a graphical
depiction of recruitment strategies. In order to achieve an optimal sample size, direct
recruitment of participants from online support sites and patient support communities, as
well as indirect recruitment of participants through health care providers, was
implemented. The goal was to achieve a sample size of 100.
Recruitment Procedures
1. Indirect recruitment.
Letters describing the study were sent to health care providers, including
oncologists and oncology nurses, from Illinois, Wisconsin and Indiana.
Descriptive flyers providing information about study participation and
eligibility criteria were included in the mailing for distribution to potential
participants. Mailing lists were purchased for this purpose, and approximately
3000 first-class mailings were sent to members of these lists.
2. Direct recruitment through health care settings.
Following initial Institutional Review Board (IRB) approval at Loyola
University Health System, additional IRB permission was sought at another
health care system and at Northwestern University (NU). The Northwestern
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IRB reviewed the Loyola IRB determination and the study protocol and did
not require a separate submission to the NU IRB. Clinicians at NU agreed to
share the flyers with patients who might be eligible, so flyers were supplied
for this purpose.
3. Direct recruitment through patient support settings.
Participants were also recruited from patient support organizations in the
Midwest. Flyers were posted at patient support centers in The Cancer Health
Alliance, including Wellness Place (Palatine), Wellness House (Hinsdale),
Cancer Wellness Center (Northbrook), The Cancer Support Center
(Homewood and Mokena), Living Well Cancer Resource Center (Geneva),
and also at Gilda’s Club (Chicago) and at the Rush University Medical Center
Gilda’s Club site. Flyers were made available at a Breathe Deep LUNGevity
community event.
4. Direct recruitment through online support groups.
Informational flyers, web site links, or study descriptions (depending on what
was allowed by site administrators) were posted on the web sites of a variety
of online patient support groups. Information was posted on the Cancer
Support Community, Colon Cancer Alliance, Inspire.com, Lung Cancer
Alliance, LUNGevity Foundation, Metavivor.org, Pink-Link.org, National
Lung Cancer Partnership, Navigating Cancer and Blood Disorders, and the
Pancreatic Cancer Action Network Survivors Network. Postings were also
shared via social media to reach a broader audience. Despite positive
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responses to initial queries about posting these announcements, many other
sites ultimately opted not to post study announcements, citing their own
research agenda, changes in policy about posting third party requests, inability
to evaluate research requests, and their desire not to inundate participants with
such requests. Many site administrators simply never responded to repeated
email requests. Using a similar strategy, one researcher reported receiving
300 responses and 135 usable data sets from participants who responded to a
study announcement on an online support group web site (e.g. LUNGevity) (J.
Cataldo, personal communication). In another study, a mailed survey about
symptoms and quality of life sent to 140 members of an online support group
of brain tumor patients generated a 52% response rate (Fox et al., 2007), but
specific mailing lists such as this were not available for this study.
5. Direct recruitment through study web site.
For all potential volunteers, an informational web site was available, and
participants originally were able to contact the researcher by phone or email if
they had questions about the study.
The original procedure required potential participants to contact the researcher to
be screened for eligibility. However, the procedure requiring contact with the
investigator was in place only for the first few months of recruitment. After several
months of recruitment activities with a low accrual rate (8 participants), and in order to
facilitate more rapid recruitment, a direct link to the study and screening questions was
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provided on a study web site and was updated at patient support communities after
consultation with the IRB and the doctoral advising committee.

Figure 3. Direct and Indirect Study Recruitment
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Sample
The sample for this study included participants receiving EGFRIs who responded
to online or other posted announcements at support sites, or who were told about the
study by their health care provider.
Inclusion criteria were as follows:
1. Treatment with an EGFRI (either a MOAB or a TKI) for at least four weeks.
These agents include afatinib (Gilotrif®), erlotinib (Tarceva®), gefinitib
(Iressa®) (continuing patients), lapatinib (Tykerb®), and the monoclonal
antibodies cetuximab (Erbitux®) and panitumumab (Vectibix.)
2. Ability to speak, read, write and understand English.
3. Age 18 years or over.
4. Ability and willingness to consent to participate in the study.
5. Ability and willingness to complete study activities, including completion of
required questionnaires online, or by completion of paper instruments.
Exclusion criteria were as follows:
1. Patients who self-reported significant dermatologic disease unrelated to cancer
treatment, such as severe acne vulgaris, erythema multiforme, psoriasis or
rosacea.
2. Patients with a poor performance status unable to complete the survey
instruments, which required 20-30 minutes to finish.
Participants responded to the following item which included the first exclusion
criteria: “I do not have one of the following skin conditions: acne vulgaris, erythema
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multiforme, psoriasis or rosacea.” The second exclusion criteria would have resulted in
patients not completing the survey, so submission of the survey assumes adequate
performance status.
Sample Size Calculation
Aims 1 and 2 were descriptive and did not require sample size calculation. Aim 3
required factor analyses for identification of symptom clusters or co-occurring symptoms,
and will be discussed further below. Sample size calculation for Aim 4, assuming a
medium effect size and a power of 0.8 at a 0.05 level of significance, ranged from 85-92
with 5 variables included in the model. If an additional two variables were entered, to
total 7, required sample size would increase to 103-104 (Newton & Rudestam, 1999), so
the initial proposed sample size was 100.
Sample Size for Factor Analysis
Sample size for this study, however, was primarily driven by the use of
exploratory factor analysis for deriving symptom clusters as described in Aim 3. Power
analysis is not used to generate a sample size for factor analysis, and there is no standard
method for calculation of an appropriate sample size.
Factor analysis procedures traditionally have been thought to require a large
sample size, but opinions vary regarding ideal sample sizes for factor analytic procedures.
Although several rules of thumb governing sample size for factor analysis appear in the
literature, stringency in their application has diminished. Traditional practice has
suggested that in order for factor analysis results to be reliable, they must be generated
from very large samples (i.e. at least several hundred up to 1000), or that sample size
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should range from 2-10 times the number of variables (Kline, 2002; Costello & Osborne,
2005; Mundfrom, Shaw, & Tian, 2005). Kline (1994) argued that the ratio of subjects to
factors should be a consideration when determining sampling adequacy, with a goal of
accruing more than 20 subjects for each factor. Ideally, a larger sample size is preferred,
but an efficient solution can result from more modest sample sizes.
The actual characteristics of the data have emerged as an important influence on
sample size (MacCallum, Widaman, Zhang, & Hong, 1999; Costello & Osborne, 2005).
The number of variables and their associated loadings constitute one important element
when considering results of a factor analysis. Stevens (2002) suggested that a factor is
reliable when one of the following conditions are met: 3 or more variables, with any n
and loadings of 0.8; 4 or more variables, with any n, and loadings of 0.6; 10 or more
variables with loadings of 0.4 and n larger than 150; factors with only a few loadings
require a sample size greater than 300 (p.395).
Other characteristics of the data, including high communalities (greater than 0.6),
overdetermination, and simple, non-overlapping factor structures, are more relevant to
the determination of an adequate sample size than just the number of variables
(MacCallum et al., 1999). Communality (h 2) reflects the percent of variance for a given
variable that is accounted for by all identified factors, and is the sum of squared loadings
across factors for that variable. When communalities are greater than 0.6, a sample size
of less than 100 may be adequate. When communalities are lower, a sample size of at
least 100 is preferred. Overdetermination, which occurs when each factor has several
high loadings, also may mitigate the need for a larger sample size. In research designed
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to test the stability of factor solutions, samples meeting the characteristics of high
communalities and a desirable level of overdetermination maintained factor structures
with a sample size as low as 60 (MacCallum et al., 1999). Mundfrom et al. (2005)
extended this work with similar samples and found adequate factor solutions with sample
sizes of 35-75. With a fairly simple factor structure, such as the one derived in the
current study, it has been noted that a sample size of 50-100 would be acceptable
(Darlington, n.d.).
Large sample sizes have generally been recommended as a strategy to overcome
measurement error. In the clinical setting, however, it has been argued that patients
symptom reports may so accurate that larger samples are not necessary (Olson, Hayduk,
& Thomas, 2014).
Statistical Analysis
Descriptive statistics, correlations, exploratory factor analysis, cluster analysis
and multiple regressions were used in this study. Data analysis was performed using
IBM Statistical Package for the Social Sciences (SPSS Version 22). Descriptive statistics
were generated for the following variables: age, educational level, gender, marital status,
primary cancer diagnosis, stage of disease, and tobacco use. Descriptive statistics for
symptom frequency, symptom distress, quality of life, EGFRI-related quality of life,
MSAS-SF (adapted), performance status and psychological status are reported.
A variety of statistical approaches have been employed to generate symptom
clusters, such as correlations, structural equation modeling, factor analysis, principal
component analysis and cluster analysis. Factor analysis based on Pearson correlation has

56
demonstrated stability in the identification of symptom clusters from different
measurement tools (Miaskowski et al., 2007; Henoch, Ploner, & Tishelman, 2009), so
exploratory factor analysis was selected as the primary method to identify symptom
clusters in the present study. A scree plot, eigenvalues, the Kaiser-Meyer-Olkin test and
Bartlett’s test of sphericity were examined to determine the adequacy of the factor
structure.
Factor analysis explores a given set of variables to determine if they possess an
underlying latent structure which can be used to explain correlations among the variables.
Kline describes a factor as a “dimension or construct which is a condensed statement of
the relationships between a set of variables” (Kline, p. 5). Royce (1963), as quoted by
Kline, stated that “a factor is a construct operationally defined by its factor loading”
(Kline, p. 5). Factor loadings are described as the relationships or correlations of a
variable with a factor (Kline, 1994). Correlation coefficients for factor loadings can
range from -1 to 1.0 (Johnson & Wichern, 2002).
Hierarchical cluster analysis was also used to confirm the symptom clusters.
Hierarchical cluster analysis procedures do not require a specific sample size as they are
an exploratory approach “without an inferential test” (Kim, Barsevick, Beck, et al.,
2012). Hierarchical cluster analysis has been used in other studies on symptom clusters,
so reexamining symptoms with this approach provides some additional support for the
clusters identified via factor analysis with the relatively small sample available in this
study (Hockenberry, Hooke, McCarthy, & Gregurich, 2011; Chen, Nguyen, Cramarossa,
et al., 2012; Chen, Nguyen, Khan, et al., 2012).
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Correlations and multivariate procedures were employed to explore the
relationships between the symptoms, the derived symptom clusters and the dependent
variables of performance status, psychological functioning and quality of life, as well as
any differences by age, gender, treatment or disease.
Instruments
The instruments selected for data collection include are listed in Table 1 and are
discussed below.

Table 1. Model Components, Variables and Measures
Model Component

Variable

Measures

Influencing Variables

Age
Gender
Primary Diagnosis
Specific EGFRI

Demographic tool

Symptoms

Symptoms
Symptom clusters

MSAS-SF (ADAPTED)

Performance

Functional performance
Psychological status
Quality of life
Dermatologic QOL

ECOG PS
MHI-5
FACT-G
FACT-EGFRI-18

Note. EGFRI: epidermal growth factor receptor inhibitor; MSAS-SF (adapted):
Memorial Symptom Assessment Scale- Short Form; ECOG PS: Eastern
Cooperative Oncology Group; MHI-5: Mental Health Index-5; FACT-G: Functional
Assessment of Cancer Therapy-General; FACT-EGFRI-18: Functional
Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18
Subscale: QOL: Quality of Life.
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Memorial Symptom Assessment Scale (MSAS-SF) (adapted)
The Memorial Symptom Assessment Scale-SF (MSAS-SF) was selected for this
study because it offers the most comprehensive cancer symptom inventory available,
measures symptoms along several dimensions, and has established psychometric
properties (Kim et al., 2009b). The original long form MSAS was developed to measure
the frequency, severity and distress of 32 symptoms associated with a cancer diagnosis,
and has established psychometric properties (Portenoy et al., 1994a; Portenoy et al.,
1994b; Portenoy et al., 1994c). The MSAS-SF is a modified version of the instrument
which also measures 32 symptoms; distress and frequency are measured for 28 physical
symptoms while frequency is measured for four psychological symptoms (Chang,
Hwang, Feuerman, Kasimis, & Thaler, 2000). The MSAS-SF was used in this study
instead of the longer original version in order to reduce response burden. Both versions of
the instrument contain blank spaces to allow for the addition of symptoms not included
on the tools, so the MSAS-SF has been adapted for this study to include additional
symptoms prevalent in this patient population. Items added to the scale included changes
in my fingernails or toenails, other changes to my fingers and toes, dry skin, changes in
hair growth on my face, changes to my eyelashes, and other changes to scalp hair.
Scoring. The scoring of the MSAS-SF is different than the original MSAS
scoring. Physical symptoms are rated with regard to the degree of distress they cause.
Participants select from the following descriptors for every physical symptom they
endorse: “no distress,” “a little bit of distress,” “somewhat distressing,” “quite a bit of
distress,” and “very much distress.” These descriptors are then coded and scored as
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follows. If a symptom is not present, it is scored as a 0. If it is present, and causes no
distress, it is scored as a 0.8., if it causes a little bit of distress, the score is 1.6, if it is
somewhat distressing, the score is 2.4, if there is quite a bit of distress, it is scored at 3.2,
and if a symptom is associated with very much distress, the score is 4.0
Psychological symptoms are rated in terms of prevalence: “rarely,”
“occasionally,” “frequently,” and “almost constantly.” Participants select one of those
descriptors for every psychologic symptom they endorse. When symptoms are present,
the scoring is as follows: 1 if the symptom is present but occurs rarely; 2 if the symptom
is present and occurs occasionally; 3 if the symptom is present and occurs frequently; and
4 if the symptom is present and occurs almost constantly. The two scoring methods
reflect the distress associated with the symptom for physical symptoms and the
prevalence of the symptom for psychological symptoms. Subscales for physical (PHYS)
and psychological (PSYCH) symptoms, as well as a global distress index (GDI), can be
generated from the MSAS but were not included in this study because additional items
were included as symptoms. Future work could explore this aspect of the scoring.
Reliability and validity. The original, condensed, and short forms of the MSAS
have been used to measure symptoms in multiple studies in oncology (Chang et al., 2000;
Kris & Dodd, 2004; Gwede, Small, Munster, Andrykowski, & Jacobsen, 2008 ; Kim et
al., 2009b; Kim et al., 2009a; Molassiotis, Wengstrom, & Kearney, 2010; Webber &
Davies, 2011; Cataldo et al., 2013; Oksholm et al., 2013; Kenne Sarenmalm, Browall, &
Gaston-Johansson, 2014; Miaskowski et al., 2014; Ritchie et al., 2014). MSAS tools have
also been used to measure symptom clusters in in other patient populations, despite the
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original purpose as an oncology symptom inventory. Representative studies of nononcology patients include nonalcoholic fatty liver disease (Houghton-Rahrig et al.,
2013), heart and lung disease (Blinderman, Homel, Billings, Portenoy, & Tennstedt,
2008; Song, Moser, Rayens, & Lennie, 2010; Strada, Homel, Tennstedt, Billings, &
Portenoy, 2013), and HIV (Aouizerat et al., 2010).
MSAS-SF psychometrics. In a sample of 299 cancer patients, the Cronbach
alpha coefficient, assessing internal reliability, ranged from 0.76 to 0.87 in repeated
administration of the MSAS-Short Form (Chang et al., 2000). Subscales of the FACT-G,
the Karnofsky Performance Status, and extent of disease served to establish criterion
validity and convergent validity for the MSAS-SF. Repeatability was evaluated by a testretest measurement at one day (0.86 to 0.94) and one week (0.40 to 0.84).
Correlation coefficients were reported to be in the appropriate direction for the
subscales of the MSAS-SF and for the FACT-G: r = -0.74 (p < 0.001) for the PHYS and
FACT-G physical well-being subscales; r = -0.68 (p < 0.001) for the PSYCH and FACT
emotional well-being subscales, and r = -0.70 (p < 0.001) for the GDI and FACT total
QOL subscales. MSAS scores reflecting a higher symptom burden would be larger, while
FACT-G scores reflecting a good quality of life would also be higher, explaining the
negative correlation.
FACT-G
In the present study, the FACT-G was used as a global measure of quality of life.
The FACT-G (Functional Assessment of Cancer Therapy-General) Version 4 is 27-item
questionnaire with well-established reliability and validity that measures quality of life
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across four domains: physical well-being (PWB), social and family well-being (SWB),
emotional well-being (EWB) and functional well-being (FWB) (Cella et al., 1993;
Webster, Odom, Peterman, Lent, & Cella, 1999). The FACT-G can be self-administered
or scored by an interviewer and can be completed in 5-10 minutes (Danhauer et al.,
2007). An item related to sexuality was not included in the present study as a similar
question about problems related to sexuality was asked on the MSAS-SF. Two
participants did not complete all items on the FACT-G Social Well-Being (SWB)
subscale, and one did not complete all items on the Functional Well-Being (FWB)
subscale, so these were scored in accordance with the procedure outlined for missing
data.
The FACT instruments have been widely used in the oncology population, and
are applicable across various cancer diagnoses. The FACT-G correlated well with most
subscales of the SF-36, and it discriminated between patients with cancer and community
dwelling elders (p < 0. 002) (Overcash, Extermann, Parr, Perry, & Balducci, 2001).
Scoring. All items are scored from 0-4, anchored at “not at all,” with a score of
zero, “a little bit,” “somewhat,” “quite a bit,” to “very much.” Some items are scored
straightforwardly, but negatively worded items are reverse scored, and all items are then
summed to obtain a subscale or total score. Higher scores indicate a better quality of life.
A total score is calculated as the sum of all four subscales, given that 80% of items have
been completed, resulting in a total score for all items that can range from 0-108 points.
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FACT-EGFRI 18
In order to more fully characterize the quality of life of patients receiving
EGFRIs, the Functional Assessment of Cancer Therapy-Epidermal Growth Factor
Receptor Inhibitor (known as the FAST-EGFRI-18 or FACT-EGFRI 18) was also used in
the present study. The EGFRI-18 is a self-report tool that was recently developed to
describe the impact of 18 EGFRI-related skin, nail and hair toxicities on the four
dimensions of quality of life incorporated in the Functional Assessment of Cancer
Therapy (FACT) instruments. This instrument provides additional condition-specific
quality of life assessment and is a companion module to the core FACT-G items.
As is customary with the construction of these additional modules, the developers
used a triangulation method, including literature review, qualitative data collection via
patient (n=20) and expert panels (n=12), and quantitative surveys, on candidate items in
order to generate the items for the EGFRI-18 (Wagner & Lacouture, 2007; Wagner et al.,
2010; Wagner et al., 2013). The initial version of the EGFRI-18 incorporates 18 items
assessing the effect of skin, nail and hair treatment-related symptoms on quality of life.
Although there are other dermatology quality of life instruments (e.g. Skindex
instruments) (Chren, Lasek, Quinn, & Covinsky, 1997), they were not specifically
designed to address the dermatologic toxicities associated with EGFRI therapy. The
authors developed this tool in response to a lack of EGFRI standardized patient-reported
outcome measures (Wagner et al., 2013), so for this reason it was selected for the present
study.
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As this is a newer tool, psychometric properties have not yet been published, and
a large cooperative group study is currently underway to validate this questionnaire in
patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib
(S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With
Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib
Hydrochloride, 2013), but no data has been reported yet.
Mental Health Inventory-5 (MHI-5)
Psychological functioning was operationalized by the mental health subscale (also
known as the MHI-5, and referred to as such in this study), which is a 5-item
questionnaire designed to assess for mental health concerns. The Mental Health Inventory
(MHI-5) has been validated as a simple tool for as a measure of general mental health and
for detecting depressive symptoms and anxiety in both a healthy population and in those
with a variety of chronic illnesses, including cancer (Ganz et al., 2003).
Respondents answer questions about their psychological well-being selecting
responses of “all of the time,” “most of the time,” “some of the time,” “a little bit of the
time,” and “none of the time.” The MHI-5 was recently evaluated in oncology patients
and was found to be brief, simple to administer, and easy for patients with a sixth to ninth
grade reading level to understand (Johns et al., 2013). The items were scored and
transformed to a scale ranging from 0 to 100, with a higher score indicating a more
optimal level of functioning. Evaluation of the MHI-5 as a screen for psychological
function revealed areas under the curve of 0.739 for anxiety disorders to 0.892 for major
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depression (Berwick et al., 1991), and 0.73 for some anxiety disorders, such as
generalized anxiety disorder (Cuijpers, Smits, Donker, ten Have, & de Graaf, 2009).
Eastern Cooperative Oncology Group
Performance Status (ECOG PS)
In this study, functional status is measured by the ECOG Performance Status
scale. Performance status scales such as the ECOG PS assess the impact of illness on the
activities of daily living and overall functional well-being. The ECOG PS quantifies a
continuum of self-care and activity, ranging from fully active and able to perform all
normal activities, to unable to perform self-care and completely disabled. In the clinical
trials and treatment setting, functional or performance status is typically scored by the
clinician. However, self-rating using the one-item ECOG PS scale has been explored,
and has been described as reasonable since patients are more attuned to their physical
condition than others may be (Ando et al., 2001). The descriptors used for each level of
the ECOG PS are self-explanatory and easily completed by patients. For example,
patients in the process of being diagnosed with lung cancer produced reliable ratings of
performance status, so the researchers concluded that patients could viably assess their
own performance status (Blagden, Charman, Sharples, Magee, & Gilligan, 2003).
In a study exploring whether performance status could be described by patients
using the Performance Status Visual Analog Scale (PS-VAS), which is a different
instrument, Gralla confirmed that patients were able to rate their own performance status,
and demonstrated adequate correlation between the scale and both the ECOG (r =.43) and
Karnofsky (r =.46) Performance Scales, suggesting that reasonably equivalent
information could be gained from any of these instruments (Gralla et al., 2005).
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The value of patient-reported performance or functional status is highlighted by
studies revealing variations in these scores between patient ratings and health care
provider ratings. One study examined ratings between patients and a variety of clinicians,
reporting that the correlations between patient- and provider-reported ECOG PS scores
varied from 0.51 (patients and registered nurses) to 0.64 (patients and radiation therapy
students as well as physicians), providing evidence of only moderate agreement (de
Borja, Chow, Bovett, Davis, & Gillies, 2004); another also found a lack of congruence in
over half of patient and physician ratings at diagnosis, with patients rating their functional
status as lower than physicians (Dajczman et al., 2008).
Ethical Considerations
Protection of Human Subjects
The Loyola University Medical Center Institutional Review Board (IRB)
classified this study as exempt as no identifiable information was collected. Anonymity
for all study participants was protected. Any study related data, including data input for
analysis, has been maintained in password-protected files managed by the investigator.
Potential risks to participants were minimal, but could include heightened stress due a
greater awareness of potential symptoms attributable to their therapies.
The web-based survey was housed by the software vendor on the secure Qualtrics
web site and all data was time-stamped and encrypted in transmission. Network security
on Qualtrics includes a Transport Layer Security (TLS) encryption connection, firewall
protection, intrusion detection and prevention, and security scans. The vendor is
prevented through confidentiality agreements from accessing or disclosing information in
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the database. Servers are located in a data center with security and environmental controls
and are backed up nightly. All data at rest are encrypted and all deprecated hard drives
where data is stored are destroyed by the United States Department of Defense methods
and delivered to a third-party destruction service (Qualtrics, 2014). A unique identifier
for each response masked each survey response, and no identifying information,
including IP address, was recorded. Survey responses are viewable to the researcher only
via a username and password.
Participants could complete the survey using the device of their choice as the
survey was optimized for mobile formats, and could be viewed on tablets, smartphones or
personal computers. In addition, completion of the instruments took approximately 20
minutes (most completed the online version in approximately 8-15 minutes, although
longer time frames were recorded), and may have taken more time if there were
connectivity or other technical issues. Participants were allowed to start the web-based
survey and return later to complete it if necessary.
For participants completing the web-based survey, eligibility requirement were
presented and then a consent form appeared prior to the study instruments. Participants
reviewed it and checked a statement indicating that they agreed to participate in the study
(“I agree to participate in this study”). Volunteers who agreed to the consent and
affirmed that they met the inclusion criteria advanced to the study questionnaire.
Participants who did not meet the study criteria or who did not agree to participate in the
study received a message thanking them for their time, but indicating that they were not
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eligible to participate. The survey software recorded the consent as part of the
questionnaire.
Participants completing paper surveys checked off the same eligibility and
informed consent prior to study enrollment. In addition, their completion of the survey
return by mail was evidence of their consent. All participants who completed the paper
survey were provided stamped, pre-addressed envelopes for return of the survey to the
investigator. The investigator’s return address was pre-printed on the return envelopes,
and in no case did any participant include their own address or any other identifying
information in the returned surveys. Data from the paper surveys was entered into the
Qualtrics’ site and paper copies were destroyed by the investigator.

CHAPTER FOUR
RESULTS
The present study was designed to explore the symptom experience of patients
receiving EGFRIs, including the identification of symptom clusters, and the impact of
any identified symptom clusters on patient outcomes. The theory of unpleasant
symptoms (TOUS) provided a useful framework from which to explore the symptom
experience in study participants. The TOUS model allowed for the measurement of
distress and frequency of symptoms, and also for evaluation of the impact of symptoms
on patient-reported outcomes, including performance, quality of life, and psychological
status. Findings from the current study can inform future work in this area and can be
replicated in larger and more purposeful samples.
Data Analysis
Statistical procedures included descriptive methods (frequencies, percentages, and
measures of central tendency), Pearson correlations, one-way ANOVA, nonparametric
Mann-Whitney U, independent t-tests, exploratory factor analysis, hierarchical cluster
analysis procedures and regressions. The demographic characteristics of participants are
presented as percentages for age range, gender, educational level, living arrangements
and relationship status. Clinical characteristics, including primary cancer diagnosis, stage
of disease, duration of EGFRI therapy and tobacco use are also reported. ECOG
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Performance Status scores are reported by percentage and frequency. For all scales and
the selected subscales, measures of central tendency were used for analysis. Data
collected using the FACT-G, EGFRI-18, MHI-5, and ECOG Performance Scale were
assessed for normality by examining skewness and kurtosis values, visual inspection of
the Kolmogorov-Smirnov (Ghasemi & Zahediasl, 2012) or Shapiro-Wilk tests of
normality, and deviations from normality are reported. The internal consistency
reliability of each instrument and relevant subscales for the FACT-G were confirmed
using Cronbach’s alpha.
Exploratory factor analysis, using principal axis factoring with an oblique rotation
was used to identify co-occurring symptoms, or symptom clusters. Multiple factor
analyses were run, using various methods and rotations, in order to find the best
solutions. The Kaiser-Meyer-Olkin measure of sampling adequacy, communalities,
Bartlett’s test of sphericity, diagonals on the anti-image correlation matrix, and inter-item
correlation coefficients were examined to determine the appropriateness of the data for
factor analysis.
Because of the small sample size, an alternative approach to deriving symptom
clusters was also implemented. Hierarchical cluster analysis was used as a comparison to
factor analysis, as HCA can be used with small samples. This additional procedure
allowed for comparison of symptom clusters identified using different statistical
approaches.
Independent t-tests, one-way ANOVAs, and non-parametric tests were used to
assess the differences on outcome variables between the identified symptom clusters.
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Variables with statistically significant Pearson correlations with the outcome variables of
quality of life, functional performance and psychological status were included in a forced
entry linear regression model to explore their effect on outcomes. Analyses were
performed using IBM Statistical Package for the Social Sciences (SPSS Version 22).
Sample Characteristics
A total of 56 participants were eligible for inclusion in the study during the
recruitment period and are included in this analysis. Participants were able to complete
the study online or on paper; 44 participants completed online surveys and 12 completed
surveys on paper.
For the online version, a total of 86 participants entered the study site over a ten
month period from June, 2013 to May, 2014, after being directed to the survey site by the
investigator or after directly responding to survey recruitment materials that were posted
on online support groups, on the survey web site, at support group settings or at health
care sites. Of this group, 69 participants completed one or more items. However, 19
failed to respond affirmatively to the study eligibility criteria, and were redirected out of
the study site. In total, 50 participants completed the consent and gained access to the
questionnaire. Six of this group started the survey, but stopped after answering a few
questions, so responses for those participants were largely incomplete and are not
included in the analysis, resulting in a completion rate for the online version of 88%
(44/50 who accessed the questionnaire and were eligible to complete it).
Most participants who completed paper copies had received information about the
study from a nurse (n =11) who had received a study recruitment letter directed to health
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care professionals. One received the paper survey from the investigator after responding
to postings about the survey. Paper copies of the surveys were supplied to participants,
and all of the distributed paper surveys were returned by pre-addressed stamped
envelope, with a completion rate of 100%. The completed surveys were anonymous, and
no identifying information was collected. All paper surveys were completed by
December, 2013.
These procedures resulted in a total of 56 participants who completed most survey
instruments and are included in the data analysis, with a total of 55 who completed all
instruments. One participant did not complete the EGFRI-18, so data is presented for the
participants who did complete these instruments. Overall, a total of 55 participants
completed all measures as procedures for missing data could be applied for the FACT-G.
As the participants were anonymous, there was no follow-up procedure for missing data.
Demographic Characteristics
Demographic characteristics of the sample are presented in Table 2. Nearly twothirds of the participants included in this sample are female. About 10% reported that
they were younger than 50 years of age, with about one-third of patients between 50-59,
and another third between 60-69 years of age. This sample, as might be anticipated in a
study conducted primarily online, appears to be well-educated, with 82% reporting that
they have received a college or graduate degree. The majority of participants (75%) are
married, and a corresponding number of participants live with a spouse (60%) or a spouse
and children (16%). Relationship status and living arrangements for participants in this
sample suggest a significant amount of social and psychological support.
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Table 2. Participant Characteristics (N=56)
Characteristic

Age

Percentage

Characteristic

N

Percentage

Male
Female

20
36

35.7
64.3

30-39
40-49
50-59
60-69
70-79
>80

1
5
18
17
2
3

1.8
8.9
32.1
30.4
21.4
5.4

Elementary
High School
College
Graduate School

0
10
29
17

0
7.9
51.8
30.4

Married
Single
Divorced
Widowed

42
1
10
3

75.0
1.8
17.9
0.4

Live with spouse
Live with spouse and children
Live with children
Live alone
Live with others not listed

33
9
3
10
1

58.9
16.1
5.4
17.9
1.8

Gender

Age

Educational Level

Relationship Status

Living Arrangements

.
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Clinical Characteristics
Clinical characteristics are reported in Table 3. Only two participants (3.6%)
reported receiving radiation therapy concurrent with the study, but 18 of 59 (30%)
indicated that they were receiving other treatments, including various chemotherapy
agents and other drugs, including trastuzumab, carboplatin, 5-fluorouracil, 5-fluorouracil
and carboplatin, cabozantinib, paclitaxel protein-bound and carboplatin, paclitaxel and
carboplatin, capecitabine, zoledronic acid, irinotecan, denosumab, letrozole, exemestane,
and experimental drug MK-2206. A total of nine participants were receiving cytotoxic
chemotherapy, including concurrent carboplatin as a single agent reported by five
participants, trastuzumab reported by four participants, and 5-FU reported by three
participants. The remaining agents listed above were reported by one or two participants,
and several participants were taking multiple agents.
Co-morbidities were reported as follows: eight participants reported a diagnosis
of diabetes; and two reported osteoporosis. A respiratory disorder, a gastrointestinal
disorder, Graves’ disease, Hashimoto’s disease, an unspecified thyroid condition,
hypertension, hemolytic anemia, and rheumatoid arthritis were each reported by one
participant.
More than half of the participants (57%) reported applying a cream that their
health care professional recommended. Sixteen reported using an oral medication, with
seven reporting doxycycline and five reporting minocycline; others reported using an
unspecified antibiotic, nystatin or Zyrtec.
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Tobacco use (smoking) was reported by 7% (n=4) of participants; 0 reported
using other tobacco products. The majority of participants (88%) (N=52) reported that
they did not currently use tobacco products, and 5% (n=3) indicated that they quit using
tobacco products on diagnosis.

Table 3. Clinical Characteristics
Characteristic

N

Percentage

Diagnosis
Breast cancer
Colorectal cancer
Head and neck cancer
Lung cancer
Pancreatic cancer
Unknown

10
7
10
29
0
0

17.9
12.5
17.9
51.8
0
0

Stage I
Stage II
Stage III
Stage IV

1
3
2
50

1.8
5.4
3.6
89.3

afatinib
erlotinib
lapatinib
cetuximab
panitumumab

2
24
10
16
4

3.6
42.9
17.9
28.6
7.1

At least four weeks
More than four weeks
More than eight weeks

5
9
42

8.9
16.1
75

Stage of disease

Educational Level

Therapy duration

Tobacco use
I currently use tobacco products 0
I quit using tobacco at diagnosis 3
I do not currently use tobacco
52

0
5
88
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Study Aim 1
The first aim of this study was to describe the symptom experience (symptom
frequency and distress) of patients receiving EGFRI therapy.
The following discussion will present information from the MSAS-SF in order to
characterize the symptom experience of the participants. Additional information on
identified symptom clusters will be presented in the discussion of Aim 3.
Memorial Symptom Assessment
Scale-Short Form (Adapted)
A total of 38 symptoms were included in the MSAS-SF (adapted), including
several not on the original instrument that are frequently experienced by patients taking
EGFRIs. As listed in Table 4, items added for this study included changes in my
fingernails or toenails, other changes to my fingers and toes, dry skin, changes in hair
growth on my face, changes to my eyelashes, and other changes to scalp hair. As
expected, several of the symptoms added to the scale were retained through factor
analysis, lending support to their inclusion in the adapted tool.
Symptom occurrence. Participants reported a mean of 11.71 symptoms (SD,
5.7; range, 1-28) over the previous week, which is consistent with other studies using the
MSAS (Portenoy et al., 1994a; Chang et al., 2000; Deshields et al., 2011; Ritchie et al.,
2014). Items marked in italics were added to the MSAS-SF for this study. The most
common symptoms included dry skin, lack of energy, dry mouth, changes in skin, feeling
sad, changes to finger or toenails, feeling worried, diarrhea, problems with sexual interest
or activity, changes in facial hair growth, and difficulty sleeping. The most frequently
occurring symptoms in a large heterogeneous sample of oncology patients reported
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similar findings using the MSAS, with lack of energy, difficulty sleeping, problems with
sexual interest or activity, pain, and feeling drowsy the most frequently endorsed
symptoms in the overall sample (Deshields et al., 2011).
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Table 4. Symptom Occurrence (N=56)

Dry skin
Lack of energy
Dry mouth
Changes in skin
Feeling sad
Changes to my finger or toe nails
Worrying
Diarrhea
Feeling drowsy
Problems with sexual interest or
activity
Changes in hair growth on my face
Difficulty sleeping
Feeling nervous
Numbness/tingling in hands/feet
Feeling irritable
Changes in the way food tastes
Other changes to the hair on my scalp
Changes in my eyelashes
Hair loss
Difficulty concentrating
Itching
Cough
Weight loss
Pain
Lack of appetite
Nausea
Shortness of breath
Other changes to my fingers or toes
Mouth sores
Constipation
"I don't look like myself"
Difficulty swallowing
Dizziness
Sweats
Feeling bloated
Vomiting
Problems with urination
Swelling of arms and legs

Percentage

N

67.9
65.5
57.1
55.4
53.6
53.6
50
48.2
46.4

38
36
32
31
30
30
28
27
26
25

44.6
44.6
44.6
42.9
42.9
41.1
39.3
39.3
37.5
37.5
35.7
33.9
32.1
32.1
30.6
30.4
28.6
26.8
25
25
21.4
21.4
19.6
16.1
16.1
10.7
8.9
8.9
8.9

Note. Items in italics were added to MSAS-SF for this study.

25
25
24
24
24
22
22
21
21
20
20
19
18
18
17
16
15
14
14
12
12
11
9
9
6
5
5
5
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Symptom distress and prevalence. Using the MSAS-SF (adapted), physical
symptoms were measured by the amount of distress caused, whereas psychological
symptoms were measured by their prevalence. The overall distress and prevalence
rankings are reported in Appendix A. When evaluated by the distress associated with
physical symptoms, or prevalence of psychological symptoms, the symptoms of dry skin,
lack of energy, worry, changes to finger and toe nails, problems with sexual interest and
activity, changes in skin, dry mouth, feeling sad, and diarrhea, were ranked as most
distressing or prevalent. While lack of energy and worry have long been considered very
common and distressing symptoms in oncology, the emergence of dermatologic
symptoms as major contributors to distress is remarkable when compared to previous
work on cancer symptoms and symptom clusters.
Physical symptoms. The most distressing physical symptoms are highlighted in
Table 5, and include five symptoms that can be described as dermatologic or
mucocutaneous, three of which were added to the adapted version of the MSAS-SF for
this study. Dry skin is the physical symptom causing the most distress in this study,
followed by lack of energy. It is notable that nausea, vomiting, and lack of appetite,
which long have been associated with cancer treatment, are less likely to be distressing in
the setting of EGFRI therapy.
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Table 5. Most Distressing Physical Symptoms (N=56)
Mean
Dry skin
Lack of energy
Changes to my finger or toe nails
Problems with sexual interest or activity
Changes in skin
Dry mouth
Diarrhea
Changes in hair growth on my face
Difficulty sleeping
Numbness/tingling in hands/feet

1.757
1.657
1.429
1.429
1.414
1.386
1.286
1.100
1.029
1.000

S. D.
1.4902
1.3802
1.4925
1.6552
1.3814
1.4269
1.5077
1.3522
1.2646
1.3495

Note: Items in italics were added to the MSAS-SF for this study.

Psychological symptoms. The prevalence of psychological symptoms
is included in Table 6. Psychological symptoms are rated by prevalence, so
that each of these symptoms occurred at least occasionally in the study
sample. Worry was the item with the highest prevalence rating.

Table 6. Prevalence of Psychological Symptoms (N=56)

Worrying
Feeling sad
Feeling nervous
Feeling irritable

Mean
1.60
1.35
1.23
1.19

S. D.
1.2746
1.1666
1.1907
1.1349
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Relationship of symptom distress and prevalence to key demographic
variables. The independent variables of gender, diagnosis, specific EGFRI therapy and
age were examined to identify any significant differences in symptom distress and
prevalence.
Gender. Overall, men reported more symptoms (M = 13.95, SD = 5.24) than
women (M =10.75, SD = 5.74), with significant differences in occurrence between
genders for the symptoms lack of energy, dry mouth, problems with sexual interest or
activity and dry skin. The most frequently reported symptoms were analyzed in terms
distress (for physical symptoms) and prevalence (for psychologic symptoms). Significant
findings are reported in in Table 7.

Table 7. Significant t-Tests of Symptoms by Gender with Descriptive Statistics
Symptom

Group
M

Dry skin
Dry mouth
Worrying

2.24
2.32
.95

Male
SD

1.18
1.39
1.05

n

M

20
20
20

1.49
.867
1.97

Female
SD

1.6
1.17
1.25

n

36
36
36

95% CI for
Mean
Difference

-1.5, -.003
-2.15, -.75
.36, 1.69

t

-2.0**
-4.16*
3.01**

df
49
54
54

Note: Only significant results are shown. * p < .05, ** p < .01

Diagnosis. Symptoms by prevalence and distress were examined for any
significant variations by primary cancer diagnosis as illustrated in Table 8. Of the most
frequently occurring symptoms, distress scores differed significantly across the diagnoses
for three symptoms: worrying, diarrhea, and dry mouth. Worry caused the most distress
in lung cancer patients. Breast cancer patients reported a higher incidence of diarrhea,
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which is not an unexpected finding, as diarrhea is a known side effect of lapatinib and
grade 1 or 2 diarrhea occurs in about 40% of patients (Moy & Goss, 2007). Similarly,
there was considerable variation across the diagnoses for dry mouth, with head and neck
cancer patients reporting a higher incidence of distress associated with this symptom.
Head and neck cancer patients may have received radiation therapy, and xerostomia is a
well-known effect of this treatment.

Table 8. Symptom Distress or Prevalence by Diagnosis
________________________________________________________________________
Symptom
Worrying
Diarrhea
Dry Mouth
________________________________________________________________________
Diagnosis
N
Mean
SD
Mean
SD
Mean
SD
Breast cancer
9
1.667 1.0000
2.844 1.3333
.533 1.1314
Colorectal cancer

7

.571 1.1339

1.143

1.1178

2.057 1.1178

Head and neck

10

1.400 1.4298

.640

1.3492

2.640 1.5572

Lung cancer

29

1.828 1.1973

1.103

1.4409

.966 1.1188

A one-way between groups ANOVA was conducted to compare the effect of
diagnosis on symptom distress (physical symptoms) and prevalence
(psychological symptom) are highlighted in Table 9.
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Table 9. One-Way Analysis of Variance Symptoms by Diagnosis

Dry mouth

Diarrhea

Worrying

Between Groups

Sum of
Squares
58.409

df
4

Mean
Square
14.602

Within Groups

116.573

51

2.286

Total

174.982

55

Between Groups

44.993

4

11.248

Within Groups

150.364

51

2.948

Total

195.357

55

Between Groups

15.105

4

3.776

Within Groups

74.252

51

1.456

89.357

55

Total
Note: **p < 0.01, * p <.05

F
6.388

Sig.
.000**

3.815

.009**

2.594

.047*

Specific EGFRI. An independent t-test demonstrated a significant difference in
symptom distress (physical symptoms) and prevalence (psychologic symptom) for
several symptoms between participants taking small molecule tyrosine kinase inhibitors
(TKIs) (lapatinib, afatinib, erlotinib) and those receiving monoclonal antibodies
(MOABS) (panitumumab and cetuximab). Drugs were grouped together by a mechanism
of action (TKIs: afatinib, erlotinib, lapatinib; MOABS: cetuximab and panitumumab) due
to the small number of participants taking one option of each class of drug (afatinib, n =
2; panitumumab, n = 4). Of the symptoms most frequently reported, participants
receiving MOABs experienced greater distress or prevalence with all of the symptoms,
with the exception of worrying, which was more often prevalent in the TKI group.
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Table 10. Descriptive Statistics and Independent t-Test Comparing
Symptoms Distress and Prevalence by Type of EGFRI

Symptom

Type of EGFRI
MOAB
M

TKI

SD

n

2.44 1.11

20

1.22 1.33 36

2.4

1.29

20

.822 1.17 36

1.48 1.28

20

.6

1.00 36

1.72 1.51

20

.6

1.07 36

Changes in skin

2.00 1.43

20

1.09 1.26 36

-2.5*

54

Worrying

1.15 1.27

20

1.86 1.22 36

2.06*

54

Lack of energy

Dry mouth

Feeling drowsy

Numbness/tingling
in hands/feet

M

SD

n

t

df

-

45

3.6**
4.6**
2.8**
3.2**

54

54

54

Note: **p < 0.01, * p <.05

In order to better understand the contribution of each specific agent to the distress
associated with each symptom, distress and prevalence scores are reported in Table 11 for
the three most frequently reported symptoms: dry skin, lack of energy and dry mouth.
For the symptom changes in skin, the distress scores are as follows: panitumumab
(M = 3.5, SD = .577), cetuximab (M = 2.25, SD = 1.9), erlotinib (M = 1.71, SD = 1.71)
and lapatinib (M = .80, SD = 1.033). Dry mouth, as noted in Table 10, caused greater
distress in the MOAB group, with group means of cetuximab (M = 3.06, SD = 1.61),
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panitumumab (M = 2.75, SD = 1.61), while less symptom distress was reported with
lapatinib (M = 1.1, SD = 1.9) and erlotinib (M = 1.08, SD = 1.3).
Lack of energy also was reported with higher frequency in participants receiving
MOAB therapy, with group means as follows: panitumumab (M = 4.25, SD = .95),
cetuximab (M = 2.75, SD 1.3426), lapatinib (M= 2.3, SD =1.7), afatinib (M= 1.5, SD =
2.12), and erlotinib (M= 1.21, SD =1.58). In addition, diarrhea appears to be associated
with lapatinib therapy (M = 3.2, SD = 1.93), F(1,3) =2.978, p = .028, with other group
means reported as follows: panitumumab (M = 2.0, SD = 1.41), afatinib (M = 1.5, SD =
2.12), erlotinib (M = 1.42, SD = 1.86, and cetuximab (M = 0.81, SD = 1.5).

Table 11. Symptom Distress by Specific Agent
____________________________________________________________________
Symptom
Dry Skin
Dry Mouth
Lack of Energy
____________________________________________________________________
Specific Agent
N
Mean
SD
Mean
SD
Mean
SD
____________________________________________________________________
Cetuximab
Panitumumab
Afatinib
Erlotinib
Lapatinib

2.25
3.5
1.67
1.71
.80

1.9
.577
1.0
1.71
1.03

3.06
2.75

1.61
1.61

1.08
1.1

1.3
1.9

4.25
2.75
1.5
1.21
2.3

.95
1.35
2.12
1.58
1.7

Age. An analysis of variance demonstrated no significant difference in distress
(physical) or prevalence (psychologic) with regard to the most frequently reported
symptoms by age of participant.
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Independent t-tests found no differences in the most frequently reported
symptoms on distress or prevalence in those who completed the study online vs. on
paper, but when all symptoms were compared, those who completed a paper survey
reported greater distress associated with feeling drowsy. Analysis of variance found no
significant differences by educational level for symptom distress or prevalence.
Comparisons between participants receiving therapies in addition to EGFRIs
yielded several significant findings with regard to severity of reported symptoms, with
the those patients reporting a greater lack of energy (M =2.73, SD = 1.609), t(54) =2.384 ,
p = .021, diarrhea (M =2.32, SD = 2.102 ), t(36.4) = 2.230 , p = .032 and problems with
sexual interest or activity (M =2.55, SD =1.993 ), t(54) = 2.295, p = .026 than those
participants receiving EGFRIs alone. This finding is consistent with what would be
expected in patients receiving multiple treatment modalities.
Other symptoms. Participants reported on any other symptoms they experienced
that were not included in the items presented to them. Responses included the following:
severe dry eye described as “very distressing;” dry eye that caused blurred vision,
requiring the use of artificial tear drops and ophthalmic ointment at night; swollen eyelids
oozing a “quasi liquid that hardens into a dry crust and is painful to remove;” excessive
nasal mucous that hardens into a dry crust;” almost constant fatigue; problems with my
fingernails “get so bad that I cannot use a knife and a fork;” swelling of lips; occasional
long bone pain at night; uncertainty, “I don't know what I am supposed to be doing with
my life;” sun avoidance that has “resulted in my giving up golf, biking and vacations at
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beach. I run from the sun and must wear a hat at ALL times. I find this very confining;”
changes to eyebrows; and foot pain.
Symptom clusters. Several procedures were used to generate factors (symptom
clusters) of symptoms based on reported frequencies. These procedures included:
exploratory factor analysis based on review of data characteristics with multiple
iterations; exploratory factor analysis based solely on original communalities; and
hierarchical cluster analysis as an alternative procedure to identify symptom clusters.
Factor analytic procedures resulted in the identification of three symptom clusters:
Factor 1, a psychological-cognitive cluster; Factor 2, a dermatologic skin and hair cluster;
and, Factor 3, a mucocutaneous and fatigue cluster. Factor 1 is very similar to clusters
previously described, Factor 2 has not been previously described, and Factor 3 is similar
to clusters previously described, but includes a treatment-related symptom. More
information on these clusters will be presented in the section on Study Aim 3.
Study Aim 2
Describe the quality of life, functional performance and psychological status of
patients receiving EGFRI therapy.
Quality of Life
Quality of life was measured in the present study by a general quality of life
instrument, the FACT-G, and a treatment-specific scale, the EGFRI-18. The FACT-G
family of instruments includes the basic core questionnaire and additional add-on panels
specific to disease or treatment. When separate disease or treatment related panels are
used, such as the EGFRI-18, the scores can be summed to yield a Total Quality of Live
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(Total QOL) score. However, both FACT-G QOL and Total QOL scores are reported in
the present study. Because the FACT-EGFRI-18 must still be refined, its sensitivity to
variations in treatment-related dermatologic quality of life is not established.
Results for these two instruments are presented here.
FACT-G. The FACT-G measures quality of life across several domains,
including Physical Well-Being (PWB, score range 0-28) with 7 items; Social/Family
Well-Being (SWB, score range in original instrument 0-28) with 6 items in this version
(score range 0-24), as a question about sexuality as not included for scoring, so this item
was prorated; Emotional Well-Being (EWB) with 6 items (score range, 0-24); and,
Functional Well-Being (FWB) with 7 items (score range 0-28). The FACT-G items
includes a Likert scale with five responses from 0-4, (0 = Not at all; 1 = A little bit;
2 = Somewhat; 3 = Quite a bit; and 4 = Very much). A total FACT-G score is derived by
adding all of the subscales. Negatively worded items are reverse scaled, resulting in a
higher score signifying a better quality of life for both the subscales and total scale. The
overall FACT-G displayed a high level of internal consistency, as demonstrated by a
Cronbach's alpha of 0.930.
Reliability statistics for the subscales are as follows: PWB subscale consisting of
7 items (α = .819); SWB subscale consisting of 6 items (α = .904); EWB consisting of 6
items (α = .847); and FWB consisting of 7 items (α = .883). As noted earlier, the current
study, the item on sexuality was deleted as there was another variable that assessed
problems with sexuality of sexual function as part of the MSAS-SF (adapted).
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When more than 50% of the subscale items are answered, the subscale can be
prorated by the following procedure: the sum of the subscale is multiplied by the number
of items in the subscale, and then divided by the number of items that have been
answered. The resulting subscale can be added to the other sub-scale scores to yield a
total quality of life score. At least 22 of 27 FACT-G items must be completed, as well as
at least 50% of the items of each subscale, in order for this procedure to be valid. All of
the subscales are required to have a total subscale score (consistent with the above
procedures) in order to calculate a total quality of life scale (Fairclough & Cella, 1996).
Results for the FACT-G are presented in Table 12, with the mean score
suggesting minimal effect on quality of life in this sample.

Table 12. FACT-G Quality of Life Descriptive Statistics (N=56)
Sample
Subscale

Range

Min

General Norms
Max

Mean

SD

Mean SD

Social Well-Being (SWB)

28

.00

28

21.68

6.59

19.1

6.8

Emotional Well-Being (EWB)

20

4

24

15.91

4.95

19.9

4.8

Physical Well-Being (PWB)

17

11

28

20.71

4.86

22.7

5.4

Functional Well-Being (FWB)

25

3

28

17.66

6.67

18.5

6.8

Total Quality of Life

77

29 106

75.96

18.59

80.1 18.8

Note: General population norms are shown in italics, and are from Brucker, P. S., Yost,
K., Cashy, J., Webster, K., & Cella, D. (2005). General population and cancer patient
norms for the Functional Assessment of Cancer Therapy-General (FACT-G) Evaluation
& the Health Professions. 2005(28), 192–211.

89
For purposes of comparison, mean scores on the total FACT-G for the general
population have been reported as 80.1 and 78.4 (Brucker, Yost, Cashy, Webster, &
Cella, 2005) and 80.2 and 80 (Espie et al., 2008), 77.95 (15.16) (Yanez, Pearman, Lis,
Beaumont, & Cella, 2013), and 78.4 (22.6) in patients with cancer (Danhauer et al.,
2007). Yanez et al. reported subscale scores as follows: PWB (M = 20.17, SD = 15.16);
SWB (M = 22.67, SD = 4.76); EWB (M = 17.52, SD = 4.48: FWB (M = 17.6, SD = 5.86).
In this sample, it is interesting to note that SWB compares favorably with the general
population means, suggesting that the participants, consistent with their relationship
status and living arrangements, benefit from close relationships.
FACT-EGFRI-18. The FACT-EGFR-18 is a companion dermatologic quality of
life instrument that addresses EGFRI treatment-related concerns. Statistics for the FACTEGFRI-18 for this sample are presented in Table 12, including percentages of total score
(where 100 percent would reflect the highest quality of life rating), in order to make the
results easier to interpret. Complete results for each item in the FACT-EGFRI-18 are
included in Table 13. Internal consistency using Cronbach’s alpha for the overall FACTEGFRI-18 was .886, with following reliability statistics for each of the subscales:
physical (7 items, α = .757); social-emotional (6 items, α = .772); and functional (5 items,
α = .750). When the both the FACT-G and the EGFRI-18 scales are combined as they are
in the current study to yield a total quality of life score, Cronbach’s alpha for all 44 items
is 0.915.
Despite similar subscales, there is discordance in the results of the two
instruments. When used as part of a total quality of life score along with the FACT-G,
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adding the EGFRI-18 effectively raised the quality of life score. As a result, the current
original version of the EGFRI-18 should be explored further with regard to sensitivity to
dermatologic quality of life in patients receiving EGFRI therapy. Participants had lower
scores on emotional and functional well-being scores on the FACT-G than on the EGFRI,
which may suggest declines in emotional and functional well-being globally, rather than
specifically related to EGFRI therapy. Since the EGFRI-18 is a new instrument, there is
no psychometric information available for comparison, but these discrepancies between
the tools are areas for further inquiry.

Table 13. EGFRI-18 Dermatologic Quality of Life (N=56)
Sub-scale

Mean (SD)

Range

Percentage

Physical

17.9 (5.6)

4-28

89

Social-Emotional

19.4 (4.6)

6-24

81

Functional

17.6 (3.2)

5-20

87

Total

54.9 (12)

14-72

76

Note: No norms available.

Test of normality. Tests of normality for the total QOL score (FACT-G added to
FACT-EGFRI-18) score were non-significant. A visual inspection of the histogram, Q-Q
plots also showed that the scores were approximately normally distributed for the FACTG and the combined FACT-G and FACT-EGFRI-18 scales (Total QOL). However, the
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Kolmogorov-Smirnov test was significant for the FACT-EGFRI-18 scale alone. In
addition, the FACT-EGFRI-18 demonstrated a negative skew, with skewness of -.994
(SE =.322) and kurtosis of 1.161 (SE = .634), indicating a long tail to the left (few lower
scores) and many higher values, again calling into question the sensitivity of the
instrument to impact of treatment on quality of life. However, since the outcome variable
of quality of life is based on the mean sum scores of the FACT-G and FACT-EGFRI-18,
described above as Total QOL, this variable will also be treated as a normal distribution.
Psychological Status
MHI-5. The MHI-5 is brief questionnaire that is used to assess mental health,
including anxiety and depression, and was used to measure psychological status in the
current study. There are several versions and available scoring procedures published, but
for this study, a five-point scale was used, and the MHI-5 score was transformed to yield
a total score of 0-100, with a higher score indicative of positive mental health
(Hoeymans, Garssen, Westert, & P., 2004). The MHI-5 scale demonstrated a high level
of internal consistency with a Cronbach's alpha of 0.906.
The MHI-5 has demonstrated good reliability (Rumpf, Meyer, & Hapke, 2001;
Friedman, Heisel, & Delavan, 2005). No formal cut-off point for the MHI-5 has been
agreed upon in the literature, with various studies citing scores from 72 (Hoeymans et al.,
2004), to 76 to (Kelly, Dunstan, Lloyd, & Fone, 2008) to ≥ 80 as consistent with good
general mental health (Clough-Gorr, Stuck, Thwin, & Silliman, 2010). An MHI-5 score
of 52 or less has been cited as indicative of depressive symptoms (Kroenke et al., 2005;
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Whang et al., 2009; Whang et al., 2012), and a score of < 65 is suggestive of mood
disorders (Rumpf, Meyer, Hapke, & John, 2001; Biddulph et al., 2014).
The MHI-5 score in the present study suggests a minimal impact on psychological
status in this sample (M =74.9, SD=16.3, range 28-100), with a negative skew and a long
tail to the left with more high scores (indicative of positive mental health). The MHI-5 is
known to have a negative skew, but previous research suggests that response models are
robust to departures from normality (Fone, Dunstan, John, & Lloyd, 2007). So although
the mean score does not approach the levels described above associated with depression
or mood disorders, the mean MHI-5 score in this sample suggests that assessment for
psychological well-being would be advisable because there appears to be some effect of
EGFRI therapy. This score compares with the FACT-G Emotional Well-Being subscale
score (M =15.9, SD = 4.95, range 4-24), which suggests some impact on emotional
dimension of quality of life.
Tests of normality. As noted above, the MHI-5 score is negatively skewed
(skewness =-.752, SE= .319). Statistical tests for normality were not in agreement, with
the Kolmogorov-Smirnov non-significant and the Shapiro-Wilk significant W = (56)
.947, p =.016. Inspection of the histogram, P-P and Q-Q plots indicated minor deviation
from a normal distribution, so this outcome variable will be treated as normally
distributed.
Functional performance/performance status. The Eastern Cooperative
Oncology Group Performance Status (ECOG PS) is widely accepted as a measure for
assessment of functional status of patients. Descriptive statistics for the ECOG
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Performance Scale are depicted in Table 14, indicating that almost 98% of participants
reported a good or very good performance status overall. No participant reported being
completely disabled and incapable of self-care.
Tests of normality. In advance of conducting inferential tests on this outcome
variable, checks of normality were conducted and, results for this variable were nonnormal with a skewness of .930 (SE = .319). Kurtosis was acceptable at .689 (SE = .628),
but the Shapiro-Wilks test for normality of data was highly significant. Inspection of the
histogram and the P-P and Q-Q plots indicated a significant deviation from the normal
distribution. A log 10 transformation, including the addition of a constant due to the
presence of zero values, improved the skewness, but the Shapiro-Wilks test was still
highly significant, so the non-parametric Mann-Whitney U test was used on the original
data to examine differences in this outcome variable between members of each cluster
and non-members. In addition, the ECOG score is categorical variable and may not be
appropriate for multiple regression.

94
Table 14. ECOG Performance Status
N=56

Score

N

Percentage

Fully active, able to carry on all pre-disease
performance without restriction.

0

26

46.4

Restricted in physically strenuous activity but
ambulatory and able to carry out work of a
light or sedentary nature, e.g., light house
work, office work.

1

24

42.9

Ambulatory and capable of all self-care but
unable to carry out any work activities. Up
and about more than 50% of waking hours.

2

5

8.9

Capable of only limited self-care, confined to
bed or chair more than 50% of waking hours.

3

1

1.8

Study Aim 3
Identify any co-occurring symptoms or symptom clusters in patients receiving
EGFRI therapy.
Symptom Clusters
Symptom clusters have been described as two or more symptoms that co-occur
and that may or may not share the same etiology (Kim, McGuire, Tulman, & Barsevick,
2005). In oncology symptom cluster research, a basic concept is that there is a shared
basis for a set of symptoms, whether caused by the treatment or the disease. This same
premise is implicit in factor analysis, in that there is an underlying or latent dimension,
possibly unobserved, that is shared by a set of variables.
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Factor analysis. Factor analysis is a multivariate procedure that enables the
researcher to reduce a set of variables into a smaller number of variables, known as
factors. Factor analysis is based on correlation between items (e.g. symptoms).
Types of factor analysis
Clarification of the definition of factor analysis used in this context is essential.
There are two types of factor analysis: confirmatory factor analysis and exploratory factor
analysis. In exploratory factor analysis, the primary aim is to explore and discover key
constructs in a set of data, while confirmatory factor analysis allows the researcher to test
hypotheses (Kline, 2002). Confirmatory factor analysis provides an opportunity for
hypothesis testing to determine if a proposed relationship between variables and
constructs actually exists.
Exploratory factor analysis. The current research used exploratory factor
analysis in order to discover symptom clusters in patients receiving EGFRIs. Exploratory
factor analysis is a non-inferential statistical procedure, and can be understood as a
heuristic technique, in that it allows the researcher to engage in a process of discovery of
relationships among variables. No statistical confirmatory test for an appropriate factor
analysis exists, and there is a significant amount of subjectivity that can come into play.
Factors derived from the same data could conceivably vary, depending on decisions made
by the researcher. However, the final factor solution is one that should be defensible. The
goal of factor analysis should be to derive a parsimonious solution of factors that makes
sense in the context of the data, while explaining variance in the data (Walker & Maddan,
2013).
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Factor analysis resonates with some symptom cluster researchers because factors
can be used to understand the relationship, and perhaps a shared biological cause, among
various symptoms, and perhaps better inform their collective management. However, as
noted, this statistical approach is based on a series of decisions that are inherently
subjective (Kim & Abraham, 2008), and which should be based on an understanding of
clinical scenarios. For this reason, the series of iterative decisions contributing to the
final factor solution are described below.
Steps in exploratory factor analysis. A general series of steps should be
undertaken in order to produce interpretable factors. First, a series of variables are
selected and measured. Various characteristics of the variables, such as normality,
skewness, and kurtosis, are observed. Inspection and evaluation of communalities is
performed in order to identify possible variables to exclude, because items with low
communalities will not contribute to the factor solution. Correlation coefficients are
examined to determine which variables to retain, as items that do not correlate with
others will not contribute to a factor solution. Along each step of the process, measures
of sampling adequacy (Kaiser-Meyer-Olkin statistic and Bartlett’s test of sphericity) are
ascertained.
Various approaches to factor extraction and rotation (oblique vs. orthogonal) are
evaluated in light of the purpose of the factor analysis, and all of these procedures are
repeated on an iterative basis in order to identify a clear factor structure. Decisions about
the number of factors to retain are made, using several rules of thumb, such as the scree
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plot, eigenvalues greater than 1 (Kaiser criteria) and total variance explained. Finally,
results must be interpreted in a meaningful way that has relevance to the application.
Measures of Sampling Adequacy
There are several measures to consider regarding the appropriateness of factor
analysis for a set of data, including the Kaiser-Meyer-Olkin (KMO) Measure of Sampling
Adequacy, Bartlett’s test of sphericity, and the anti-image correlation matrix, which are
all included the factor analysis procedures in SPSS.
The KMO statistic represents the amount of variance in a set of variables that may
be resulting from underlying factors. KMO values, which are based on correlations and
partial correlations, have been characterized by Kaiser (Zilmer & Vuz, 2010) in the
following way: .90 or above “marvelous,” .80 or above, “meritorious,” .70 or above
“middling,” .60 or above, “mediocre,” .50 or above “miserable,” and below .50 as
“unacceptable.” As previously noted, a KMO for a set of variables of at least 0.6 is
suggested for factor analysis (Tabachnik & Fidell, 2001), or the variables included in the
solution should be reexamined or a larger sample generated (Field, 2009, p. 647).
Individual variables with a KMO of less than 0.5 should be considered for elimination
(Walker & Maddan, 2013). Elimination of variables with low KMO values is
recommended, and will have the effect of raising the overall KMO statistic for the entire
set of variables. As variables are removed, and factor analysis procedures are repeated,
changes occur in the individual and overall KMO statistic.
Correlation provides the basis for factor analysis, so there must be some
correlation among variables in order for them to “hang together” so that factors can be
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identified. Bartlett's test of sphericity determines whether a correlation matrix is an
identity matrix, where all diagonal values are 1 while off-diagonal values are 0. An
identity matrix would be evidence of a lack of correlation among variables, and a set of
such variables would not generate factors. In Bartlett’s test of sphericity, if the p value is
significant, the null hypothesis that the population matrix is an identity matrix would be
rejected. Rejecting the null hypothesis is required for a set of data to be factor analyzed.
However, Bartlett’s test is often significant, and relying solely on this parameter to
determine sampling adequacy is inadvisable.
Another step in determining sampling adequacy is inspection of the anti-image
correlation matrix, which displays the negative of the partial correlations. Since this is an
anti-image, desirable values should be low, closer to zero. Large values are problematic
as such variables will have low correlations with other variables, and they should be
considered for elimination from factor analysis if a theoretical or methodologic argument
can be made for doing so (Walker & Maddan, 2013).
Decision-Based Factor Analysis Procedure
The first step in the process of generating a factor analysis in the current study
was to examine the 38 symptoms included in the MSAS-SF (adapted) in order to
determine which items should be retained and which could be removed due to low
correlations with other symptoms. In a study with many variables, there may be
thousands of correlations, and “without a simplifying procedure such a matrix would be
incomprehensible” (Kline, 2002, p.4). With the original correlation that included all
measured symptoms, the initial KMO measure of sampling adequacy was unacceptable at

99
.384, indicating that the current set of variables were not suitable for factor analysis,
although Bartlett’s test of sphericity was significant, providing an example of its frequent
significance and lack of reliability as a measure of sampling adequacy. Additional
examination of the data was required. Several approaches were used to identify which
symptom variables to retain, including examination of inter-item correlations,
consideration of symptom occurrence and prevalence as a criterion for retaining variables
(symptoms), and iterative examination of the anti-image correlations.
Following the convention suggested by others, the criteria of symptom occurrence
of at least 20% -25% was used as a first step for consideration of variables to include in
the factor analysis (Gleason et al., 2007; Kim et al., 2009b; Baggott, Cooper, Marina,
Matthay, & Miaskowski, 2012). Symptom severity or distress has also been used as a
basis for deciding which symptoms to retain in factor analysis (Kim et al., 2009b), but
there is not much difference between ranking the symptoms occurrence and severity, so
frequency or prevalence was chosen as the approach here.
Using symptom frequency or prevalence as a criteria for exclusion, the following
eight symptoms were removed, with their communalities shown in parentheses: problems
with urination (.081), swelling of arms and legs (0.149), vomiting (0.142), feeling bloated
(.095), dizziness (0.179), difficulty swallowing (0.232), and sweats (0.04). The
communalities of all of the removed variables were low, which made them good
candidates for removal from factor analysis. However, despite removing these symptoms,
the KMO remained unacceptable at 0.436.
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Inter-item correlations were then examined for all symptom variables, and those
with correlations below .300, including the symptoms changes in finger and toe nails,
difficulty sleeping, and itching, were removed from the factor analysis, which improved
the KMO to 0.500, with Bartlett’s test of sphericity remaining significant.
Communalities were again inspected, and variables deleted from the exploratory factor
analysis due to low communalities were pain, diarrhea, changes in the way food tastes,
nausea, numbness and tingling in fingers and toes, problems with sexual interest or
activity and shortness of breath. Using this approach improved the KMO to 0.730,
x2(105) = 301.994, (p = .000).
The anti-image correlation matrix was then examined for measures of sampling
adequacy. The anti-image correlation matrix includes the KMO values for each
individual variable along the diagonal, and, as noted earlier, any values less than .500
suggest that the item should be removed from analysis (Field, 2009, p. 659). All of the
remaining items had measures of sampling adequacy greater than 0.639. The offdiagonal elements should be close to zero, which was the case for many. The determinant
for this set of factors was .002. In addition, each variable had at least one inter-item
correlation at or near 0.400, and all communalities were above .300, ranging from .339
to .791.
As noted above, the goal of a factor analysis is to develop a solution that makes
sense with regard to its application, is relatively easy to interpret, and possesses a simple
structure with few or low cross-loadings. The iterative procedures described here resulted
in such a factor structure. In the final solution, principal axis factoring using an oblique
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rotation (Oblimin with Kaiser normalization) retained the following variables: difficulty
concentrating, “I don't look like myself,” changes in my eyelashes, dry skin, feeling sad,
worrying, feeling irritable, feeling nervous, other changes to scalp hair, hair loss, dry
mouth, lack of energy, feeling drowsy, changes in hair growth on my face and other
changes to my fingers or toes. In this model, the three factors retained explained 48.03%
of the total variance, and is shown in Tables 15 and 16.
Rationale for oblique rotation. As factor analysis is an exploratory procedure,
multiple procedures were run through SPSS in order to identify the optimal factor
structure and to explore the effect of various methods of rotation and extraction.
Principal components analysis was executed on the symptom variables in order to explore
the data and to compare the results with iterations using other factor analysis procedures,
including principal axis factoring (PAF), using both orthogonal (Varimax) and oblique
(Oblimin and Promax) rotations. Maximum likelihood rotation and unweighted least
squares methods, using both orthogonal and oblique rotation, were also performed, and
each procedure yielded very similar results, but the above model best fit the data.
Selection of oblique rotation
Ideally, because the symptom variables in this study are derived from patient selfreport, they would best be examined through an oblique rotation, which allows variables
to load on several factors. Additionally, correlation coefficients in the factor structures
were high, supporting the use of oblique rotation. In a real world setting, it is very likely
that there would be variables that would cross-load on more than one factor, so oblique
rotations, such as Oblimin with Kaiser normalization should be strongly considered. In
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other applications, orthogonal solutions might be preferred due to the inherent
simplification of their interpretation, so this type of rotation was also explored. However,
in a clinical setting, a symptom in one factor might very likely also be present in another
factor, and oblique rotation allows this redundancy to occur, and has been suggested as a
reasonable approach in symptom cluster research (Skerman, Yates, & Battistutta, 2009).
Factor Solutions
As noted above, a three factor solution was derived: Factor 1: a psychologicalcognitive cluster (feeling nervous, feeling sad, worrying, feeling irritable, difficulty
concentrating, and “I don't look like myself”); Factor 2: a dermatologic skin and hair
cluster (changes in eyelashes, dry skin, hair loss, changes in facial hair growth and other
changes in scalp hair); and, Factor 3: a mucocutaneous-fatigue cluster of dry mouth,
feeling drowsy, lack of energy, difficulty concentrating, and other changes to fingers or
toes. Note that lack of energy and difficulty concentrating loaded on Factors 1 and 3,
lending justification to an oblique solution. Difficulty concentrating is a common
symptom in patients being treated for cancer, so cross-loading is not problematic.
Factor loadings are presented in Table 15 and 16 and include the structure
(correlations between factors and variables) and pattern (factor loadings) matrices. With
an oblique rotation, it is important to report both the structure and the pattern matrix
(Pett, Lackey, & Sullivan, 2003; Thompson, 2004). Each factor had several excellent or
very good loadings, and as previously described, high loadings of .600 or more with four
or more variables can mitigate somewhat a small sample size (Stevens, 2002).
Cronbach’s alpha for this set of symptoms (n=15) was .739. The factor loadings are

103
generally in the categories considered good to excellent ( > .70 – excellent; .63 - very
good; > .55 – good; > .45 – fair; > .32 – poor) (Comrey & Lee, 1992).
Eigenvalues for each factor are as follows: Factor 1 (psychological-cognitive),
with an eigenvalue of 4.046 (23.96% of variance explained); Factor 2 (dermatologic skin
and hair), with an eigenvalue of 2.497 (13 % of variance explained); and, Factor 3
(mucocutaneous and fatigue cluster), with an eigenvalue of 2.162 (11.07% of variance
explained. A cumulative explained variance of 48.03 % resulted with this factor solution.
In all iterations of factor analytic procedures, the scree plot (a graphic plot of
eigenvalues) was examined. In the final solution, the scree plot suggested at least a three
factor solution (Figure 4). Although a 4 factor solution was also generated, few items
loaded on this fourth factor.
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Table 15. Principal Axis Factor Analysis with Direct Oblimin Rotation
Structure Matrix Based on Iterative Process (N=56)
____________________________________________________________________________

Structure Matrix
Symptom

Factor 1

Feeling nervous

.885

Feeling sad

.805

Worrying

.782

Feeling irritable

.667

“I don't look like myself”

.525

Factor 2

Other changes scalp hair

.618

Dry skin

.676

Changes in eyelashes

.619

Hair loss

.588

Changes in facial hair growth

.549

Factor 3

Other changes to fingers or toes

.633

Dry mouth

.620

Feeling drowsy

.579

Lack of energy

.584

Difficulty concentrating

.476

.533

Note: Factor loadings under .450 are suppressed.
Factor 1 Psychologic-Cognitive Eigenvalue of 4.046 (23.96% of variance explained)
Factor 2 Dermatologic Skin and Hair Eigenvalue of 2.497 (13.00 % of variance explained)
Factor 3 Mucocutaneous and Fatigue Eigenvalue of 2.162 (11.074% of variance explained)
Cumulative variance of 48.031% explained.
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Table 16. Principal Axis Factor Analysis with Direct Oblimin Rotation Pattern Matrix
Based on Iterative Process (N=56)
Pattern Matrix Factor
Loadings
Symptom

Factor 1

Feeling nervous

.877

Feeling sad

.827

Worrying

.814

Feeling irritable

.603

“I don't look like myself”

.494

Factor 2

Other changes scalp hair

.636

Dry skin

.663

Changes in eyelashes

.646

Hair loss

.568

Changes in facial hair growth

.531

Factor 3

Other changes to fingers or toes

.716

Dry mouth

.629

Feeling drowsy

.543

Lack of energy

.561

Difficulty concentrating
.449
Note: Factor loadings under .40 are suppressed.
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Figure 4. Scree Plot for Factor Solutions

Factors Based on Communalities
The previous discussion detailed an iterative process of examining the symptom
variables and taking steps to ensure that the data was appropriate for factor analysis. In
order to confirm the set oof factors derived, the complete set of variables was reexamined
and the original communalities
ommunalities for the full set of variables were reviewed. Variables with
a communality value below 00.300 were eliminated, and factor
actor analytic procedures were
run using PAF with an oblique rotation in an effort to replicate the derived factors.
Although elimination of variables with communalities below 0.5 has been recommended,
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the cut-off of .300 was chosen so that variables demonstrating some evidence of
correlation could be retained.
Using the single criteria of communality, variables removed for the first iteration
of factor analysis included: diarrhea (0.026), sweats (0.04), changes in finger and toe
nails (0.064), problems with urination (0.081), bloating (0.095), pain (0.100), itching
(0.112), problems sleeping (0.116), changes in the way things taste (0.133), vomiting
(0.142), swelling of arms and legs (0.149), numbness and tingling of fingers and toes
(0.168), dizziness (0.179), cough (0.189), nausea (0.201), lack of appetite (0.206),
constipation (0.211), mouth sores (0.211), problems with sexual interest or activity
(0.219), shortness of breath (0.224), difficulty swallowing (0.232), and weight loss
(0.255), and changes in skin (0.279).
The resulting set of symptoms for factor analysis included: feeling nervous,
feeling sad, worrying, feeling irritable, feeling drowsy, lack of energy, difficulty
concentrating, “I don’t look like myself,” dry mouth, hair loss, other changes to scalp
hair, changes to hair growth on my face, dry skin, changes in my eyelashes, and other
changes to my fingers and toes. The KMO for this set of variables was .732 (x2 (120)
=331.416, p = .000).
For this set of variables, the scree plot and eigenvalues > 1 (Kaiser rule) suggested
a three or four factor solution. A four factor solution was examined, but variables
(feeling drowsy, “I don’t look like myself,” dry mouth, difficulty concentrating, lack of
energy, changes in hair growth on my face, hair loss, dry skin and feeling irritable) crossloaded and factor loadings were low (<.400) for eleven variables. Therefore, a three
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factor solution generated by PAF (Oblimin with Kaiser normalization) was selected and
included: Factor 1 (psychological-cognitive), with an eigenvalue of 4.154 (23.02 % of
variance explained); Factor 2 (dermatologic skin and hair cluster), with an eigenvalue of
2.638 (13.02% of variance explained); and Factor 3 (mucocutaneous-fatigue), with an
eigenvalue of 2.226 (10. 8% of variance explained). A cumulative variance of 46.85%
was explained by this solution (Table 17).
Approaches comparison for factor analysis. The factors generated by these
two methods (the first which took repeated iterations) are very similar, and provide
validation of the first method. The first set of factors was used to generate the factor
scores used to explore differing effects on outcome variables. All further discussion
regarding factors and the identified symptom clusters will relate to those developed using
the first (iterative approach) method.
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Table 17. Exploratory Factor Analysis Results Based on Communalities (N=56)

Symptom

Factor Loadings
Factor 1
Factor 2

Feeling nervous

.885

Feeling sad

.803

Worrying

.779

Feeling irritable

.664

“I don't look like myself”

.524

Other changes scalp hair

.610

Dry skin

.652

Changes in eyelashes

.578

Hair loss

.615

Changes in facial hair growth

.526

Factor 3

Dry mouth

.646

Feeling drowsy

.602

Lack of energy

.548

Difficulty concentrating

.405

.497

______________________________________________________________________
Note: Factor loadings under .40 are suppressed.
Factor 1 Psychologic-Cognitive
Eigenvalue of 4.154 (23.02 % of variance explained)
Factor 2 Dermatologic Skin and Hair Eigenvalue of 2.638 (13.02% of variance explained)
Factor 3 Mucocutaneous and Fatigue Eigenvalue of 2.226 (10. 8% of variance explained)

Cumulative variance of 46.85% explained.

Factor Correlation Matrix
For the final solution using the first method described, the factor correlation
matrix indicates that Factor 1 is not correlated with Factor 2 (.099), and is only weakly
correlated with Factor 3 (.228). Factor 2 is not correlated with Factor 3 (.034).
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Correlations less than 0.1 are negligible. So despite an oblique rotation where factors are
“allowed” to correlate, the factors in this solution do not correlate, so the three factor
solution is supported. Only one item (difficulty concentrating) loads on multiple factors
(Factors 1 and 3), and this is logical given the clinical meanings of both of these clusters.
Symptom clusters. Three symptom clusters were generated using the procedures
described above. A psychological-cognitive cluster, a dermatologic skin and hair cluster,
and a mucocutaneous and fatigue cluster. Each of these clusters will be discussed in
more depth in chapter five in the context of previous work on symptom clusters.
Factor 1: Psychological-cognitive. A mood-related, affective, emotional, or
psychoneurologic cluster, including the symptoms of feeling irritable, feeling nervous,
worrying, feeling sad, difficulty concentrating and “I don’t look like myself” was
identified in this sample. Previous oncology symptom cluster research has provided
ample evidence for similar clusters in patients with various cancer diagnoses.
Factor 2: Dermatologic skin and hair cluster. The second cluster includes dry
skin, changes in eyelashes, hair loss, changes in facial hair growth and other changes in
scalp hair, and can be interpreted as an EGFRI treatment-related dermatologic skin and
hair cluster. Although these symptoms have been previously described (Lacouture et al.,
2011), the finding of a symptom cluster generated by factor analytic procedures is novel.
A skin and hair-related symptom cluster would have been expected to occur in this
sample. Nail changes did not cluster with these symptoms.
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Factor 3: Mucocutaneous and fatigue cluster. The third factor identified
includes dry mouth, feeling drowsy, lack of energy, difficulty concentrating, and other
changes to fingers or toes, so it echoes previous work, but includes a new element (other
changes to fingers and toes) reflecting EGFRI therapy. This cluster has two components:
dry mouth and changes to fingers and toes being the mucocutaneous aspect, and feeling
drowsy, lack of energy and difficulty concentrating contributing to the fatigue aspect.
Hierarchical Cluster Analysis
In view of the small sample size for this study and the caveats regarding factor
analysis with small samples, the data were assessed by hierarchical cluster analyses
(HCA) using Ward’s method with squared Euclidean distances. This method has been
used to generate symptom clusters in patients with heart failure using a version of the
MSAS (MSAS-HF) (Song et al., 2010).
Like factor analysis, cluster analysis allows for discovery of relationships between
variables. In HCA, each variable starts as a separate cluster and the procedure then
reduces the number of clusters until all items are grouped in one large cluster. Distance
scores range from 0-25, and as the distance becomes less, the symptoms begin to cluster.
By observing the dendrograms generated by the procedures, one can identify how items
cluster at various distances. The first HCA was run with all 38 symptoms included, and
generated the dendrogram shown in Figure 5. Viewing the clusters from right to left,
there is a clear branching of three large clusters with this first iteration. The first cluster
includes difficulty with urination, swelling of arms and legs, vomiting, bloating, sweats,
dizziness, nausea, difficulty swallowing, mouth sores, “I don’t like the way I look,”
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numbness and tingling in my fingers and toes, difficulty sleeping, shortness of breath,
constipation, pain, cough, drowsiness, other changes to fingers and toes and itching. This
cluster might be described as a general sickness cluster.
The second cluster derived by HCA of all 38 symptoms includes lack of energy,
dry mouth, skin changes, feeling nervous, feeling sad, feeling irritable, worrying,
difficulty concentrating, weight loss, changes in appetite and taste changes. This cluster
might be described as a mood-anorexia cluster.
The third cluster generated by the first iteration of hierarchical cluster analysis
includes changes in eyelashes, scalp hair changes, hair loss, changes in facial hair growth,
dry skin, diarrhea, problems with sexual interest and performance, and changes in fingers
and toenails, which could be labeled as a treatment-related dermatologic skin, hair and
nail cluster.
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GENERAL SICKNESS CLUSTER

MOOD ANOREXIA CLUSTER

DERMATOLOGIC SKIN HAIR AND NAIL CLUSTER

Figure 5. Hierarchical C
Cluster
luster Analysis of All Symptoms
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Another HCA was run with the final set of symptoms included in the initial
(iterative) exploratory factor analysis procedures previously described. The dendrogram
presented in Figure 6 indicates the presence of three symptom clusters which mirror those
generated by factor analysis. The first cluster (psychological-cognitive) includes
difficulty concentrating, feeling irritable, feeling nervous, feeling sad, worrying, and “I
don’t look like myself,” the second cluster (mucocutaneous and fatigue) includes dry
mouth, lack of energy, feeling drowsy, and other changes in fingers and toes. Changes in
eyelashes, other changes in scalp hair, hair loss, changes in facial hair growth and dry
skin are included in the final cluster (dermatologic skin and hair). As depicted on the
dendrogram, symptoms cluster together at lower distance scores.
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PSYCHOLOGICAL COGNITIVE CLUSTER

MUCOCUTANEOUS FATIGUE CLUSTER

DERMATOLOGIC SKIN AND HAIR CLUSTER

Figure 6. Hierarchical Cluster Analysis with Symptoms
Retained in Factor Analysis
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Study Aim 4
Explore the relationships between any identified co-occurring symptoms or
symptom clusters and key variables, including gender, age, primary cancer, type of
EGFRI, and the outcome variables of quality of life, functional performance and
psychological status.
The factor solution identified by an iterative process in exploratory factor analysis
(the first method described) was used for all analyses. Factor scores were used to identify
the symptom cluster membership of each participant so that group differences could be
explored. Several options are available for generating factor scores, including the three
so-called “refined” methods: regression, Bartlett, and Anderson-Rubin, all of which are
included as options in SPSS. In order to generate factor scores in this study, the
regression method was selected. In this method, the regression factor score estimates the
location of each individual on the factor (DiStefano, Zhu, & Mindrila, 2009). When
using this approach to factor score generation, the scores are standardized to a mean of
zero and a standard deviation equal to the squared multiple correlations between factors
and variables in a PAF (Tabachnik & Fidell, 2001).
First, regression factor scores were obtained, and then the scores were described
by quartile. Each participant was then assigned a 0 or 1 to describe membership in each
of the three factors (symptom cluster groups). If a participant’s factor score was at or
above the 70th percentile, they were assigned to the factor; scores below the 70th
percentile were not described as exhibiting that symptom cluster. Because an individual
could be experiencing multiple symptoms, membership in more than one cluster was
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permitted. Members of the symptom cluster group could then be compared on outcome
variables to non-members of the cluster. An alternative approach was also used,
examining the correlation of the regression scores for each participant with the outcome
measures. Results from each of these methods are described below.
For the hierarchical regression procedures, the regression factor scores were then
used as independent variables in a multiple regression model to identify predictors of the
outcome variables: quality of life, functional performance, and psychological status.
Independent t-tests and one-way ANOVA assessed the impact of membership in each
symptom cluster on psychological status and quality of life. The impact of symptom
clusters on performance was tested using a non-parametric test. All of these findings
should be replicated in an adequately powered sample.
Factor 1: Psychological-Cognitive Cluster
Independent t-tests compared members with non-members of this cluster. Both
psychological status and quality of life were significantly different in the psychologicalcognitive cluster. The psychological outcome, measured by the MHI-5, demonstrated a
highly significant difference. As would be expected, participants with this symptom
cluster experienced an effect on psychological status as illustrated by lower mean scores
on MHI and FACT-G (Tables 18 & 19).
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Table 18. Independent Samples t-Test Comparing Means of Psychological-Cognitive
Cluster to Others
t

df

Sig. (2-tailed)

M

SD

60.47

16.55

81.23

11.72

118.06

19.04

135.03

24.41

65.12

17.98

80.69

16.98

Psychological Status
Factor 1 (n=17)

-5.357

54

.000

Others (n=39)
Total QOL
Factor 1

-2.544

54

.014

Others
FACT-G
Factor 1

-3.101

54

Others

.003

———————————————————————————————————

Quality of life, as measured by the Total QOL score (FACT-G plus EGFRI-18),
was also significantly different between the two groups, with members of the cluster
(N=17) indicating a lower QOL (M = 118.06, SD = 19.04, N = 17) compared to nonmembers (M = 135.02, SD = 24.41, N = 39), t(54) = -2.544, p = .014. Scores for the
FACT-G, as well as three of the four subscales, (SWB, PWB, EWB), which are not
shown here, were also significant, with cluster group members indicating a lower quality
of life. Non-parametric Mann-Whitney U independent t-tests were also run including
these dependent variables, confirming these results.
Using the alternative approach examining correlations, the Cluster 1 factor score
demonstrated highly significant negative correlations with the MHI-5 scores (r = -.726,
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p = .000), the FACT-G score (r = -.559, p = .000), and the Total QOL score (r = -.416,
p = .001), again confirming the association between the presence of the psychologiccognitive factor and lower psychological well-being and quality of life.
Factor 2: Dermatologic Skin and Hair Cluster
An interesting finding related to quality of life emerged when examining the
group means for Factor 2, the dermatologic skin and hair cluster. Contrary to
expectations, no significant difference between the Factor 2 members (M =51.47, SD =
14.75, N = 17) and non-members (M =56.42, SD = 10.49, N = 38) was demonstrated on
the EGFRI-18 score, which is designed specifically to measure quality of life in this
patient population. The sensitivity of the EGFRI-18 to the impact of dermatologic skin
and hair symptoms on quality of life should be further explored.
However, the Total QOL score (FACT-G plus EGFRI-18 scores), and the PWB
subscale t(54) =-3.245, p =.002 all revealed significant differences, suggesting a differing
impact of this cluster on QOL. In addition, the results for the MHI-5 (psychological
status) were significant, indicating a negative effect of this cluster on psychological status
when compared with the group without this symptom cluster. A nonparametric MannWhitney U was run because of non-normality of the FACT-G and ECOG scales, with
significant results for both the FACT-G QOL (p = .014) and the Total QOL (p = .031)
confirming a significant impact of the dermatologic skin and hair cluster on quality of life
and performance.
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Table 19. Independent Samples t-Test Comparing Means of Dermatologic Skin and
Hair Cluster to Others
t

df Sig. (2-tailed)

Mean

SD

Psychological status
Factor 1 (n=17)
Others (n =39)
Total QOL

-2.162

54

.035

68.00
77.95

19.13
14.21

Factor 1
Others
FACT-G QOL

-2.320

54

.024

119.00
134.62

23.82
22.87

Factor 1
Others

-2.331

54

.024

67.53
79.64

16.79
18.32

In the alternative approach using regression scores in a correlation procedure,
Factor 2 correlated with the Total QOL score (r =-.344, p =.00), the FACT-G (r =-.344, p
=.01), the ECOG Performance Scale (r =-.409, p =.002), and the MHI (r =-.282, p
=.035), suggesting an impact of this cluster on all outcome variables.
Factor 3: Mucocutaneous and Fatigue Cluster
For Factor 3, the mucocutaneous and fatigue cluster, there are several statistically
significant findings. FACT-G scores were significantly different in a positive direction
between members of this cluster and non-members. This trend continued for two
subscales of the FACT-G, with the both the FWB subscale scale score higher (M = 21.06,
SD = 5.14, N = 17) than non-members (M = 16.18, SD = 6.77, N = 38), t(39.763) =
2.953*, p =.005, and the SWB subscale higher (M =24.65 , SD =4.07 , N = 17) than non-

121
members (M =20.38 , SD = 7.08, N = 38), t(49.64) = 2.83*, p =.007, two-tailed,
indicating a better QOL in cluster members.
Conversely, there appears to be a negative effect of Factor 3 membership on the
EGFRI-18 score (dermatologic quality of life) compared to non-members. This is an
interesting finding, as the only dermatologic symptom retained in this cluster was other
changes to my fingers and toes, so further exploration of this relationship is warranted.
However, this statistical significance did not hold for the total QOL score (FACT-G and
EGFRI-18), which indicated no difference between the groups.

Table 20. Independent Samples Comparing Means of Mucocutaneous-Fatigue
Cluster to Others
t

df

Sig. (2-tailed)

Mean

SD

Dermatologic QOL
Factor
Others
QOL

(n=17)
(n =38)

Factor 3 (n =17)
Others (n =39)

-2.689

53

.010

48.70
57.66

13.79
10.21

2.71

45

.010

84.35

12.99
19.59

72.31

Since both the FACT-G and the EGFRI-18 (separately) are not normally
distributed, a nonparametric Mann-Whitney U test was performed for each of these
outcome variables, and both confirmed a significant difference associated with cluster
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membership in cluster members for both the FACT-G, U = 208.5, p = .028, and the
EGFRI-18, U = 187.00, p = .013. The test for ECOG was non-significant.
In the alternative procedure, the EGFRI-18 score yielded the only significant
finding (r = -.429, p <.001), suggesting a relationship between Cluster 3 and
dermatologic quality of life.
Symptom Clusters and Outcomes
The relationship between the identified symptom clusters and outcomes is
summarized in Table 20. Both Factors 1 and 2, the psychologic-cognitive cluster, and the
dermatologic skin and hair cluster have a negative relationship with quality of life.
Factor 3, the mucocutaneous-fatigue cluster, has a highly significant negative impact on
dermatologic quality of life, but the other symptom clusters do not. Both the
psychological-cognitive cluster and the dermatologic skin and hair cluster (Factors 1 and
2) are related to psychological status, with the greatest negative correlation between
Factor 1 and this outcome. A positive correlation between Factor 2, the dermatologic skin
and hair cluster and functional performance suggests a possible connection between
treatment with EGFRI therapy and improvement in performance status, but this possible
relationship requires further study. All of these findings should be confirmed in an
adequately powered sample.
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Table 21.Correlation between Symptom Clusters and Outcome Measures
Factor 1

Factor 2

Dermatologic
QOL
n=55

Factor 3
-.429
.001

Psychological
status
n =56

-.727
.000

-.282
.035

Total QOL

-.416
.001

-.389
.003

-.559
.000
56

-.344
.009
56
.409
.002

n=56
Quality of Life
n=56

Performance/
Functional
Status
n=56
Note: Factor 1 is the psychological-cognitive symptom cluster; Factor 2 is the
dermatologic skin and hair cluster; Factor 3 is the mucocutaneous-fatigue cluster.

Multiple Regressions
Stepwise hierarchical multiple regressions were used to determine which, if any,
of the independent variables, including symptom clusters, significantly predicted the
various outcome variables. Demographic variables, including gender, level of education,
age, stage of illness, primary diagnosis, concurrent therapy, relationship status, method of
survey completion (online vs. paper), length of EGFRI therapy, and specific EGFRI
therapy were entered into each regression. The results of the regression are as follows.
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Quality of Life
Factors 1 and 2 predicted the Total QOL score (sum of the FACT-G
and EGFRI-18), explaining about 31 % of the variance of the overall score,
R2 =.311, F (2, 53) =11.95, p < .001. For the FACT-G alone, Factors 1 and 2 predicted
about 41% of the variance in quality of life R2 =.415, F (2, 53) =18.79, p < .001.
For dermatologic quality of life, as measured by the EGFRI-18, Factor 3 predicted 18%
of the variance, R2=.184, F(1,53)= 11.95, p < .001. Regression models for quality of life
are presented in Tables 22 and 23. As noted, results should be confirmed in a larger,
adequately powered sample.

Table 22. Regression Model with Predictors for Quality of Life
Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta

t

Sig.

Total QOL
(Constant)
Factor 2
Factor 1 Score
FACT-G QOL

129.875
-10.134
-10.133

2.720
3.116
2.894

(Constant)

75.964

1.935

Factor 1
Factor 2

-10.675
-6.742

2.059
2.217

-.371
-.400

47.749 .000
-3.252 .002
-3.501 .001

39.253 .000
-.545
-.320

-5.183 .000
-3.041 .004
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Table 23. Regression Model with Predictors for Dermatologic Quality of Life
Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta

t

Sig.

EGFRI-18
(Constant)
Factor 3

54.944

1.482

-5.79

1.675

37.083 .000
-.429

-3.457 .001

Psychological status. The independent predictors Factor 1 (psychologicalcognitive), Factor 2 (dermatologic skin and hair), as well as marital status, significantly
contributed to the prediction of scores on the MHI-5, as noted on the regression model in
Table 24. These variables explain about 63% of the variance in this measure, with Factor
1 explaining the largest proportion of variance in psychological status scores, R2 =. 528,
F(1, 54 ), p < .001.
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Table 24. Regression Model with Predictors for Psychological Status

Model

Unstandardized
Coefficients
B
Std. Error

(Constant)
69.348
Marital status
3.634
Factor 1
-13.207
Factor 2
-5.076
Note: Dependent variable is MHI-5.

2.633
1.468
1.493
1.570

Standardized
Coefficients
Beta

t

26.333
.216 2.476
-.767 -8.844
-.274 -3.234

Sig.

.000
.017
.000
.002

Inspection of the correlations of the (Table 25) psychological symptoms with the
MHI-5 reveals that all of the symptoms had a highly significant and negative correlation,
yielding preliminary evidence of the importance of addressing psychological symptoms
in an effort to improve patient outcomes such as psychological status. These results
should be replicated in an adequately powered sample. Clearly, psychological symptoms
exert a major impact on outcomes in patients receiving EGFRIs, so psychological
assessment should be conducted on all patients receiving these medications.
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Table 25. Correlations of Psychological Symptoms and Outcomes
FACT-G

QOL Total

MHI-5

Feeling sad

-.566**
.000

-.458**
.000

-.769**
.000

Worrying

-.473**
.000

-.291*
.029

-.572**
.000

Feeling irritable

-.288*
.032

-.272*
.043

-.506**
.000

Feeling nervous

-.530**
.000

-.411**
.002

-.682**
.000

ECOG PS

.284*
.034

Note. QOL Total includes FACT-G: Functional Assessment of Cancer Therapy-General;
FACT-EGFRI-18: Functional Assessment of Cancer Therapy-Epidermal Growth Factor
Receptor Inhibitor-18 subscale; ECOG: Eastern Cooperative Oncology Group; MHI-5:
Mental Health Index-5. ** indicates p < .001, * indicates p < .05, two-tailed.

Performance status. For the ECOG scale, Factor 2 explained 16% of the
variance in functional status, but the other symptom clusters did not contribute to the
model, R2 =. 167, F(1, 54 ) + 10.857, p < .002.
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Table 26. Regression Model with Predictors for Performance Status
Unstandardized
Coefficients
B
Std. Error

Model

Standardized
Coefficients
Beta

t

Sig.

(Constant)

.661

.089

7.452

.000

Factor 2

.334

.101

.409 3.295

.002

Note: Dependent variable is ECOG PS.

CHAPTER FIVE
DISCUSSION
This study was designed to characterize the symptom experience of patients
receiving EGFRI therapy and to describe how this experience affects key outcome
variables, including quality of life, performance and psychological status. Patients with
solid tumors including lung cancer, colon cancer, head and neck cancer, and breast cancer
who were receiving an EGFRI for at least four weeks were included in the sample. This
chapter will review the key findings from this study, highlight new data, and integrate
this information with current knowledge on this topic.
The theory of unpleasant symptoms guided the conception and design of this
study. In this model, the symptom experience is viewed as multidimensional,
encompassing aspects of distress, quality, intensity and timing. Consideration is given
within the model’s framework to the coexistence of symptoms and their collective impact
on performance, as well as to the idea that symptoms may both influence and be
influenced by the interaction of situational, psychological and physiologic factors.
Performance in this study was conceived broadly to include the dimensions of quality of
life, psychological status and functional performance. The collective impact of
symptoms (as symptom clusters) on these outcomes was explored. Three symptom
clusters were identified, including one that is well-established in the literature, a novel
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dermatologic skin and hair cluster likely related to EGFRI therapy, and a third cluster
similar to another well-established cluster, but with an additional mucocutaneous
component that is also related to EGFRI therapy.
Study Aim 1
Describe the symptom experience (symptom frequency and distress) of patients
receiving EGFRI therapy.
Symptom Experience
An extensive symptom battery, the MSAS-SF (adapted), was used to capture the
most common and distressing symptoms associated with EGFRI therapy, using the past
seven days as a time frame. The instrument included 38 symptoms, and participants were
asked to select the symptoms that they experienced over the last week, and to indicate
how much the symptom distressed them (physical symptoms) or how frequently the
symptom occurred (psychological symptoms). Participants were also asked to identify
any symptoms they were experiencing that did not appear on the instrument.
As noted in chapter four, several symptoms known to occur with frequency in
patients taking EGFRIs were added for the purposes of this study. Although all
symptoms were endorsed by some patients, the symptoms that were selected by over 40%
of participants are discussed below. The EGFRI-18, a dermatologic quality of life
instrument specifically designed for use with EGFRIs, was also used to gain an additional
understanding of the symptom experience, and will be discussed in the section on
outcomes.
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Most Frequently Identified Symptoms
The most frequent symptoms identified by over 40% of participants included dry
skin, lack of energy, dry mouth, changes in skin, feeling sad, changes to fingers or toe
nails, worrying, diarrhea, feeling drowsy, problems with sexual interest or activity,
changes in facial hair growth, difficulty sleeping, feeling nervous, numbness or tingling
in hands or feet, and feeling irritable. The most distressing or prevalent symptoms were
dry skin, lack of energy, worrying, changes to finger and toe nails, problems with sexual
interest or activity, changes in skin, dry mouth, feeling sad, diarrhea, feeling nervous,
feeling irritable, and changes in facial hair growth.
These symptoms differ substantially from the typical set of symptoms associated
with cancer treatment. Recognition of the unique symptom profile of the EGFRIs by
health care providers is essential. Recently, following a systematic review of the
literature and consensus process, a panel of experts recommended a set of 12 symptoms
to be included as patient-reported outcomes for clinical trials. The group recommended
that fatigue, insomnia, pain, anorexia, dyspnea, cognitive problems, anxiety, nausea,
depression, sensory neuropathy, constipation and diarrhea be included in this dataset
(Reeve et al., 2014). Approximately half of these symptoms are not relevant in to this
study, but they are symptoms that have been prominent in oncology care for a prolonged
period of time. Whether all patients are best served by this core set of measures remains
to be evaluated, and this study suggests that traditionally important symptoms may still
be important, but are being eclipsed by the side effects of new treatments.
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Symptom prevalence and distress studies in oncology are limited by the
instruments used to measure them, and most of the common symptom measurement
batteries do not include symptoms relevant to the patient receiving EGFRI therapy. This
same scenario probably applies to other novel agents as well, so practitioners, educators,
and researchers should be aware of this when reviewing and adopting assessment tools
and instruments for research, as well as when consulting the literature for patient
management issues.
Participant-identified symptoms. Eleven participants responded to a question
asking them to list other symptoms that did not appear on the study questionnaire. Two
participants mentioned severe dry eye, with one describing it as very distressing and
another noting that in interfered with vision, caused blurring and required the use of
artificial tear drops and eye ointment at night. One participant described “swollen eyelids
with oozing quasi liquid that hardens into a dry crust,” and that was painful to remove.
Another noted excessive nasal mucous that hardened into a crust that was also painful to
remove. The additional symptoms identified by participants are similar to responses
provided in an evaluation of the EGFRI-18, where nasal crusts and eye sensitivities were
also among several additional suggested by patients (Boers-Doets et al., 2013). These
findings point to the need for possible ophthalmologic or oncodermatology referral for
patients receiving EGFRI therapy.
Several items appeared on the instrument but were understood differently by
participants, so they were suggested as additions, including “fatigue” (lack of energy),
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“rash” (changes in skin), and “changes to my eyebrows” (changes to hair growth on my
face). Other physical symptoms each mentioned by one participant included occasional
long bone pain at night, lip swelling quite a bit, and feet hurting in the morning. Finally,
one participant offered “I don’t know what I am supposed to be doing with my life.
Uncertainty, I guess.” This comment underscores the existential plight of the patient with
advanced cancer, and draws attention to the need to address not only physical, but
psychological symptoms as well in assessment, care and research related to oncology
patients.
Additional work is needed to identify an optimal set of items to measure the
EGFRI symptom experience, as the current study captured most, but not all relevant
symptoms. In future research on EGFRIs, more explicit reference to a rash that is more
specifically described would be beneficial, rather than addressing it generally as changes
in skin. Additional symptoms such as eye changes and crusting, changes in eyebrows,
and nasal crusts should also be included. In the present study, more general items
(changes to skin and changes to hair growth on my face) were chosen in an effort to
minimize the number of variables, but they may not have fully captured the nuances of
the dermatologic toxicities experienced by patients. Future studies could continue to
refine the list of symptoms relevant to EGFRI therapy, and to explore the validity and
reliability of a revised MSAS instrument, the MSAS-EGFRI.
Study Aim 2
Describe the quality of life, functional performance status and psychological
status of patients receiving EGFRI therapy.

134
As described in chapter four, participants in this study reported reasonably good
quality of life, functional performance status and psychological well-being. The impact of
EGFRI therapy on these outcomes was not consistent, with the most significant effects
seen on dermatologic quality of life and psychological well-being, so these are areas that
should be explored further.
Various instruments should be compared in order to identify the optimal
measurement strategy for these outcomes. Whether the EGFRI-18 is the best
dermatologic quality of life instrument for this patient population remains an open
question, so comparisons with other tools are suggested. Future studies could compare
the relative merits of the Skindex instruments with the EGFRI-18 in order to establish an
optimal dermatologic quality of life measurement strategy in the setting of EGFRI
therapy. The MHI-5 is a simple instrument that could be used more frequently in the
clinical setting, and could also be compared to other instruments that assess
psychological distress.
Study Aim 3
Identify any co-occurring symptoms or symptom clusters in patients receiving
epidermal growth factor receptor inhibitors.
Symptom Clusters
Data derived from MSAS-SF (adapted) provided the basis for identification of
symptom clusters using exploratory factor analysis. A three cluster solution was
identified, including one symptom cluster similar to others previously identified (a
psychological-cognitive cluster), a novel cluster possibly related to treatment
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(dermatologic skin and hair cluster) that has not been previously identified in symptom
cluster research, and a third cluster similar to previously described clusters (lack of
energy, difficulty concentrating, feeling drowsy) but with a mucocutaneous component
(dry mouth and other changes to fingers and toes), which may reflect the impact of
EGFRI therapy and is labeled as a mucocutaneous and fatigue cluster. The symptom
clusters are identified here both by their factor number, indicating the order in which they
were identified by factor analysis, and the descriptive name given to them to characterize
the symptoms that grouped together. All three of these clusters must be replicated using
a larger sample and a longitudinal design.
Factor 1, the psychological-cognitive cluster, comprised of feeling irritable,
feeling nervous, worrying, feeling sad, difficulty concentrating, and “I don’t look like
myself,” is similar to clusters described in other work, as stated in chapter four. Although
there are several similar clusters described in the literature, they are not identical, largely
due to differences both in instrumentation (instruments with fewer or different
symptoms) and in the sample (e.g. all breast cancer patients). These psychoneurologic
clusters often include sleep disturbances, as well as anxiety, depression and other moodrelated symptoms. However, despite some variation in specific symptoms, this type of
symptom cluster does seem to be prevalent and consistent across many different studies
(Kirkova, Walsh, Aktas, & Davis, 2010; Jiménez et al., 2011; Kirkova, Aktas, Walsh, &
Davis, 2011; Yennurajalingam et al., 2013; Thomas et al., 2014), and is consistent with
the experience of living with advanced cancer.
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Researchers have theorized that clusters including emotional or behavioral
symptoms and general sickness symptoms may be attributable to underlying
psychological or neurological dysfunction (Kim, Barsevick, Fang, & Miaskowski, 2012),
with the suggestion that a common biological pathway, such as proinflammatory
cytokines, the hypothalamic-pituitary-adrenal axis system and the 5-HT system, may
contribute to the development of these symptoms. Sickness symptoms have been linked
to cytokine neuroimmunologic mechanisms (Lee et al., 2004; Myers, 2008), as has been
demonstrated in the animal model, with comparisons drawn to the responses seen in
oncology patients (Cleeland et al., 2003).
Although definitive work in this area remains to be conducted (Dantzer, Meagher,
& Cleeland, 2012), those experienced in caring for oncology patients recognize that these
symptoms often cluster together. Symptoms such as fatigue, reduced appetite, sleep
disorders, and altered mood and cognition may be related to the expression of
inflammatory mediators that can affect the brain and the subjective symptom experience
(Dantzer, O’Connor, Freund, Johnson, & Kelley, 2008). Beginning evidence that EGFRIs
play a role in cytokine regulation has been published (Paul et al., 2014). In vitro work in
EGFRI-treated head and neck cancer cells suggested that EGFRIs are associated with the
production of proinflammatory cytokines, but the mechanisms for this need to be more
fully explained and then explored in the clinical setting (Fletcher et al., 2013).
Factor 2, a possibly treatment-related dermatologic skin and hair cluster has not
been described before in symptom cluster research using factor analytic procedures.
This cluster includes dry skin, changes in eyelashes, hair loss, changes in facial hair
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growth and other changes in scalp hair. Notably, nail changes and changes in fingers and
toes did not correlate with the other symptoms in this cluster, which is an unexpected
finding. As noted in chapter four, other treatment-related and diagnosis-related symptom
clusters have been described, but no EGFRI-related clusters have yet been identified
using factor analytic techniques or any other statistical approach. This work represents
the first documentation of a symptom cluster that appears to be associated with EGFRI
therapy, and this finding should be replicated in a larger sample.
Other treatment-related symptom clusters have been previously described in
various patient populations (Honea, Brant, & Beck, 2007; Kirkova et al., 2011), such as
in patients receiving chemotherapy (Aprile, Ramoni, Keefe, & Sonis, 2008; Yamagishi,
Morita, Miyashita, & Kimura, 2009; Hockenberry et al., 2010; Baggott et al., 2012);
chemoradiation (Wang et al., 2006) and radiation therapy (Kim et al., 2009b; Kim et al.,
2009a), but not in patients receiving EGFRIs. Treatment-related clusters have also been
identified in patients with breast cancer (Kim, Barsevick, Tulman, & McDermott, 2008);
in head and neck cancer, with symptoms including radiodermatitis, dysphagia, pain, taste
disturbance, fatigue, radiomucositis, and dry mouth (Xiao et al., 2013); in patients treated
with specific therapies for liver cancer, as evidenced by a gastrointestinal symptom
cluster with higher severity scores (Wang, O'Connor, Xu, & Liu, 2012); with brain
tumors, including a language cluster and a mood cluster (Gleason, et al., 2007);and in
patients with prostate cancer where bowel and bladder symptoms were observed
(Maliski, Kwan, Elashoff, & Litwin, 2008).
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Factor 3, a mucocutaneous and fatigue cluster, includes dry mouth, other changes
to fingers or toes, feeling drowsy, lack of energy and difficulty concentrating. While lack
of energy, dry mouth and psychological symptoms have long been documented in
oncology patients, skin and nail changes have not been commonly reported in previous
work. Skin, hair and nail issues, as well as mucocutaneous symptoms, have emerged as
key problems for intervention in this population of patients, so their inclusion in a
symptom cluster is an important finding. Aside from the symptom other changes to
fingers and toes, clearly linked to EGFRI therapy, this symptom cluster could also be
related to the same proinflammatory mechanisms described above in the discussion on
Factor 1.
Others have described similar clusters (without the changes to fingers or toes) that
include feeling drowsy and lack of energy, albeit with some variation in the symptoms
secondary to instrumentation. Similar fatigue-related clusters have included lack of
energy, feeling drowsy, difficulty sleeping, problems with urination, feeling irritable
(Kim et al., 2009a); pain, lack of energy, feeling drowsy, difficulty sleeping, and sweats
(Kim et al., 2009b); fatigue, sleep disturbance, lack of appetite, and drowsiness (Chen &
Tseng, 2006); fatigue, weakness, anorexia, lack of energy, dry mouth, early satiety,
weight loss, and taste change (Walsh & Rybicki, 2006); sadness, dry mouth, drowsiness,
shortness of breath, sleep disturbance, appetite changes, fatigue, pain, and numbness
(Wang, Tsai, Chen, Lin, & Lin, 2008).

139
Findings Contrary to Previous Studies
Contrary to previous work in symptoms clusters (Chen & Lin, 2007; Fan et al.,
2007; & Skerman, Yates, & Batistutta, 2012), gastrointestinal symptoms were not
reported by a majority of patients, and no appetite or gastrointestinal symptom cluster
was identified in the present study. In previous studies, an array of different
gastrointestinal clusters have been documented, often including nausea and vomiting,
lack of appetite, feeling bloated, dry mouth, changes in the way food tastes, and similar
symptoms (Cherwin, 2012), often associated with chemotherapy or radiation therapy.
However, in the present study, the majority of patients did not receive concurrent
chemotherapy.
Dry mouth was a very prevalent and distressing symptom for participants in this
study, experienced by over 57%, and ranked fifth in distress. However, it did not seem to
cluster with other gastrointestinal symptoms. Although diarrhea and changes in the way
food tastes were experienced respectively by 48.2 and 39.3% of participants, these
symptoms also did not correlate strongly with other gastrointestinal symptoms, or even
any other symptoms at all as they were not retained in factor analysis.
Other symptoms long associated with cancer therapy, including weight loss, lack
of appetite, nausea, mouth sores, constipation, feeling bloated, and vomiting, also did not
occur in a majority of participants. Perhaps these findings may be a function of the
smaller sample size, so it is possible that with a larger sample, such symptoms would
have emerged with greater frequency. However, this variation from previous research is
likely explained by the prevalence of targeted therapies in this sample, with only 19
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participants reporting that they were also receiving additional therapies, as described in
chapter four, and of this group, only 8 were receiving drugs classified as chemotherapy,
while two reported receiving concurrent radiation therapy.
Study Aim 4
Explore the relationships between any identified symptom clusters and key
variables, including gender, age, primary cancer diagnosis, EGFRI, and the outcome
variables of quality of life, functional performance and psychological status.
No consistent relationships were identified between any demographic or clinical
variables, although the distress and prevalence of several symptoms did vary on the basis
of gender, primary cancer diagnosis, and specific EGFRI therapy. For example, dry
mouth was most distressing in head and neck and colorectal cancer patients, who are
likely to be receiving MOABs, and diarrhea was more common in breast cancer patients
who could be taking lapatinib. Gender played a role with regard to some symptoms. Men
reported more symptoms, and were more likely to report lack of energy, dry mouth,
problems with sexual interest or activity and dry skin, while women were more likely to
report worry. The finding with dry skin is interesting, and may suggest that men are less
likely to apply lotions and creams as part of routine skin care, so they may need to be
educated to do so.
Symptom Clusters and Outcomes
The relationships between the identified symptom clusters and the outcome
measures were explored to determine any differing impact of symptom clusters with the
intention of generating hypotheses for further exploration. This study is among the first
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to explore how symptom clusters, including a newly identified symptom cluster, affect
quality of life, psychological status, and performance. Although the findings here are
preliminary, it appears that different symptom clusters can impact outcomes to varying
degrees. Identifying those symptom clusters that create the most negative impact on
performance and other outcomes would be beneficial for patients.
For example, the association between the psychologic-cognitive symptom cluster
and adverse psychological status should be confirmed, providing evidence of the need for
more widespread implementation of psychosocial interventions for patients with cancer.
The effect of symptoms on performance, as postulated in the theory of unpleasant
symptoms, was demonstrated by a patient comment reflecting the unique impact of
dermatologic symptoms associated with EGFRI therapies. This narrative offered by a
participant highlights the distress and inconvenience of both skin and nail issues, and
underlines how performance of everyday activities and recreational pursuits can be
affected:
The problem with my fingernails sometimes gets so bad that I cannot use a knife
and fork. The limitation of having to stay out of the sun has resulted in my giving
up golf, biking and vacations at beach. I run from the sun and must wear a hat at
ALL times. I find this very confining.
Other studies have demonstrated a negative impact in subgroups of patients with
high levels of predetermined symptoms on functional status and quality of life
(Miaskowski et al., 2006; Pud et al., 2008; Dodd et al., 2010), but these studies explored
an a priori symptom cluster of fatigue, sleep disturbance, depression and pain. For
example, Miaskowski et al. (2006) found that in participants reporting “all high” levels of
symptom severity for pain, fatigue, sleep disturbance and depression reported a lower
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quality of life and lower functional status in contrast to those who reported less symptom
severity. Future studies with larger samples could evaluate high, moderate and low
distress in symptom clusters to explore the impact on outcomes. To some extent, this
was addressed by comparing symptom cluster members to those without the symptom
cluster, but this work could be extended.
Future work in this area could also address the concept of the sentinel symptom,
which is defined as a candidate symptom that heralds the presence of a symptom cluster
(Brown et al., 2011), and could further explore the role of age and gender. Based on the
factor loadings in the present study, the symptoms of feeling nervous, dry skin and
changes to fingers and toes could be possible sentinel symptoms that could signify other
symptoms that cluster together. Assessment strategies that call attention to such sentinel
symptoms could help prioritize which symptoms to focus on in clinical encounters.
Limitations
This exploratory study is a preliminary work, and as such, has several significant
limitations, but perhaps the most relevant to its validity is inherent self-selection. The
“passive” study recruitment strategy could result in selection bias affecting the findings.
When respondents opt in to research, there may be pre-existing differences between study
participants and others who either choose not to participate or who are unaware of a
study. However, participants may be more likely to self-select when the research is about
something that affects them. Women are more likely to complete health-related surveys
(Eysenbach & Wyatt, 2002), which is reflected in the study sample. Specific issues
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related to the sample characteristics that impact the validity of this study are outlined
below.
Sample Characteristics
A number of sample characteristics in this study may limit applicability to the
general population of patients receiving EGFRI therapy, including sample size,
educational status, social engagement, performance status, and gender.
Small Sample Size
Because a larger sample size (n =100) was sought, this study primarily used a
web-based survey. This approach was designed to facilitate recruitment and study
enrollment from a broad population, and the majority (80%) did complete the study
online. Participant recruitment occurred over an eleven month time frame, and multiple
direct and indirect recruitment strategies were utilized. Recruitment materials were
posted at multiple sites online, on a study web site, and at cancer support locations; letters
explaining the study and research flyers were mailed to a large number of practitioners.
Despite multiple study recruitment procedures over an extended time period, however,
the desired sample size could not be accrued, so this may limit both the internal and
external validity of the study.
Performance Status
Even with advanced disease, most participants were well enough to use a
computer or to complete a paper survey. In addition, most reported a good performance
status, so the findings of this study are applicable to patients with a similar performance
status and may not reflect those whose performance is compromised by illness.
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Participants who completed the study online were well enough to use technology to
access information and support; those with a limited performance status may not have
spent the time online that would lead them to study recruitment materials, or they may
have begun the study, but did not complete it. In addition, those who received recruitment
flyers from their health care provider may also have had a better performance status, as
sicker patients may not have been told about the study.
Race and Ethnicity
As this was an exploratory study, questions about race and ethnicity were not
included. In future work, this information, along with skin phenotype, could be included.
There is a possible link between skin phenotype and increased skin toxicity (Lacouture,
2006), as noted in chapter two. At least one study suggests that erlotinib skin toxicity is
associated with skin phenotype (Luu et al., 2011), so consideration of this patient
characteristic could be an area for additional study related to EGFRI-related skin
symptoms.
Educational Level and Access to Technology
Computer literacy and greater comfort with online activities may be associated
with educational level, so it is possible that the study sample was self-selected with
regard to comfort with online activities, impacting the external validity of these findings.
Although a recent survey suggests that over 80% of the US population uses the Internet,
including an equal number of men and women, there are variations in terms of utilization
with respect to age, educational level, ethnicity, and household income ("The Web at
25.," 2014). Participants in this study were highly educated, with most reporting a
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college education, so findings may not apply to those with less education or less
computer literacy.
Support Group Engagement
Because study information was posted in various cancer support groups and in
cancer support settings, the study may also be biased to reflect the experience of
participants who are more socially engaged rather than those who are isolated and not
connected to live or online support groups. Patients who participate in support groups
have been described as more likely to be female, younger, educated, without a partner,
and with more formal support than those who do not choose to participate in such groups
(Grande, Myers, & Sutton, 2006). With the exception of partner status, this sample
reflects these characteristics.
Although the research on support group engagement is inconsistent, what is
available suggests that a minority of patients express an interest in becoming engaged
with support groups of any kind, whether live or online (Van Uden-Kraan et al., 2011).
A recent study reported that only about one-third of lung cancer patients planned to
participate in support groups (Xu et al., 2014), while another survey of NexCura panel
participants indicated that only about 25% of patients participated in support groups
(Morse, Gralla, Petersen, & Rosen, 2014). As the latter sample was drawn from a
population of patients who agreed to be a part of an online research panel (inactive as of
this writing), it is likely that this estimate is high and far fewer patients actually do
participate in cancer support groups. Many online studies utilize panels for recruitment,
and this option was explored with the current study, but was cost-prohibitive. With
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funding, a more purposeful sampling strategy could be implemented to reflect
demographics of patients receiving EGFRI therapy. Since this study was launched,
additional options for research participant recruitment have become available, and could
be used in the future.
Cross-Sectional Design
Consistent with the descriptive nature of this study, a cross-sectional design was
used, so changes in symptom clusters over time were not assessed. The natural course of
symptoms associated with EGFRI therapy may evolve over time, so this snapshot of the
patient experience does not characterize its changing course. The temporal evolution of
EGFRI-related symptoms is discussed below.
Skin changes. Skin changes, such as folliculitis, are monomorphic, suggesting
that lesions develop simultaneously at a point in time (Sinclair, 2014). Palliation of these
changes in order to enhance adherence to therapy may be essential to optimal treatment
outcomes. More experience has been gained with prophylactic treatment, so it is possible
that patients in this study benefited from the suggested therapies. Over half of patients
reported using a special cream, and about one-third indicated that they were receiving a
medication for treatment of skin changes.
Dry skin. The onset of dry skin (xerosis) often occurs after four weeks of
therapy, but will increase over time as therapy continues, with almost all patients
demonstrating this symptom after six months of treatment (Lacouture & Lai, 2006;
Mitchell, Perez-Soler, Van Cutsem, & Lacouture, 2007; Osio et al., 2009; Sinclair, 2014).
Because the study was cross-sectional, the extent of dry skin experienced by patients
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receiving EGFRI therapy in this sample may be underestimated. However, it is the most
commonly occurring symptom reported, experienced by about 70% of participants.
Utilizing a longitudinal approach, this percentage could be significantly higher.
Nail changes. Incidence of paronychia also increases over time, so nail changes
could be more prevalent in with a longitudinal time frame (Chanprapaph et al., 2014),
and may be a more distressing and frequent symptom as time on therapy increases.
Hair changes. Hair changes are considered a late toxicity and would also be
more pronounced after several months of therapy. Therefore, hair changes could become
a more prevalent symptom over time, a finding that would be noted with a longitudinal
study design. Patients treated over six months experience many different changes to hair
texture and growth, as well as alopecia that can affect the scalp and other areas of the
body. Although well over a third of participants reported various changes in hair growth,
the frequency of these changes could also be significantly greater over time.
Interestingly, there is a tendency for hair growth on the face to increase, particularly in
patients who receive erlotinib, as well as for changes to occur in eyelashes, with most of
these changes occurring between 4-8 weeks of therapy and persisting over time (Wu et
al., 2011).
Given the changing nature of the symptoms associated with EGFRIs, whether the
impact of these symptoms on quality of life, functional performance and psychological
status would be different over time is a question that could be pursued in future research.
All of these outcomes could be positively impacted by successful therapy, as well as
adversely affected by failing therapy, so a longitudinal time frame would capture these
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changes. In addition, more research about basic demographic variables, such as age and
gender, could reveal new insights into the symptom experience in patients treated with
EGFRIs.
Measurement Issues
In this exploratory study, a key aim was to describe the symptom experience of
patients receiving EGFRIs. The MSAS-SF was adapted to include additional symptoms
associated with EGFRI therapy, including dry skin, changes to my finger or toe nails,
changes in hair growth on my face, other changes to scalp hair, changes in my eyelashes
and other changes to my fingers and toes. The results indicate that the EGFRI symptom
experience differs from that traditionally associated with cancer therapy. Many of the
symptoms listed on the original MSAS-SF were not selected by respondents to this
survey, and future studies might include fewer items, eliminating those experienced by
few patients. Additional items, as suggested by participants, could include dry eyes, eye
discharge and crusting, changes to eyebrows, changes to hair texture, eyelid changes,
itchy scalp, rash and nasal changes.
In preparation for this study, the Skindex instruments were reviewed for possible
inclusion in the study (Chren, Lasek, Quinn, Mostow, & Zyzanski, 1996; Chren et al.,
1997; Chren, Lasek, Sahay, & Sands, 2001). As the Skindex instruments were not
specific to this type of oncologic therapy, and were designed for quality of life
measurement in general dermatologic practice, an instrument specifically designed for an
oncology population was selected instead. It would be interesting to revisit these
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instruments and evaluate them against the FACT-EGFRI-18 in measuring dermatologic
quality of life in patients receiving EGFRIs.
As noted in chapter four, the items in the EGFRI-18 selected by most participants
were included in the Physical subscale (e.g. “My skin or scalp itches,” “My skin or scalp
feels dry,” “My skin or scalp feels irritated,” “My eyes are dry.”) or reflected a response
to a physical symptom (“I am bothered by hair loss.”)
Implications for Nursing
Practice
This exploratory study of the symptom experience of patients receiving EGFRIs
represents the first attempt to more fully characterize the multidimensional effects of this
treatment on the whole person and not just on hair, skin and nails. Previous work has
been focused primarily on dermatologic side effects of treatment while performance,
quality of life and psychological well-being have not been holistically assessed (White et
al., 2011). The present study underscores that although skin, hair and nail changes are
prominent components of this experience, other symptoms may also be frequent and
patients would benefit from thorough, systematic assessment and from effective palliative
and preemptive management. With an average of 11 symptoms reported by patients in
this sample, the question is raised as to whether clinicians are addressing that number of
symptoms in the course of routine care, and if not, how are patients navigating their
symptom experience?
As part of the recruitment process for this study, many patient support and
information sites were visited by the researcher. Common topics of conversation on
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these sites included rash and other skin, nail, and hair changes, with patients exchanging
suggestions and their own experiences. Some mentioned that their nurse or physician
provided guidance to them, but many were turning to the wisdom of experienced group
members for practical suggestions. If this is where patients gather their self-care
information, that may be empowering to patients, but it does reflect possible missed
opportunities for nursing care to guide patients to evidence-based care management
strategies.
Consistent with exemplary oncology nursing practice, holistic assessment of the
patient experience should be the basis of comprehensive patient care that incorporates
multiple disciplines. Identification of co-occurring symptoms or symptom clusters should
be a priority in order to streamline and deliver care more effectively and economically.
Nurses should be aware of the most common and the most distressing symptoms
experienced by patients, and should be aware of the concept of symptom clusters and
how to assess them.
This study suggests that outcomes such as quality of life, performance and
psychological status may be impacted differently depending on the constellation of
symptoms, or symptom clusters, that patients may be experiencing. An awareness of the
impact of symptom clusters on specific outcomes can guide busy practitioners to provide
tailored and pre-emptive support, education and self-management strategies for patients
based on their symptom experience.
Psychosocial assessments, in particular, should be undertaken with all patients
receiving these therapies. The first factor to emerge in factor analysis procedures was the
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psychological-cognitive cluster, which suggests that patients on EGFRI therapy should be
evaluated as to their psychological status across the treatment continuum. A variety of
brief screening tools for assessing anxiety, depression and psychological status are
available, and their implementation at various points along the EGFRI therapy trajectory
could help identify patients with issues related to psychological status.
Nursing interventions for the psychological-cognitive cluster could include a set
of interventions such as skin toxicity management (e.g. antibiotics and topical therapies),
cognitive behavioral strategies (Wagner & Lacouture, 2007), a telephone or online
support group, a sleep hygiene plan (pharmacologic and non-pharmacologic), a plan for
energy conservation, and an exercise program. This anticipatory guidance would be an
improvement over the prevailing standard of care which tends to focus primarily on skin
issues, which if severe enough, might generate a referral for dermatologic care or
psychological support. Helping patients to continue therapy through enhancing their
coping skills and by addressing symptoms and associated quality of life issues could
improve adherence and the effectiveness of treatment.
Education
A paradigm shift in the education of oncology nurses to embrace a wider range of
treatment-related symptoms is underway and should continue as new therapies emerge.
Competency in the assessment and management of skin, hair and nail changes, as well as
other symptoms caused by EGFRIs, should be fostered in settings where EGFRIs are
included in patient treatment plans. In addition, wider dissemination of the recommended
management strategies for EGFRI side effects is necessary. Although some patients
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require referral to dermatologists, nurses working at the top of their licensure are capable
of making patient self-care recommendations, as well as advising patients about over the
counter products, as long as they have participated in continuing education and
professional development regarding these symptom management strategies. When
medical management is necessary, the astute nurse can be instrumental in making timely
referrals.
Patient education materials highlighting proactive symptom management and
preventive care strategies should be included in the teaching materials for patients who
are receiving EGFRI therapy. As each individual patient may have varying needs based
on occupation, social roles, activities of daily living, and lifestyle considerations, nurses
should be attuned to how high frequency and highly distressing symptoms may impact a
given patient and should augment patient education accordingly. For example,
individuals who use their hands frequently in their work, such as homemakers, nurses or
other health care workers, massage therapists, restaurant workers, clerical and retail staff,
hospitality and service workers, mechanics and others, as well as those who enjoy
hobbies requiring manual work like gardening or fishing, are at particular risk for
exacerbation of EGFRI-related issues.
Research
Skin, hair and nail changes are frequently experienced by patients receiving these
therapies, but evidence-based therapies are lacking for many of the symptoms. Dose
modifications and therapy interruption may occur in a significant number of patients
(Boone et al., 2007), so optimal preventive and management strategies will provide a
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basis for optimal therapy. Most recommendations for EGFRI symptom management are
anecdotal in nature and have not been rigorously evaluated, with some exceptions.
The Multinational Association for Supportive Care in Cancer (MASCC) Skin
Toxicity Study Group recently published clinical practice guidelines for the prevention
and treatment of dermatologic toxicities (Lacouture et al., 2011). Although some of the
guidelines are based on research, other recommendations are based on expert opinion and
panel consensus due to a lack of relevant studies. As noted by MASCC, data from other
similar skin conditions provided the basis for some recommendations; as a result, it is
entirely possible that outcomes from these treatments may not be optimal for the
dermatologic changes caused by EGFRIs. As a result, many opportunities for
interventional and comparative effectiveness trials remain.
Nurses have long managed patients’ skin conditions, and oncology nurses have
claimed symptom management as their forte. Since patients report itchy, dry, flaky and
irritated skin, changes in hair, and changes in fingers and toes frequently, nurse-led
protocols to ameliorate these symptoms should be evaluated in partnership with
practitioners with dermatologic experience. While many of the interventions suggested
by MASCC are pharmacologic agents, many are not, so teams including dermatologists,
advanced practice nurses and oncology nurses could collaborate on research evaluating
these treatments. Such interdisciplinary work would be an ideal approach to generating
evidence-based care protocols. Implementation of funded, longitudinal research is also
essential in order to document not only the trajectory of the symptom experience of

154
patients receiving EGFRIs, but also to determine optimal points for intervention across
the treatment continuum.
In a sample of colorectal cancer patients receiving panitumumab and combination
chemotherapy, a pre-emptive skin treatment regimen that included skin moisturizer,
sunscreen, topical steroids, doxycycline, and an educational video aimed at minimizing
skin irritation, was compared to a reactive treatment protocol. Participants kept a diary of
symptoms that also recorded treatment compliance (Lacouture, Mitchell, et al., 2010).
Results indicated that patients receiving the pre-emptive regimen experienced a
significantly lower rate of > Grade 2 or greater skin toxicity (29% vs. 62%). The reactive
treatment group demonstrated a greater decline in quality of life scores. Although this
regimen only evaluated one EGFRI, the findings are encouraging and might be evaluated
with other therapies. Interestingly, diarrhea was also lessened in the pre-emptive
treatment group, most likely due to treatment with an antibiotic, providing an example of
how a set of interventions could target multiple symptoms.
Cognitive-behavioral strategies that address the psychological impact of
symptoms associated with EGFRIs could be evaluated in collaboration with
psychologists and social workers as a strategy to address multiple symptoms, such as
those represented in the psychological-cognitive cluster. Cognitive-behaviors skills can
help patients to cope with physical discomfort, and also with mood-related symptoms
(Wagner & Lacouture, 2007), such as worrying or feeling nervous, and could impact
overall performance outcomes as well. Specific strategies, such as symptom reframing
and positive imagery, have been described (Wagner & Lacouture, 2007).
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As noted in the discussion on Factors 1 and 2, exploration of the underlying
mechanisms of the psychological-cognitive cluster and the general sickness cluster,
including the role of cytokines, is an area for future research.
Conclusion
In summary, this study has added to nursing science in several key areas. First,
the symptom experience of patients receiving EGFRIs has been more fully characterized.
Evidence has been presented that those patients who receive EGFRI therapy experience a
significant symptom burden related to their disease and treatment that includes
dermatologic symptoms, but also includes a wide variety of other symptoms that require
assessment and management, such as mood and affective symptoms. Not all symptoms
that are common in the oncology patient population are relevant in these patients, and
other symptoms that are less well recognized can cause distress and impact performance.
In addition, psychological symptoms should be assessed as they are commonly
experienced by patients receiving EGFRIS. Future work should include updated
symptom instruments that incorporate high frequency symptoms associated with specific
therapies.
Secondly, three symptom clusters have been identified in this patient population:
a psychological-cognitive cluster, which can impact psychological status; a treatmentrelated dermatologic cluster with skin and hair changes that has not been previously
identified as a symptom cluster; and, a mucocutaneous and fatigue cluster which can
affect performance and elements of QOL and which included a treatment-related
symptom not previously included in similar clusters. The identification of these symptom
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clusters offers an opportunity to explore interventions that impact more than one
symptom and which may enhance care while reducing costs.
Finally, the theory of unpleasant symptoms (TOUS) provided a multidimensional
infrastructure for the measurement of symptoms and their impact on outcomes in patients
receiving EGFRIs. In the TOUS model, a synergistic effect occurs when several
symptoms are experienced simultaneously and have a multiplicative effect (Lenz et al.,
1997). Interaction between and among concurrent symptoms resulted in different
impacts on outcomes, supporting a basic premise of the model. In addition, the notion
that psychological symptoms should be included in the model, separate and apart from
psychological influencing factors, was enhanced through this work. Future work can
explore and test whether interventions aimed at psychological symptoms can ameliorate
or modify other symptoms and the subsequent performance outcomes experienced by
these patients.
Future studies should include larger samples, equal numbers by gender, and a
longitudinal design in in order to confirm the findings of the current study. Because there
were variations in symptoms experienced by patients receiving TKIs vs. MOABs, future
studies could compare symptom clusters between these groups in order to further refine
identified symptom clusters and to enhance tailoring of symptom management
interventions. Careful evaluation and comparison of instruments to assess symptoms in
this group of patients should be undertaken, as it is possible that the ideal instrument does
not exist, and could be developed or further refined in future work. Evaluation of the
available instruments for dermatologic quality of life is recommended. In addition, more
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comprehensive assessment of patients receiving EGFRIs should be undertaken in order to
identify effects of therapy on psychological status and all facets of quality of life. Care
management strategies for skin, nail and hair changes should be evaluated in
interventional studies that include both physiologic and psychological assessments.

APPENDIX A
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N = 56
Dry skin
Lack of energy
Worrying
Changes to my finger or toe nails
Problems with sexual interest or activity
Changes in skin
Dry mouth
Feeling sad
Diarrhea
Feeling nervous
Feeling irritable
Changes in hair growth on my face
Changes in the way food tastes
Difficulty sleeping
Numbness/tingling in hands/feet
Hair loss
Changes in my eyelashes
Other changes scalp hair
Feeling drowsy
Difficulty concentrating
Weight loss
Itching
Cough
Pain
Other changes to my fingers or toes
Mouth sores
Lack of appetite
Shortness of breath
“I don't look like myself”
Nausea
Constipation
Difficulty swallowing
Dizziness
Sweats
Feeling bloated
Vomiting
Swelling of arms and legs
Problems with urination

Mean
1.757
1.657
1.607
1.429
1.429
1.414
1.386
1.357
1.286
1.232
1.196
1.100
1.057
1.029
1.000
.971
.929
.929
.914
.829
.786
.757
.729
.700
.686
.686
.671
.614
.557
.543
.457
.443
.314
.286
.257
.186
.186
.157

Std. Deviation
1.4902
1.3802
1.2746
1.4925
1.6552
1.3814
1.4269
1.1666
1.5077
1.1907
1.1349
1.3522
1.3991
1.2646
1.3495
1.4206
1.3796
1.3014
1.1760
1.2009
1.2440
1.1459
1.1342
1.1320
1.2340
1.3072
1.1083
1.1415
1.1809
.9167
.9262
1.0110
.7423
.7062
.7795
.6288
.5706
.5588
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N = 55
Percent (n)

Mean, SD

I am bothered by a change in my skin’s sensitivity to
the sun.

29 (16)

2.84 (1.36)

My skin or scalp itches.

76 (42)

2.31 (1.32)

My skin bleeds easily.

53 (29)

3.02 (1.15)

My skin or scalp is dry or “flaky.”

80 (44)

2.07 (1.35)

My skin or scalp feels irritated.

76 (42)

2.53 (1.20)

My eyes are dry.

64 (35)

2.62 (1.37)

I am bothered by sensitivity around my fingernails or
toenails.

31 (17)

2.51(1.43)

My skin condition affects my mood.

35 (19)

3.45 (.899)

I feel unattractive because of how my skin looks.

35 (19)

3.29 (1.15)

I am embarrassed by my skin condition.

44 (24)

3.27 (1.05)

I avoid going out in public because of how my skin
looks.

16 (9)

3.69 (.79)

I am bothered by increased facial hair.

44 (24)

3.02(1.31)

I am bothered by hair loss.

55 (30)

2.71 (1.46)

Functional
My skin condition interferes with my social life.

18 (10)

3.29 (1.15)

Sensitivity around my fingernails makes it difficult to
perform household tasks.

47 (26)

2.96 (1.31)

My skin condition interferes with my ability to sleep.

15 (8)

3.76 (.693)

Changes in my skin condition make daily life difficult.

27 (15)

3.6 (.74)

The skin side effects from treatment have interfered with
household tasks.

29 (16)

3.55 (.84)

Physical

Social/emotional
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NAME of HEALTH CARE PROFESSIONAL
ADDRESS
Dear Dr. or Nurse:
I am writing to tell you about an oncology nursing research study being conducted as part of my
doctoral nursing program at Loyola University, Chicago. As an oncology clinical nurse
specialist certified as an advanced practice nurse in oncology, I am interested in learning how to
help patients manage the symptoms associated with their cancer treatment. This study is an
anonymous survey that focuses on the symptom experience of patients receiving epidermal
growth factor receptor inhibitors (EGFRIs) as part of their therapy. As you know, the
dermatologic symptoms associated with EGFRIs have been studied, but less is known about the
overall impact of these treatments on the development of other symptoms, such as pain and
insomnia, and on health-related quality of life.
I am asking for your help in identifying patients who may meet the following criteria:
•
At least 18 years old
•
Currently taking one of these medications: cetuximab (Erbitux®), panitumumab
(Vectibix®), erlotinib (Tarceva®), gefitinib (Iressa®), and lapatinib (Tykerb®) for at
LEAST FOUR WEEKS
•
Able to read and understand English
•
Willing to complete an anonymous online or paper survey
•
NOT diagnosed with a skin condition NOT related to treatment, such as acne
vulgaris, erythema multiforme, psoriasis, or rosacea
Participation in the study would involve completion of online OR paper instruments. The survey
instruments will take no longer than 20-30 minutes to complete. There are no interventions
associated with this study, and no blood samples or other lab work will be performed. No
personal health information or other identifying information will be collected, and participants
will not be asked for your name or the name of any care providers.
We hope that the study will benefit future patients receiving these medications.
Please contact me at 224-735-1118 for questions about the study. Several patient flyers are
included in this mailing, so if you have patients who you feel would be appropriate for
participation, please share this information with them. Patients may contact me directly if they
have any questions or an interest in participating and I will pre-screen them for the study.
Thank you in advance for considering this request for assistance in identifying patients eligible
for this study.
Sincerely,
Josie Howard-Ruben, MS, RN, APN-CNS, AOCN, CHPN
Doctoral Student, Loyola University
XXXXXXX(VM)
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The Symptom Experience of Patients Receiving Epidermal Growth Factor Inhibitors
(EGFRIs)

Would you like to be part of a nursing research study that explores the symptom experience of
patients who take EGFRIs as part of their cancer treatment?
EGFRIs include drugs such as cetuximab (Erbitux), panitumumab (Vectibix), erlotinib (Tarceva),
gefitinib (Iressa), or lapatinib (Tykerb).
These medications are used to treat several cancers such as breast cancer, colon cancer, head and
neck cancer, lung cancer, and pancreatic cancer.
• Are you at least 18 years old?
• Are you currently taking one of these medications: cetuximab (Erbitux®), panitumumab
(Vectibix®), erlotinib (Tarceva®), gefitinib (Iressa®), and lapatinib (Tykerb®)?
• Have you been taking this medication for AT LEAST FOUR WEEKS?
• Able to read and understand English?
• Are you willing to complete an anonymous online or paper survey?
• Are you NOT diagnosed with a skin condition NOT related to treatment, such as acne
vulgaris, erythema multiforme, psoriasis, or rosacea?
If you answered YES to these questions, you may be eligible to participate in a nursing research
study.
The purpose of this trial is to create a complete picture of the symptoms experienced by patients
receiving drugs classified as epidermal growth factor inhibitors (EGFRIs). These drugs may
cause skin, nail, and hair changes, as well as other symptoms.
This study will explore the impact of these symptoms on patient well-being and quality of life.
To participate in the study, you will complete an anonymous survey. The survey will take about
20-30 minutes to complete.
This study is being conducted as part of a doctoral nursing program at Loyola University,
Chicago.
For information and to be screened for participation, please call Josie Howard-Ruben at 224XXXXX or email XXXXX@luc.edu.
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Home page
The Symptom Experience of Patients Receiving Epidermal Growth Factor Receptor
Inhibitors (EGFRIs)
This nursing research study explores symptoms experienced by patients who are taking
EGFRIs, and is being conducted by a doctoral nursing student at Loyola University,
Chicago.
We are interested in learning more about the symptoms experienced by patients who take
EGFRIs, as well as the impact of these symptoms on quality of life and well-being.
If you are taking one of these medications for cancer, you may qualify to participate in
this study. Please click on the STUDY PARTICIPATION link at the top of this page.
If you would like more information, of you have questions about the study, please click
on the link FOR MORE INFORMATION.
What is an EGFRI? Page
EGFRIs
Epidermal growth factor receptor inhibitors (EGFRIs) are a newer kind of cancer
treatment called targeted therapy. They are used to treat several different cancers,
including breast cancer, colon cancer, head and neck cancer, lung cancer and pancreatic
cancer. To qualify for this study, you would have to be taking one of the following:
•cetuximab (Erbitux)
•panitumumab (Vectibix)
•gefitnib (Iressa )
•erlotinib (Tarceva)
•lapatinib (Tykerb)
STUDY PARTICIPATION page
Do I qualify?
If you meet the following criteria, you are eligible to participate in this study.
• You are at least 18 years of age.
• You are CURRENTLY taking one of these medications: cetuximab (Erbitux®),
panitumumab (Vectibix®), erlotinib (Tarceva®), gefitinib (Iressa®), or lapatinib
(Tykerb®).
• You have been taking the medication for at least four weeks.
• You are able to read and understand English.
• You are willing and able to complete the study questionnaires, either online or on
paper.
• You do NOT have a skin condition UNRELATED TO YOUR TREATMENT,
such as acne vulgaris, erythema multiforme, psoriasis, or rosacea.
If you choose to participate in this research study, you will be asked to complete a 20-30
minute online survey one time only.
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There are no costs to participating in this survey other than the time you spend
completing it.
No information will be collected that will reveal your identity, so the survey is
anonymous.
If you prefer a paper copy of the survey, or if you have any questions about the survey,
please contact Josie Howard-Ruben by email at XXXXXX@luc.edu or by using the For
More Information link.
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Q1 The Symptom Experience of Patients Receiving Epidermal
Growth Factor Receptor Inhibitors
This study has been approved as exempt by a Loyola University of Chicago Institutional
Review Board. This nursing research study is being conducted as part of my doctoral
nursing program at Loyola University in Chicago. Purpose of the study: The purpose
of this survey is to learn more about the symptom experience of patients receiving
treatment with epidermal growth factor receptor inhibitors (EGFRIs), and to find out how
these symptoms affect quality of life, well-being and performance. These treatments may
cause skin, hair, and nail side effects, and other symptoms. We would like to know more
about all of these side effects in order to help patients manage the symptoms better. If
you have been receiving one of these medications, including cetuximab (Erbitux®),
panitumumab (Vectibix®), erlotinib (Tarceva®), gefitinib (Iressa®), afatinib (Gilotrif®)
and lapatinib (Tykerb) for at least four weeks, you may be eligible for this study. Use
the arrow keys at the bottom left to move to the next page.
Q2 Are you eligible to participate?
You must meet the following criteria to be eligible to participate in this study.
You must be at least 18 years old.
You are currently taking one of these medications: cetuximab (Erbitux®), panitumumab
(Vectibix®), erlotinib (Tarceva®), gefitinib (Iressa®), afatinib (Gilotrif®) and lapatinib
(Tykerb®).
You have been taking this medication for at least four weeks.
You are able to read and understand English.
You are willing and able to complete the study questionnaires.
You do NOT have a skin condition UNRELATED TO YOUR TREATMENT, such as
acne vulgaris, erythema multiforme, psoriasis, or rosacea.
If you choose to participate in this research study, you will be asked to complete an
online survey that will take less than 20-30 minutes to finish.
There are no costs to you for participating in this survey other than the time you spend
completing it. If you prefer a paper copy of the survey, one can be mailed to you.
XXXXX@luc.edu.
If you would like to volunteer for this survey, please go to the next question where your
consent will be recorded.
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Q3 You are invited to participate in a research study about your experiences with
your cancer treatments.
We are interested in learning more about the symptoms you are experiencing as a result
of your treatment and how those symptoms are affecting your quality of life, ability to
function and well-being.
The survey will take no more than 20-30 minutes.
No costs are associated with this survey, and there are no risks associated with
participation.
Please verify that the following statements are correct by checking ALL of the boxes.
 I understand that participation in this study is voluntary.
 I understand that participation or lack of participation in this study has no effect on
my care.
 I have been taking one of the listed medications for at least four weeks.
 I am at least 18 years old.
 I can read and understand English.
 I do not have one of the skin conditions listed: acne vulgaris, erythema multiforme,
psoriasis or rosacea.
 I agree to participate in this study.
If I agree to participate in this study Is Not Selected, Then Skip To End of Survey
Q4
Thank you so much for agreeing to complete this survey, and your willingness to share
your experience to help others.
Please answer the following questions so that we can get a complete picture of the
symptoms you are experiencing.
Ideally, you should complete the survey in one sitting, but you can pick up where you left
off if you are interrupted.
Josie Howard-Ruben, MS, RN, APN-CNS, AOCN, CHPN Doctoral Student Loyola
University, Chicago
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Q5 Which of the following medicines are you currently taking as part of your
treatment?
 erlotinib or Tarceva
 gefitinib or Iressa
 lapatinib or Tykerb
 cetuximab or Erbitux
 panitumumab or Vectibix
 afatinib or Gilotrif
 None of the above
If None of the above Is Selected, Then Skip To End of Survey
Q6 How long have you been on this medication?
 Less than four weeks
 At least four weeks
 More than four weeks
 More than eight weeks
If Less than four weeks Is Selected, Then Skip To End of Survey
Q7 Please tell us your gender.
 Male
 Female
Q8 Please tell us about your marital status.
 Married
 Single, but not widowed or divorced
 Divorced
 Widowed
Q9 Please choose the description that best describes your living arrangements.
 Live with spouse
 Live with spouse and children
 Live with children
 Live alone
 Live with others not listed
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Q10 What is your highest level of education?
 Elementary school
 High school
 College
 Graduate school
Q11 Please tell us your age.
 18-29
 30-39
 40-49
 50-59
 60-69
 70-79
 80-89
 90-99
Q12 First, please tell us about your overall health. Which of these choices best
describes your health right now?
 Fully active, able to carry on all pre-disease performance without restriction
 Restricted in physically strenuous activity but ambulatory and able to carry out work
of a light or sedentary nature, e.g., light house work, office work
 Ambulatory and capable of all self-care but unable to carry out any work activities.
Up and about more than 50% of waking hours
 Capable of only limited self-care, confined to bed or chair more than 50% of waking
hours
 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
Q13 What is your primary cancer diagnosis?
 Breast cancer
 Colorectal cancer
 Head and neck cancer
 Lung cancer
 Pancreatic cancer
 Do not know
 Other (please write in below) ____________________
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Q14 Do you know the stage of your cancer?
 Stage I
 Stage II
 Stage III
 Stage IV
 Do not know
Q15 Are you receiving any other medication for your illness that is not listed above,
such as chemotherapy?
 Yes
 No
Answer If Are you receiving any other medication for your illness t... Yes Is Selected
Q16 You indicated that you are receiving other chemotherapy treatments. Can you
tell us what those medications are?
Q17 Are you receiving radiation therapy at this time?
 Yes
 No
Q18 Are you being treated for any of the following illnesses, other than cancer?
 No
 Heart disease
 Diabetes
 Stroke
 Respiratory disease, including asthma or COPD
 Osteoporosis
 Vascular disease
 Gastrointestinal disease, including stomach, colon, liver or pancreas
 Obesity
 Other ____________________
 I choose not to answer this question
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Q19 Are you receiving any treatment for your skin condition RELATED TO YOUR
CANCER THERAPY? You can check all that apply.
 I am not receiving treatment for my skin.
 I use a special soap.
 I use sunscreen.
 I apply a cream that my health care provider suggested.
 I take an oral medication. If you know the name of the medication, please write it in
below. ____________________
Q20 Please describe your current tobacco use.
 I currently smoke tobacco products.
 I currently use other tobacco products.
 I quit using tobacco products when I was diagnosed with this illness.
 I do not currently use tobacco products.
Q21 Redacted instrument due to copyright.
Q26 Mental Health Inventory 5 items (MHI-5) (Ware & Sherbourne, 1992) How
much, during the past 4 weeks, did you feel very nervous?
 All the time
 Most of the time
 Some of the time
 A little of the time
 None of the time
Q27 How much, during the past 4 weeks, have you felt so down in the dumps,
nothing could cheer you up?
 All the time
 Most of the time
 Some of the time
 A little of the time
 None of the time
Q28 How much, during the past 4 weeks, have you felt calm and peaceful?
 All the time
 Most of the time
 Some of the time
 A little of the time
 None of the time
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Q29 How much, during the past 4 weeks, have you felt down-hearted and
depressed?
 All the time
 Most of the time
 Some of the time
 A little of the time
 None of the time
Q30 How much, during the past 4 weeks, have you been happy?
 All the time
 Most of the time
 Some of the time
 A little of the time
 None of the time
Q31 Next, we would like to ask you more about your symptoms. Learning more about
symptoms you are experiencing may help us to identify better ways to help you manage
these symptoms. If you have not experienced the symptom in the last seven days, mark
"no."If you have experienced the symptom, please tell us how much it has DISTRESSED
or BOTHERED you. Please follow the directions below.
Q32 Memorial Symptom Assessment Scale-SF (Adapted)
This survey asks about your symptoms.
Instructions: Symptoms that patients may experience will be listed. If you have had the
symptom DURING THE PAST WEEK, please check that symptom. If you check yes
for a symptom, you will be asked how much the symptom DISTRESSED or
BOTHERED you.

177
Q33 During the PAST WEEK, did you have any of the following symptoms?
Please scroll down the page to make sure you see all the symptoms.
CHECK If
you had
symptom
in last
week
YES

If you checked YES, how much did the symptom
DISTRESS or BOTHER you? Click on the box and select
the description for this symptom.

Not all

A little
Bit

Somewhat

Quite a
bit

Very
much

Difficulty
concentrating













Pain













Lack of energy













Cough













Changes in skin













Dry mouth













Nausea













Feeling drowsy













Numbness/tingling
in hands/feet













Difficulty sleeping













Feeling bloated













Problems with
urination













Vomiting













Shortness of
breath













Diarrhea













Constipation













Sweats













Mouth sores













Problems with
sexual interest or
activity
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Lack of appetite













Dizziness













Difficulty
swallowing













Changes in the
way food tastes













Weight loss













Hair loss













Other changes to
the hair on my
scalp













Changes in hair
growth on my face













Changes in my
eyelashes













Swelling of arms
and legs













"I don't look like
myself"













Itching













Dry skin













Other skin
changes













Changes to my
finger or toe nails













Other changes to
my fingers or toes
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Q34 Below are other commonly listed symptoms.
Please indicate if you have had the symptom DURING THE PAST WEEK, and if so,
how OFTEN did it occur?
IF YES, how often did it occur?

Check YES if
you had the
symptom in
the last
week

Rarely

Occasionally

Frequently

Almost
constantly

YES

Feeling sad











Worrying











Feeling
irritable











Feeling
nervous











Q35
IF YOU HAD ANY OTHER SYMPTOMS DURING THE PAST WEEK, PLEASE TYPE
IN BELOW AND INDICATE HOW MUCH THE SYMPTOM HAS DISTRESSED OR
BOTHERED YOU.
Q36 Redacted due to copyright.
Q37 Overall, how would you rate the experience of completing this survey?
 Very Difficult
 Difficult
 Somewhat Difficult
 Neutral
 Somewhat Easy
 Easy
 Very Easy
Q38 Thank you for participating in this nursing research study. If you would like to learn
about the results of this study, please visit www.symptomclusters.com where we will
post information about any publications that result from this research study. You may
also contact me by email at XXXXXX@luc.edu or by phone at XXXXXX. THANK YOU!
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Qualitative Research Matrix: Impact of Epidermal Growth Factor Receptor Inhibitors on Quality of Life
Author/Citation:
Wagner, L. and Lacouture, M.,
2007.
Dermatologic toxicities
associated with EGFR
inhibitors: the clinical
psychologist's perspective.

Purpose: To explore
dermatologic-related symptom
burden and HRQL in patients
receiving an EGFRI.
Theoretical framework:
Not stated.
Research question:
What are the most bothersome
aspects of dermatologic
toxicities associated with
EGFRIs? What is the impact of
these symptoms on HRQOL?
Participants/Setting:
20 oncology patients at
Northwestern University and 12
expert clinicians
Clinicians included four

Author/Citation:
Wagner, L, Berg, S., Gandhi, M.,
Hlubocky, F., Webster, k., Aneja,
M., Cella, D., and Lacouture, M.
(2013)
The Development of a Functional
Assessment of Cancer Therapy
(FACT) questionnaire to assess
dermatologic symptoms
associated with epidermal growth
factor receptor inhibitors. (FACTEGFRI-18)
Purpose: To describe the process
of developing the FACT-EGFRI18, used to measure HRQOL in
patients receiving EGFRIs.
Theoretical framework: Not
stated, but presumed to be
HRQOL.
Research question:
What are the most bothersome
aspects of dermatologic toxicities
associated with EGFRIs? What is
the impact of these symptoms on
HRQOL?
Participants/Setting:
20 oncology patients at
Northwestern University and 12
expert clinicians
Clinicians included four oncology

Author/Citation:
Coleman, S., Kovtun, I., Nguyen, P.
L., Pittelkow, M. and Jatoi, A.
(2011), A qualitative study of the
ramifications of rash from epidermal
growth factor receptor (EGFR)
inhibitors.

Author/Citation:
Boers-Doets, C.B., Gelderblom,
H., Lacouture, M.E., Epstein, J.B.,
Nortier, J.W., & Kaptein, A.A.
Experiences with the FACTEGFRI-18 instrument in EGFRIassociated
mucocutaneous adverse events.
Support Care Cancer. 2013

Purpose: To explore the full impact
of the EGFRI rash.

Purpose: The aim of this study
was to identify how the EGFRI-18
performed as a measure of quality
of life in patients taking EGFRIs.
Theoretical framework:
Not stated.

Theoretical framework:
Not stated.
Research question: Not stated.

Research question:
Is the EGFRI-18 linguistically
valid in a Dutch population?

Participants/Setting
15 patients at Mayo Clinic who had
a past or current rash from an
EGFRI, including 10 men, and 5
women with an average age of 58.

Participants/Setting:
10 participants in the Netherlands,
including 6 males, 4 females. Most
colon cancer, followed by lung
cancer and breast.
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nurses, three oncologists, three
dermatologists, one dermatology
nurse and one ophthalmologist.
In the second part of the study,
patient participants included 16
women and 7 male patients
receiving EGFRIs.

Diagnoses included colon cancer
(7), head and neck cancer (5), lung
cancer (2) and pancreatic cancer (1).
About half of the patients were
receiving cetuximab.

Ethics: IRB approval
Northwestern.

Ethics IRB Approval Mayo Clinic.

Method:
Triangulation approach included
20 interviews with patients and
12 expert clinicians.

Method:
A sequential, iterative process
was described including literature
review, open-ended qualitative
interviews with both experts and
two groups of patients.

Method:
Structured interview with follow-up
questions that were recorded and
transcribed.

Data Gathering and Analysis:
Qualitative interviews; method
of analysis not described.
Lists of items that were rated by
patients and clinicians.

Data Gathering and Analysis:
Qualitative interviews analyzed
by thematic content analysis
(symptom burden, interference in
physical and social function ,
emotional well-being including
distress and self-image). Separate
counts of frequency by clinicians
and patients were used to generate
priority items.

Data Gathering and Analysis:
Questions focused on rash and were
based on the literature and clinical
concerns. Questions were structured,
but an opportunity for free response
was allowed. Transcripts were
reviewed and when new themes no
longer emerged, enrollment stopped.
An inductive qualitative approached
was used to identify and categorize

oncology nurses, three
oncologists, three
dermatologists, one
dermatology nurse and one
ophthalmologist.
Patient participants were
predominantly white women
with a mean age of 57 years.
Diagnoses included 55% lung
cancer, 35% colorectal cancer,
and 5% pancreatic sample.
Ethics:
Not discussed

Ethics:
Stated that study was exempt from
review due to the noninterventional nature.
Method:
Proctored administration of
EGFRI-18 followed by a structured
interview to assess items/s personal
relevance to participant, as well as
their comprehension of each item.
Data Gathering and Analysis;
Verbatim recording of comments.
No formal analysis process.
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Patients and clinicians rated 62
themes, with two investigators
candidate items and could add any reviewing transcripts.
of their own items if not included,
and ten were asked to rate the top
20 items relevant to EGFRI
toxicity. A second group of
patients (n=24) completed
preliminary questionnaires with
38 items, as well as interviews.
Results/Findings:
Patients identified physical
symptoms as most important,
rating burning, stinging,
irritation, pain and dry eyes as
their top five concerns.
Clinicians also selected physical
symptoms, but put a greater
priority on items reflecting
social well-being.
NCI-CTC grading: 15% Grade
1, 40% Grade 2, and 45% Grade
3, indicating fairly significant
symptom burdens.

Results/Findings:
The 38-item version
of the EGFRI was reduced to an
18-item version to measure
HRQOL
developed to measure HRQL
among
patients receiving EGFRIs.

Results/Findings:
The face and nose were described as
the most problematic areas for rash,
and most patients reported
discomfort associated with it. One
patient reporting being hospitalized
for a morphine drip for pain control.
60% reported that the rash made
them feel hopeful (in that the
treatment was working).
Four key themes emerged: physical
discomfort, concerns about
appearance, social isolation, and
medical morbidity. Patients initially
denied social isolation, but their
comments proved otherwise.

Results/Findings:
Participants could not always relate
an item to quality of life. Family
members often prompted
participants about specific
situations where QOL was
impacted by EGFRI treatment.
Physical symptoms were most
associated with an impact on
quality of life. Patients had a
tendency to rate severity of
symptom rather than its impact on
QOL. Other items were suggested
such as eye sensitivity, runny nose,
bloody or crusty nasal cavity, skin
sensitivities, and oral issues.
Instrument more focused on
cutaneous than mucosal adverse
events.
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Limitations—Comments
Small sample size. Not well
developed in terms of
formality of qualitative
method. No IRB information.

Limitations—Comments
Extension of previous work.
Small sample and one setting of
care.

Limitations—Comments
Small sample size with majority of
patients receiving cetuximab so may
not apply to TKIs.

Limitations—Comments
Small sample size. May not be
applicable across cultures.
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